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Abstract 
The present thesis reviews the development of a formal enantiodivergent 
synthesis of the (+)- and (-)-isomers of balanol. This approach commences from a 
cis-dihydrodiol derived from the enzymatic dihydroxylation of bromobenzene. The 
stereochemistry of the diol is used to direct the synthesis of two different aziridines, 
each used in the formal synthesis of one enantiomer of balanol. Also described are 
several enantioselective approaches to (+ )-codeine. Each strategy begins with the 
enzymatic dihydroxylation of p-bromoethylbenzene and involves a Mitsunobu 
inversion and intramolecular Heck reaction as key steps. 
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1. Introduction 
Under normal physiological conditions, the chemical reactions required by a 
living organism proceed too slowly to be useful. Enzymes make life possible by 
catalyzing the reactions required to construct amino acids, nuc1eotides, carbohydrates, 
lipids, and other essential materials. They are also responsible for assembling the 
unessential compounds, collectively known as secondary metabolites. The ability to 
reproduce these natural products via synthesis was not realized until Wohler's urea 
synthesis in 1828. Since that time, chemists have sought to mimic the reactions 
catalyzed by enzymes through the development of countless reagents and procedures. 
One of the most impressive features of enzymes is their ability to carry out 
transformations in a stereo-, regio-, and chemoselective manner. Today, many of the 
reactions performed by enzymes have an equivalent in organic chemistry. Procedures 
to selectively reduce ketones, oxidize olefins, and form carbon-carbon bonds have all 
been accomplished. One exception is the selective dihydroxylation or -aromatic 
substrates 1 (Figure 1). Catalyzed by the toluene dioxygenase (TDO) enzyme, this 
reaction yields cis-dihydrodiols 2. The utility of these metabolites has been well 
established in the synthesis of many natural products by the Hudlicky group and 
others. 1 
6 _to_lu_e_ne_d_io_x.:....:Y9=--e_na_s_: R h OH 
UOH 
2 
--
-
natural products 
Figure 1. Stereoselective dihydroxylation of arene substrates by toluene dioxygenase 
1 
In the present study, the value of the cis-dihydrodiol metabolites will be demonstrated 
through their use in the synthesis of balanol (3), and codeine (4). 
HO 
HO 
P 
HO "H 
OH C)-NrO-0H 
~ 0 
(+)-balanol (3) 
Me:~~, 
"I'"NMe 
HO .0 
(+ )-codeine (4) 
Figure 2. (+)-balanol (3) and (+)-codeine (4) 
Balanol (3) was first isolated from the fermentation broth of Verticillium 
balanoides by researchers at Sphinx Pharmaceuticals in 1993 while screening for 
inhibitors of protein kinase C (PKC).2 PKC enzymes are involved in the signal 
transduction pathways that regulate thousands of processes in the body. Their 
overactivity has been implicated in a number of diseases, making antagonists of PKC 
an attractive drug lead.3 
The synthetic strategy outlined in this thesis is enantiodivergent, with both the 
natural (-)- and the unnatural (+ )-enantiomers of balanol (3) arising from a single 
compound. In each case a vinyl aziridine was fabricated from the cis-dihydrodiol 5 
obtained in the fermentation of bromobenzene. The key step was the selective 
opening of the aziridines 6 and 7 with an oxygen nucleophile (Figure 3). This was 
followed by reduction of the vinyl halide and an oxidative cleavage/ reductive 
amination protocol to install the azepane ring. 
2 
LOH 
U OH 
5 
(xBr OR e---"" RO : OR 
RN'" 
6 
6:
Br 
OR 
e---"" RO OR 
RN 
7 
1. vinyl halide reduction 
2. oxidative cleavage! 
reductive amination 
(+)-balanol (3) 
(-)-balanol (3) 
Figure 3. Enantiodivergent synthesis of (+)- and (-)-balanol from homochiral diol 5 
The analgesic and antitussive properties of opiate alkaloids have been known 
for thousands of years. Currently, codeine (4) is the most widely used opiate for the 
treatment of chronic pain and is one of the most widely prescribed drugs in the 
world.4 Opiate alkaloids are harvested from the opium poppy species which grow 
predominantly in Asian countries, including Iran, Afghanistan, Turkey and India. In 
order to relieve the Western world's reliance on these countries, a fully synthetic 
route to opium alkaloids is required. 
The Hudlicky group has long been focused on developing a practical synthesis 
of opium alkaloids. The current thesis will outline our application of the cis-
dihydrodiol derived from the TDO-mediated dihydroxylation of (2-
bromoethyl)benzene (8) to the synthesis of (+)-codeine (4). Conversion of diol 8 to 
vinyl p-ethylamine 9 setup a Mitsunobu inversion of the allylic oxygen by 5-
bromovanilin derivative 10. This was followed by a Heck cyclization to form 
advanced intermediate 12. A large portion of the presented work focuses on the 
installation of the two remaining rings. These cyclizations, followed by inversion of 
the distal oxygen, provide access to (+)-codeine (4). 
3 
M.o~ 
&"' J6NRMe MeO O~NRMe a ~,~ R HO". ~ HO". ~ Mitsunobu ~ Heck NRMe - - - I - (+)-codeine (4) HO'" /./ RO'" RO"- RO'" 
8 9 11 12 
Figure 4. The synthetic strategy towards (+)-codeine (4) 
4 
2. Historical 
2.1 Aromatic Ring-Hydroxylating Dioxygenases 
2.1.1 History of Aromatic Dioxygenases 
Research into the enzymatic processing of aromatic substrates began in the 
early twentieth century with StOrmer's observation that the Bacillus hexcarbavorum 
species of bacteria could use xylene and toluene for growth.5 In 1957, Haccius and 
Helfrich reported the isolation of pyrocatechol from the fermentation of benzene by 
Nocardia coralline.6 Soon after, Marr and Stone proposed that trans-l,2-
dihydroxycyclohexa-3,5-dienes were the intermediates in catechol formation and not 
phenols.? In 1968, Gibson demonstrated that Pseudomonas putida oxidized cis-
cyclohexa-3,5-diene-l,2-diol (13) at rates far higher than the trans substrate.8 He also 
established nicotinamide-adenine dinucleotide (NAD+) and iron as required cofactors. 
These observations led directly to a proposed mechanism of pyrocatechol (14) 
formation during the microbial processing of benzene (15) (Figure 5). 
t; 
0 /"""'0.. 0 [a~ 0] a~ OH ((OH 1,--"- 1- - 1 ~ 0 ~.: 0 ~ .: OH ~ OH 
H H 
15 16 13 14 
Figure 5. Gibson's proposed mechanism of pyrocatechol (14) formation from 
benzene (15). 
Gibson also discovered that P. putida could process halogenated aromatic 
hydrocarbons into their corresponding cis-dihydrodiols.9 The halocatechols were 
isolated in relatively low yields compared to their alkyl counterparts. It was theorized 
5 
that the halocatechols were chelating with the iron required for the initial 
oxygenation. 
2.1.2 Stereochemistry of Enzymatic Dihydroxylations 
In order to elucidate the method of oxygen fixation into aromatic substrates, 
Gibson developed a mutant strain (P. putida 391D) which accumulated, what he 
believed to be, the (+ )-cis-2,3-dihydroxy-l-methy1cyc1ohexa-4,6-diene (17) 
intermediate during the fermentation of toluene (18).10 At the time, all of the available 
evidence indicated that both mammalian and microbial metabolism of aromatic 
substrates went through the trans-diol intermediate. 11 It was believed that the trans 
stereochemistry arose from the hydrolysis of a cis-epoxide.12 Unsure of the relative 
stereochemistry, Gibson condensed the acetylated derivative of 17 with maleic 
anhydride to form I-methyl-2,3-diacetoxybicyc10(2,2,2)-7-hexene-5,6-dicarboxylic 
anhydride (19) which was hydrogenated to produce 20 (Figure 6). 
6 ,tH_ o :: o :: Wl:OAO o~~O - o -~ .: OH 
.: OAe :: OAe H o H o H8 
18 17 19 20 
Figure 6. Relative stereochemistry proof of (+ )-cis-2,3-dihydroxy-l-
methy1cyc1ohexa-4,6-diene (17) 
Spectroscopic analysis revealed that the vicinal protons HA and HB in 20 are cis in 
relation to reach other, thus confirming the relative structure of 17. In an ensuing 
publication Gibson incubated P. putida 391D with benzene in the presence of 1802.13 
The mass spectra of the cis-l ,2-dihydro-l ,2-dihydroxybenzene metabolite indicated 
an incorporation of two isotopic oxygens, presumed to be from the same molecule. 
6 
This was strong evidence for the mechanism hypothesized by Gibson, which proceeds 
through a cyclic peroxide intermediate 16. 
The absolute stereochemistry of several trans-diols obtained from mono- and 
polycyclic aromatic substrates were established by 1971.14,15 Gibson determined the 
absolute stereochemistry of the cis-dihydrodiol 17 shortly afterwards.16 A palladium 
catalyzed hydrogenation of 17 produced cis,trans- and cis,cis-3-methylcyclohexane-
1,2-diols, 21a and 21b respectively (Figure 7). The corresponding monobenzoate 
derivatives were prepared and found to be separable via chromatography on silica gel. 
Subsequent hydrolysis furnished pure samples of the two diastereomers 21a and 21b. 
Oxidation of the latter with Jones reagent yielded the known (-)-2(R)-methyladipic 
acid (22). Comparison to literature values17 established the absolute stereochemistry 
of 16 as IS,2R (as depicted in Figure 6). 
hydrogenation ce' OH 
17 • OH + 
21a 
~OH 1. Jones oxidation ~ _ I 
UOH 2. purification' HO"""""'-/""'-/ "y0H 
o 
21b (R)-(-)-methyladipic acid (22) 
Figure 7. Absolute stereochemical proof of cis-dihydrodioI17r; 
The specific enzymes responsible for the aforementioned catabolism of 
toluene by P. putida were isolated and identified by Gibson in 1989.18 Sequencing 
information was used to construct clones of Escherichia coli JM 1 09 that 
overexpressed TDO (todCIC2BA). The implication of this work will be discussed in 
future sections of this thesis. 
7 
2.1.3 Mechanistic Views 
Despite over 50 years of research, the exact mechanism of TDO catalyzed 
oxidations remains unsolved. The crystal structure of the closely related naphthalene 
dioxygenase (NDO), solved by Ramaswamy and Gibson in 2003,19 has provided 
some valuable insight. Gibson's initial mechanism (Figure 5) involves the 
cycloaddition of singlet oxygen to the aromatic substrate. This high-energy process is 
considered unlikely. Research into the cis-dihydroxylation of indole has identified an 
iron bound peroxide species as a possible intermediate.20 Another possibility is a 
[3+2] cycloaddition between an iron peroxide species 23 and the aromatic substrate 
24 (Figure 8).1 Following reduction of the peroxide linkage in 25, a suprafacial 
migration of the iron- hydroxyl in 26 would form the last required carbon-oxygen 
bond. The lack of definitive evidence for, or against, a specific mechanism leaves this 
topic at the forefront of dioxygenase research.21 
6 ~:~~:.;:"&:b 
I 
24 25 Ln 
R R R 
reduction. )-yOH suprafacia~ )-yO_H __ )-yOH 
UFeOH hxdro~yl U o U OH 
I migration I 
~ ~ ~ ~L .~ 
n 
Figure 8. Plausible mechanism for TDO-catalyzed dihydroxylations. 1 
2.1.4 Application of cis-Dihydrodiols in Synthesis 
Since its discovery, the TDO enzyme has been incubated with hundreds of 
compounds in an attempt to understand substrate specificity. The dihydroxylation 
reactions catalyzed follow a similar pattern of regio-, stereo- and enantioselectivity. A 
widely accepted model was developed by Boyd, and predicts that smaller substituents 
(Rs) will enter the binding pocket in preference to larger substituents (Rd (Figure 
8 
9).22 Boyd demonstrated that larger differences in relative size between Rs and RL 
yield higher enantiomeric excess values. 
Figure 9. Model for predicting the stereo- and regioselectivity of TDO 
dihydroxylations 
In the 1970's, application of cis-dihydrodiols in the synthesis of more 
complex molecules seemed unreasonable. Gibson's mutant P. putida 391D strain 
could only produce the desired metabolites in minute quantities (e.g. 243 mg! L for 
the production of toluene derived diol 17).10 In contrast, the recombinant E. coli 
(pDTG601) expression system is controlled by the tac promoter, which expresses the 
TDO gene upon induction by isopropyl ~-D-l-thiogalactopyranoside (IPTG).18 This 
method can supply multigram quantities of enantiopure cyc1ohexadienedJ.ols for use 
in synthesis.23 
Researchers at Imperial Chemical Industries PIc are credited with the first 
synthetic application of the cis-dihydrodiols. In 1983, they employed the diol derived 
from benzene 13 in the synthesis of polyphenylene (30) (Figure 10).24 In 1987, Ley 
reported the synthesis of (+I-)-pinitol (31) from the same dio1.25 This marked the first 
exploitation of the stereochemistry contained in the cis-dihydrodiol metabolites. 
9 
tot~ Iaylor (1983)24 (X0H _ Le.o...Y..:...{1_98_7:.-)25 __ ::::,... OH 
n 
30 13 
QH 
MeO~OH 
HO\"~OH 
OH 
31 
Figure 10. Preliminary applications of cis-dihydrodiols 
The first enantioselective application of the cis-dihydrodiols was Hudlicky's 
formal total synthesis of PGE2a (32) in 1988.26 Prostanoid synthon 33, which was 
previous converted to 32 by Johnson?? was prepared in only 3 steps from the cis-
dihydrodiol diol17 (Scheme 1). This synthesis was a drastic improvement over those 
previously reported, and demonstrated the remarkable value of the diol metabolites. 
(x0H ... 9:0H 0 ... [0):0] A..o ref 27 ~O .,," r\ ~ 0 X ~ X --~~ ==::: '=/ L-C02H 
::::,... OH 0 ~ 0 O~ ,,' --
HO 0 HO: 
17 34 35 33 32 OH 
Reagents and conditions: (i) 2,2-dimethoxypropane,pTsOH, r.t.; (ii) a) 0 2/03, EtOAc, -78°C; b) Me2S, 
O°C; (iii) Alz03 (neutral), DME, reflux 
Scheme 1. Hudlicky's enantioselective formal total synthesis of PGE2a (32)26 
Since Gibson's initial isolation of cis-dihydrodiols in 1968,8,9c; over 400 
different metabolites of TDO have been identified. l However, only a small percentage 
have found applications in synthesis. The majority of natural products and other 
targets synthesized have originated from the dihydroxylation products of benzene, 
toluene, chlorobenzene or bromobenzene. Research into the applications of these and 
other cis-dihydrodiols has been led by Ley, Boyd, Banwell and Hudlicky. The most 
significant contributions of each researcher will be discussed in further detail. 
In addition to the synthesis of (+I-)-pinitol (31),25 Ley has also constructed 
both the (+)- and (-)-enantiomers of conduritol F (36) from cis-cyclohexa-3,5-diene-
10 
1,2-diol (13).28 The synthesis begins with a one-pot procedure to form epoxy 
carbamate 37 in 47% overall yield from 13 (Scheme 2). Regioselective ring opening 
with (R)-( + )-sec-phenethyl alcohol in the presence of tetrafluoroboric acid-diethyl 
ether complex furnished separable diastereomers 38a and 38b. The final two 
deprotection reactions occurred during a single dissolving metal reduction. 
QH QH 
OH 0,. 
ce ..l.!!.- Y"'y-O)=o :::::,... OH ~o 
'-...--°U: 0 . HOU: OH I )=o~ 
Ph :::::,... 0 :::::,... OH 
iii 
-
38a (+)-36 
+ 
OH OH 
13 37 '(0"'6·,\0 0 ~ Ho'··6·,\OH 
Ph :::::,... ,.,j= :::::,... "'OH 
38b (-)-36 
Reagents and conditions: (i) (MeO)zCO, MeUNa+, MeOH; (ii) mCPBA, DCM; (iii) (R)-(+)-sec-
phenethyl alcohol, HBF4,OEt2, DCM; (iv) NalNH3(l), Et20, -78°C 
Scheme 2. Ley's enantiodivergent synthesis of (+)- and (-)-conduritol F (36),z8 
Boyd has developed routes to several pyranose carbasugars (pseudosugars) all 
originating from the iodobenzene derived cis-dihydrodiol 39.29 Two such examples 
are carba-p-D-altropyranose (40) and carba-a-L-galactopyranose (41). PJ,:otection of 
39 as its acetonide followed by an osmium tetroxide-mediated dihydroxylation gave 
vinyl iodide 42 (Scheme 3). Installation of the methyl acrylate functionality was 
accomplished via a palladium(II)acetate catalyzed carbonylation in the presence of 
methoxide. Catalytic hydrogenation with 5% Rh/Alz03, followed by treatment with 
excess benzoyl chloride provided diastereomers 43a and 43b, which were then 
separated via preparative layer chromatography (PLC). In each series, reduction of all 
three esters was achieved with LiAIH4 and aqueous trifluoroacetic acid catalyzed the 
acetonide deprotection. 
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39 42 42 
g02Me 
BZO".c)::X 
OBz 
43a 
+ 
C02Me 
BzO,.6::X 
OBz 
43b 
HO ....... 
... ex= OH ~. 
HO" . OH 
OH 
40 
HO ~ .2xoH 
HO" : OH 
OH 
41 
Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH; (ii) OS04, NMO, Me2CO, H20; (iii) 
Pd(OAc)2, CO (1 atm) , NaOAc·3H20, MeOH; (iv) 5% RhlA120 3, EtOH, H2 (55 psi); (v) BzCI, 
pyridine; (vi) LiAIH4' THF, reflux; (vii) TFA-THF-H20 (1:8:2), 50°C 
Scheme 3. Boyd's synthesis of pyranose carbasugars 40 and 41.29 
Banwell has employed the toluene derived cis-dihydrodiol 7 in the synthesis 
of linear triquinane-type sesquiterpenoids, including (+ )-hirsutic acid30 and (-)-
hirsutene (44).31 Synthesis of the latter commenced with a Diels-Alder cycloaddition 
between 7 and 2-cyclopenten-I-one (45) to form the syn-addition product 46 with 
minimal contamination by the anti-isomer (Scheme 4). The acetonide derivative of 46 
was treated sequentially with KHMDS, then methyl iodide to install the gem-methyl 
l2 _ 
groups. Reduction of ketone 47 with LiAIH4 setup a Barton-McCombie 
deoxygenation sequence which was followed by acidic hydrolysis of the acetonide. 
Selective oxidation of the less hindered alcohol with 4-acetamido-TEMPO and 
protection of the remaining alcohol as its ~-methoxyethoxymethyl ether yielded 
ketone 49. A subsequent triplet sensitized photolysis reaction on 49 gave the oxa-di-
x-methane rearrangement product 50. Reductive cleavage of the cyclopropyl group 
with tri-n-butyltin hydride produced triquinane 51. Removal of the ketone 
functionality was accomplished with a similar reduction! Barton-McCombie 
12 
procedure. Removal of the MEM group under acidic conditions followed by a PCC-
promoted oxidation set up a Wittig reaction to produce (-)-hirsutene (44). 
a:: ero 
7 45 
C(P<~' H " • "1 \H xii-xvii W<~ H xi ~H~., H ~. ~. "'1/ "'1/ o \H 0 \H 
OMEM OM EM 
(-)-44 51 50 
x 
H~ 
48 
Viii,iX! 
" 
-- H ii,' MEMO H O~_ 
49 
Reagents and conditions: (i) 19 kbar; (ii) 2,2-dimethoxypropane, p-TsOH, H20; (iii) LiHMDS, Mel, 
THF; (iv) LiAIH4' THF, O°C-50°C; (v) NaH, THF, CS2, Mel; (vi) n-Bu3SnH, AIBN, PhMe, reflux; 
(vii) AcOH, THF, H20, 60°C; (viii) 4-NAc-TEMPO,p-TsOH, DCM, O°C; (ix) Hiinig's base, MEM-Cl, 
DeM, r.t.; (x) hv (triplet), Me2CO; (xi) n-Bu3SnH, AIBN, PhH, r.t.; (xii) NaBH4, MeOH; (xiii) NaH, 
THF, CS2, Mel; (xiv) n-Bu3SnH, AIBN, PhMe, reflux; (xv) PPTS, t-BuOH, reflux; (xvi) PCC, DCM, 
r.t.; (xvii) CHr +PPh3-Br, KHMDS, toluene, 
Scheme 4. Banwell's synthesis of (-)-hirsutene (44).30 
Hudlicky has utilized cis-dihydrodiols derived from the TDO-mediated 
dihydroxylation of halogenated aromatic substrates in the synthesis!? of several 
Amaryllidaceae alkaloids.32 Included is the first total synthesis of (+ )-pancratistatin 
(52) from (lS-cis)-3-bromo-3,5-cyclohexadiene-l,2-diol (5).33 The acetonide 
derivative of 53 was subjected to an copper-catalyzed aziridination procedure 
described by Evans,34 before reducing the vinyl bromide with tri-n-butyltin hydride. 
Directed ortho metalation of amide 55, followed by treatment with copper(I) cyanide, 
formed a lithium cyanocuprate species (Ar2Cu(CN)Lh) which selectively opened 
tosyl aziridine 54. Conversion of 56 to its Boc derivative allowed for the removal of 
the tosyl group via a dissolving metal reduction. Removal of the silyl group with 
13 
TBAF was followed by reduction of the dimethyl amide with sodium 
bis(methoxyethoxy) aluminum hydride. Benzyl protection of the phenol produced 
aldehyde 57 which was converted to its methyl ester via a diazomethane protocol. 
Acidic removal of the acetonide and VO(acach-catalyzed epoxidation with di-tert-
butyl peroxide produced oxirane 58. Treatment with aqueous sodium benzoate at 
lOO°C resulted in the stereoselective opening of the epoxide, thermal cleavage of the 
Boc carbamate, and cyclization to the o-lactam. Finally, a palladium(II)hydroxide 
catalyzed hydrogenation removed the benzyl group to provide (+ )-pancratistatin (52). 
Br Ox 
t(H~ (X°X' <JQl ~ ~ 0 NHTs ~ : 0 o .0- CONMe2 OH TsN'" 
OTBS 
5 54 55 56 
OH 
v-ix 1 
WOO 0 J< 
<0 I~ .: OH~t 0 NHBoc x-xii <0 --o .0- NH 0 
OH 0 OBn 
(+)-52 58 57 
ti 
Reagents and conditions: (i) 2,2-dimethoxypropane,p-TsOH, DCM; (ii) PhI=NTs, Cu(acach, CH3CN; 
(iii) nBu3SnH, AIBN, THF, PhMe, reflux; (iv) a) s-BuLi, TMEDA, THF, -90°C; b) CuCN, -90°C to -
20°C; c) 55, BF3,Et20, -78°C to r.t.; (v) a) s-BuLi, THF; b) (BOC)20; (vi) Na/ anthracene, DME, _78°C; 
(vii) TBAF, THF, O°C; (viii) SMEAH, THF, morpholine, -4SoC; (ix) BnBr, K2C03, DMF; (x) a) 
NaCI02, KH2P04, 2-methyl-2-butene, t-BuOH, H20; b) CH2N2, Et20; (xi) AcOH, THF, H20, 60°C; 
(xii) t-BuOOH, VO(acach, PhH, 60°C; (xiii) H20, BzO-Na+ (cat), 100°C; (xiv) Pd(OHh/C, H2 (latm), 
EtOAc 
Scheme 5. Hudlicky's synthesis of (+)-pancratistatin (52).33 
The preceding syntheses show only a fraction of the molecules made through 
use of arene cis-dihydrodiols. Comprehensive reviews on the subject have been 
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published in 199335 and in 20091 by Hudlicky. Also available is a more complete 
compilation of the known metabolites of TDO.36 
2.2 Balanol 
2.2.1 Discovery of Balanol 
The compound now named balanol (3) was originally isolated from 
Cordyceps ophioglossoides in the 1970's by researchers at the Universitat Ttibingen 
in Germany.37 They named their metabolite ophiocordin and demonstrated its 
antibiotic properties against several fungal strains. Derivatives of the 59 were made 
and subjected to standard analytic techniques (i.e. mass spectroscopy and NMR), 
allowing for a structure to be proposed (depicted in Figure 11 as 59).38 Thirteen years 
later, two independent research groups again isolated balanol (3) from three separate 
fungal species. A group at the Roche Nippon Research Center isolated a fungal 
metabolite from Fusarium merismoides Corda and Fusarium aquaeductuum Lagh.39 
They named their metabolite azepinostatin, but conceded that they were not the first 
I' 
group to isolate the compound. They credited a group from the Sphinx 
Pharmaceuticals for the initial isolation of balanol (3) from Verticillium balanoides.2 
In their publication, the Sphinx group noted that balanol (3) was a structural isomer of 
ophiocordin (59). For reasons not disclosed they obtained a sample of 59 and 
compared it to 3.40 It was concluded that they were indeed the same molecule and that 
the structure assigned by the Sphinx group was the correct one. 
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balanol (3) ophiocordin (59) 
Figure 11. The structure of balanol (3) compared to the proposed structure of 
ophiocordin (59). 
2.2.2 Activity of Balanol 
Although the Sphinx Pharmaceutical group was not the first to isolate balanol, 
they were the first to demonstrate its nanomolar activity against the protein kinase C 
(PKC) family of enzymes.2 Subsequent research has established that inhibition is a 
result of competition between balanol and ATP.41 A solved crystal structure of 
balanol bound in the A TP binding site of a PKC enzyme has revealed details on the 
mechanism of inhibition.42 The p-hydroxybenzamide group (A) occupies the adenine 
sub site, hexahydroazepine ring (B) occupies the ribose subsite and the benzophenone 
portion (C and D) mimics the triphosphate subsite (Figure 12).43 Balanol has a nearly 
3000 times greater affinity for the binding site compared to ATP.44 
16 
Figure 12. Balanol and ATP superposition.43 
Analogs of balanol have been synthesized and screened for activity against 
PKCs and other kinases.44,45 Some compounds containing the balanol core 
(hexahydroazepine ring) showed activity against members of the protein kinase A 
family of enzymes as well as PKCs. Any inhibitor of protein kinases (PK) is of 
interest to medicinal chemistry since kinases have broad biological effects in the cell. 
Protein kinases are enzymes that catalyze the addition of a phosphate group on 
to another protein.46 Typically, the addition of a phosphate changes the function of the 
target protein. The signal transduction pathways that convert external stimuli into 
cellular responses are under the control of this system. The addition of a phosphate to 
a protein can be compared to an on/off switch. An estimated 2% of the human 
genome codes for kinases, attesting to their importance in the body.47 Disruptions in 
protein kinase activity have been linked to a myriad of diseases. It has been 
speculated that inhibitors of PKs would have wide ranging therapeutic value.48 
Currently, PK inhibitors are being investigated for their potential use in the treatment 
of asthma, Alzheimer's disease, arthritis, multiple sclerosis, diabetes, cancer, and 
17 
many other diseases.49 The wide spread application of PK inhibitors, such as balanol, 
make their synthesis an important goal. 
2.2.3 Selected Syntheses of Balanol 
Synthesis of (-)-balanol, the natural enantiomer, and (+)-balanol have been an 
objective of researchers for over fifteen years. The following section will review a 
selection of the more than 30 formal and total syntheses accomplished to date. The 
first published total synthesis of balanol has been credited to the Nicolaou group,50 
although the first completed total synthesis belongs to the Sphinx Pharmaceutical 
group.51 
Lampe and Hughes (1994)51-2 
The Sphinx group, led by Lampe and Hughes, designed a synthesis in which 
the benzophenone and the hexahydroazepine portions would be generated separately 
and then coupled together later. Creation of the benzophenone segment began with 
the differential protection of arene 60 as its benzyl and tert-butyl esters (Scheme 6). 
Transmetalation of 61 followed by treatment with carbon dioxide gave a carboxylic 
acid species which was converted into acid chloride 62 with oxalyl chloride. 
Acylation of aryl bromide 63 with 62 and tert-butoxide yielded ester 64. Subsequent 
transmetalation with n-butyllithium catalyzed a rearrangement to the ortho-substituted 
benzophenone 65. A two-step oxidation, first pyridinium dichromate then tetra-n-
butyl ammonium permanganate, converted the primary alcohol of 65 into the 
corresponding carboxylic acid. The last sequence was a benzyl protection, thermal 
hydrolysis of the tert-butyl ester, and conversion to its acid chloride 67. 
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OSn 
65 
! ix-xi 
OSn 
66 
61 
OSn 
62 
~' j~1 
63 OH 
64 
OSn 
67 
Reagents and conditions: (i) BnBr, K2C03; (ii) NaOH; (iii) cm, t-BuOH, DBU; (iv) n-BuLi, _78°C; 
(v) CO2; (vi) (COCI)z; (vii) t-BuOK, THF; (viii) n-BuLi, THF, -78°C; (ix) PDC, DMF; (x) BU4NMn04, 
pyr; (xi) BnBr, K2C03; (xii) quinoline, 205°C; (xiii) (COCI)z, DMF 
Scheme 6. Lampe and Hughes' synthesis of the benzophenone portion of balanol. 51-2 
The synthesis of the azepane core of balanol was accomplished from 
hydroxylysine 68 (Scheme 7). Conversion to its lactam with hexamethyldisilazane in 
xylenes followed by the slow addition of isopropanol, set up a reduction which 
furnished azepane 69. Selective protection of the secondary amine with Boc 
anhydride was followed by protection of the primary amine as an aryl ester to give 
amide 70. Treatment with previously synthesized benzophenone 67 in triethylamine 
produced fully protected balanol derivative 71. After hydrogenation of the benzyl 
groups and acidic hydrolysis of the Boc carbamate, balanol (3) was obtained. 
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OH 
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,N 0 
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68 69 70 
BnO 
o 
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~oc 0 
balanol (3) viii-ix 
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71 
Reagents and conditions: (i) (TMS)zNH, xylenes, reflux; (ii) isopropanol; (iii) IN HCI; (iv) BH3, THF; 
(v) (BOC)20, NaOH; (vi) p-BnOC6H4COCI, NaOH, DCM; (vii) 67, NEt3, DCM; (viii) H2, Pd(OH)zIC; 
(ix) TFA 
Scheme 7. Lampe and Hughes synthesis of balano1.51 -2 
Nicolaou (1994)50,53 
Nicolaou's synthesis of balanol followed the same strategy employed by 
Lampe and Hughes. They first synthesized the benzophenone portion and then 
coupled it to the azepane portion. Nicolaou used an almost identical approach to make 
benzophenone 67 and therefore it will not be reviewed. Preparation of the azepane 
core started from homochiral amino acid D-serine (72) which was differentially 
protected three times to yield ester 73 (Scheme 8). Reduction with DIBALH followed 
by treatment of the resulting amino aldehyde with Brown's 
diisopinocamphenylborane reagent (Allyl-B(IIpch) gave alcohol 74. Protection as its 
acetonide was followed by mesylation and displacement with azide to give 76. 
Reduction, CBz protection and desilylation allowed for the key step, a 7-exo-tet 
cyc1ization initiated by treatment with tert-butoxide in THF which made azepane 78. 
Removal of the protecting groups and derivatization with p-(benzyloxy)benzoyl 
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chloride was followed by a 2-chloro-l-methylpyridinium iodide mediated coupling 
reaction with the benzophenone fragment 67. The synthesis was completed by 
removal of the last protecting groups to yield balanol (3). 
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balanol (3) 
Reagents and conditions: (i) (BochO, NaOH, 1,4-dioxane, H20, 0-25 DC; (ii) K2C03, Mel, DMF, 0-
25°C; (iii) TPSCI, imidazole, DMF, 25°C; (iv) DIBALH, toluene, -78°C; (v) Allyl-B(llpc)2' Et20, -
78°C, ethanolamine; (vi) 2,2-dimethoxypropane, CSA, CH2CI2, 25°C; (vii) 9-BBN, THF; then NaOH, 
H20 2; (viii) MsCI, Et3N, CH2CI 2, DoC; (ix) NaN3, DMF, 25°C; (x) H2, Pd/C, THF; (xi) Benzyl 
chlorocarbonate, NaOH, 1,4-dioxane, H20, DoC; (xii) TBAF, THF, 25°C; (xiii) MsCI, ijt3N, CH2CI 2, 
DoC; (xiv) KOtBu, THF, 25°C; (xv) TFA, CH2Cb, 25°C; (xvi) p-(benzyloxy) benzoyl chloride, Et3N, 
0-25°C; (xvii) 67, 2-chloro-I-methylpyridinium iodide, DMAP, NEt3' DCM; (xviii) H2, Pd black, THF, 
H20, AcOH. 
Scheme 8. Nicolaou's synthesis of balanol. 50,53 
Vicker (1995)54 
Vicker's preparation of the benzophenone portion of balanol began with the 
formation of the Grignard reagent of 81 followed by its reaction with acid chloride 80 
(Scheme 9).54 Oxidation of the methyl groups of 82 with permanganate and 
21 
manipulation of the two phenol groups gave 83. Removal of the remaining methyl 
furnished 84 which was benzyl protected to yield benzol?henone 85. 
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C02H OH co H r1-ry2 
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viii-ix 1 
Bn02C B 0 ~ .... nVYI(C02H 
yYy 
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-
OMe (Yr!( 
Y'lfY OMe 0 OMe 
82 
ii-iv 1 
C02H OH co H r1-ry2 
Y'lfY OH 0 OMe 
83 
Reagents and conditions: (i) Mg, THF; (ii) KMn04, pyridine (aq.); (iii) SOC}z, MeOH; (iv) BBr3, 
DCM; (v) SOC12, MeOH; (vi) NaH, BnBr, DMF; (vii) BBr3, DCM; (viii) NaH, BnBr, DMF; (ix) 
Na2C03 (aq.), EtOH 
Scheme 9. Vicker's synthesis of the benzophenone portion of balanol. 54 
Vicker's preparation of the hexahydroazepine portion of balanol began from 
ketone 86, which was treated with ethyl diazoacetate under Lewis acid conditions to 
initiate a methylene insertion on the unhindered side to create ester 87 (Scheme 10). 
Acidic hydrolysis and decarbonylation was followed by displacement of the bromide 
with azide to furnish ketone 88. Selective reduction with sodium borohydride 
produced a 2.4: I ratio of trans- and cis-isomers, which were separated via column 
chromatography. Azide reduction and formation of the p-(benzyloxy) benzoyl amide 
derivative allowed for the completion of the synthesis through a similar coupling 
22 
method employed by Nicolaou.50,53 Separation of (-)- and (+)-balanol (3) was 
accomplished through use of an HPLC protocol. 
6"' N Ts 
86 87 88 
(-)- and (+)-balanol (3) ix-xi 
--
OH 
iv-v.. c) .. 'NH2 
N 
Ts 
89 (+/-) 
Vi-Viii! 
OH 
c)"'~rrO-oBn 
~Bz 0 
79 (+/-) 
Reagents and conditions: (i) N2CHC02Et, BF3-Et20, DCM; (ii) HCI, dioxane; (iii) NaN3, AcOH, 
DMF; (iv) NaBH4' EtOH; (v) LiAIH4' THF; (vi) HBr (aq.); (vii) NEt3, DCM, 18-crown-6, benzyl 
chloroformate; (viii) p-(benzyloxy) benzoyl chloride, Et3N, DCM; (ix) 85, 2-chloro-l-
methylpyridinium iodide, DMAP, NEt3, DCM; (x) H2, Pd black, EtOAc, H20, AcOH; (xi) HPLC 
separation. 
Scheme 10. Vicker's synthesis of (-)- and (+ )-balanol. 54 
Tanner (1995)55-6 
Tanner has published several approaches to balanol through selective epoxide 
t; 
and aziridine openings. The two examples presented both start with epoxide 90, 
obtained in 90% e.e. via a previously described Sharpless asymmetric epoxidation.57 
In the first route, compound 90 was converted into its ditosylate in a two step 
procedure and then cyclized in the presence of cesium carbonate (Scheme 11). The 
selective epoxide opening of 91 was intensely studied by Tanner.56 When LiN3 was 
used, a 97:3 ratio of separable isomers was obtained. Mesylation of 92 followed by 
reduction of the azide functionality with LiAI~ formed aziridine 93 upon protection 
with p-methoxybenzyl chloride. Opening of the aziridine 93 with aqueous p-TsOH 
23 
gave a 98:2 ratio of regioisomers in favour of 94, a known degradation product of 
balanol. The second approach used an in situ acyl transfer reaction to transform 
alcohol 90 into cyclic-carbamate 96 in two steps. Alcohol 96 was converted to its 
ditosylate and then cyclized in similar manner to the first approach. Hydrolysis of 97 
furnished alcohol 98, a compound Tanner argues could be converted to balanol. 
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Reagents and conditions: (i) p-TsCI, NEt3, DMAP, DCM; (ii) N-tosylimidazole, BU4NF, THF; (iii) p-
ToIS02NH2, CS2C03, DMF, r.t.; (iv) LiN3, DMF, 90°C; (v) MsCI, NEt3, DCM; (vi) LiAIH4, THF, 
50°C; (vii) p-MeOC6H4COCl, NEt3, DCM; (viii) p-TsCI, H20, THF; (ix) BCI3, DCM; (x) Na(Hg), 
Na2HP04, MeOH, reflux; (xi) BnN=C=O, NEt3, DCM; (xii) NaH, THF, r.t.; (xiii) p-TsCI, NEt3, DCM; 
(xiv) BU4NF, THF; (xv) p-TsCI, NEt3, DMAP, DCM; (xvi) p-ToIS02NH2, CS2C03, DMF, r.t.; (xvii) 
LiOH, THF, H20, EtOH, reflux 
Scheme 11. Two of Tanner's approaches to balanol. 55,56 
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Naito (1997)58-9 
Naito's synthesis of the benzophenone portion begins with the methylated 
derivative of chrysophanic acid 99. Reductive methylation furnished anthracene 
derivative 100, which was irradiated as an ether solution with a halogen lamp in the 
presence of oxygen (Scheme 12). The resulting oxygen adduct was treated with 
sulfuric acid to yield carboxylic acid 101. Bromination and subsequent treatment with 
boron tribromide introduced the desired carboxylic acid functionality. The final 
manipulations and benzyl protections produced intermediate 85, a commonly 
employed coupling partner in the synthesis of balanol. 
OMe 0 OMe 
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OMe 0 OMe 
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C02H OMe 
101 ! iv-vi 
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Reagents and conditions: (i) a) Na2S204, BU4NBr, THF, H20; b) 6N KOH, Me2S04, r.t.; (ii) O2/ hv, 
Et20, H2S04, acetone; (iii) NaH, Mel, DMF; (iv) NBS, AIBN, CCI4, reflux; (v) BBr3, DCM, r.t.; (vi) 
BnBr, K2C03, DMF; (vii) CaC03, H20, dioxane, reflux; (viii) Pr4NRu04, NMO, MeCN; (ix) NaCIOz, 
NaH2P04, 2-methyl-2-butene, THF, t-BuOH, H20. 
Scheme 12. Naito's synthesis of the benzophenone portion of balanol. 58,59 
Naito's synthesis of the hexahydroazepine ring begins with the SmI2-catalyzed 
cyc1ization of aldehyde 103 (Scheme 13). Removal of the benzyl group and 
replacement with the p-(benzyloxy) benzoyl group fashioned racemic 105. 
Immobilized lipase and vinyl acetate was used to selectively esterify 105, resulting in 
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96% e.e. of the desired isomer 106. Conversion to known intermediate 79, followed 
by coupling with the previously described benzophenone portion 85, gave the target 
molecule. 
~O OH OH rrNOBn~ d"INHOBn~d"'N~ 
N-' N N ~OBn 
Boc Boc Boc 0 
103 (+/-) 104 
balanol (3) vi-vii 
-
(+/-) 105 
OAc 
79 ~ O'''N~OB' 
Boc 6  
106 
Reagents and conditions: (i) SmI2, HMPA, t-BuOH, -78°C; (ii) a) H2, Pt02, MeOH; b) p-(benzyloxy) 
benzoyl chloride, NaHC03, H20, DCM; (iii) immobilized lipase, vinyl acetate, t-BuOMe, 45°C; (iv) a) 
TFA, DCM; b) CBz-Cl, Na2C03, H2), acetone; (v) KOH, MeOH, r.t.; (vi) 85, 2-chloro-l-
methylpyridinium iodide, DMAP, NEt3, DCM; (vii) H2, Pd black, HC02H, r.t. 
Scheme 13. Naito's synthesis ofbalano1.58,59 
Trost (2007)60 
Trost completed a formal synthesis of (+ )-balanol (3) through use of a 
dynamic kinetic asymmetric allylic amination and acyl migration of vinyl aziridine 
107 with imido carboxylate 108.60 The stereochemistry of this palladium-catalyzed 
reaction was controlled by diphosphine ligand 109 and produced dicarbamate 110 
with an e.e. of 88% (Scheme 14). Ring closing metathesis with Grubb's IT catalyst 
provided tetrahydroazepine 111, which was selectively oxidized with a 
hydroboration-oxidation procedure. Global deprotection furnished p-amino alcohol 
112 which has previously been converted to (+)-balanol (3) by Lampe and Hughes.52 
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H 
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l~~yOBn ~NJ 0 
BnO~O 
iii-iv 
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110 
0yOBn QN" 
O)-OBn 
111 
Reagents and conditions: (i) 6 mol % 109, 2 mol % [{(l13-C3Hs)PdClhl, 10 mol % Et3N, CH2CI2, 
35°C; (ii) 5 mol % Grubb's II catalyst, CH2C}z, 35°C; (iii) a) BH3-THF; b) NaB03"H20, DoC; (iv) H2, 
Pd(OH)2, MeOH, then HCl. 
Scheme 14. Trost's synthesis of (+)-balano1.6o 
Hudlicky (2008)61-2 
Hudlicky has disclosed an enantiodivergent synthesis of (-)- and (+ )-balanol 
from a single achiral starting materia1.61 ,62 Reaction of vinyl epoxide 113 with a (-)-
menthol version of the Burgess reagent 11463 produced a diastereomeric JJair of cis-
cyclic sulfamidates 115a and 115b (Scheme 15). Their reaction with ammonium 
benzoate produced a separable mixture of trans-amino alcohols 116a and 116b, 
precursors to (-)- and (+)-balanol respectively. Basic ester hydrolysis followed by 
treatment with sodium hydride furnished a cyclic carbamate, resulting from 
displacement of chiral auxiliary group, which was then reacted with 4-
benzyloxybenzoyl chloride to produced carbamate 117. Azepane 118 was formed via 
an osmium-tetroxide dihydroxylation, periodate cleavage and reductive amination 
sequence. Mild hydrolysis gave alcohol 119, a compound previously converted to (-)-
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balano1.52 An identical sequence was also carried out on 116b to produce a formal 
intermediate in the synthesis of (+ )-balanol. 
o 0 11 ... 0 11",0 
9-s: OM* o-s,'" OM* OBz H 
00 .,N-i c)N-i ii 6·"Ny OM* 0+ 0 -- + .0 .0 .0 0 
9Bz H 
('y-NyOM* 
V 0 
113 
ix (-)-balanol (3) -
115a 
60H,~t ~n 9 
119a OBn 
115b 116a 116b 
M* = (-)-menthyl 1 iii-v 1 iii-ix 
o J(0 (+)-balanol (3) (?q~6'Nq 
118a OBn 117a OBn 
viii 
--
Reagents and conditions: (i) 114, THF, 70°C; (ii) a) NH4C02Ph, DMF, 50°C; b) H2S04, THF, H20; 
(iii) IN NaOH, MeOH; (iv) NaH, THF, reflux; (v) 4-benzyloxybenzoyl chloride, DCM, DMAP, NEt3; 
(vi) OS04, NMO, DCM; (vii) a) NaI04, acetone-H20 (8:2); b) BnNH2, MeOH, AcOH, NaCNBH3, 3A 
MS, -78°C to Lt.; (viii) IN NaOH, THF, -20°C; (ix) ref 52. 
Scheme 15. Hudlicky's enantiodivergent synthesis of (-)- and (+ )-balanol. 61,62 
A number of other formal syntheses of balanol have been published; some 
target the azepane core64-84 while others the benzophenone fragment. 85-93 
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2.3 Opiate alkaloids 
2.3.1 History 
It is impossible to determine the exact time and place opium poppy (Papaver 
somniferum) was first cultivated, although it is generally accepted that the Sumerians 
were among the first.94 The Sumerians flourished from 4000 to 3000 BC between the 
Tigris and Euphrates rivers in modern day Iraq, and it was here where the earliest 
record of opium poppy was found. While excavating the ancient city of Nippur, a 
Sumerian spiritual centre, researchers from the University of Pennsylvania discovered 
several tablets inscribed in Cuneiform.95 They describe the collection of poppy juice 
in the early morning from plants they called "Gil Hul" meaning "joy plant". The 
ancient Assyrians were also known to gather and use the secretions of poppy plants. 
They named the juice collected "arat-pa-pal" and some have speculated that the Latin 
word "Papaver" is derived from this term.96 The conquest of Assyria by the Persians 
sparked the spread of opium (which they called theriac, malideh and afiun) out of 
Mesopotamia. In ancient Egypt opium use was generally associated wi!h religious 
ceremonies although it appears to be used in medicine as well. The Ebers papyrus (ca. 
1553-1550 BC) is a medical text that describes the use of opium as a "remedy to 
prevent excessive crying".94 Thoth, the god of letters, was believed to have invented 
opium and to have taught mortals how to cultivate and use it. Furthermore, the 
ancient city of Thebes is the inspiration for the name of the opiate alkaloid 
"thebaine" . 
Ancient Greece is the source for most of the modern terminology associated 
with opium. The word "opium" is derived from either "opos" or "opion" meaning 
29 
juice and poppy juice respectively.96 Many of the ancient Greek gods were associated 
with opium, including Hypos (sleep), Nyx (night), Th~natos (death), and Morpheus 
(dreams) the source of the name "morphine". Ancient Greeks regarded opium as a 
symbol for consolation and oblivion. Thus, they depicted all their nocturnal gods 
wearing a wreath of poppy blossoms. In Homer's "The Diad" and "The Odyssey" 
opium is mentioned as an intoxicating and pain-relieving substance. The deadly 
effects were also known, opium in combination with hemlock were used to execute 
condemned individuals in ancient Greece. 
The Arabs are credited with spreading opium throughout most of the ancient 
world. They called opium poppy "Abou-el-noum" meaning father of sleep. The 
famous Arabian physician Avicenna (loth century) wrote a thesis about opium and its 
effects; he later died from opium abuse. Arab traders brought opium to China 
somewhere between the 11th and 13th centuries AD.95 It was initially used by only the 
socially elite for the control of dysentery. Soon after, European traders brought the 
habit of tobacco smoking from the Americas to China, where it quickly gained 
ti 
popularity. The last Ming emperor Tsung Chen viewed tobacco as an evil from the 
New World and banned its use in 1644.94 In response, the Chinese people began the 
practice of smoking opium with tobacco in gradually increasing amounts. The 
problem grew quickly and soon 25% of the population was smoking pure opium. 
Much of the opium used in China originated from the Bengal region of India 
where it was produced and traded by the East India Company. This British company 
had a complete monopoly on trade in the region and made opium one of most 
prevalent commercial crops by the end of the 18th century. The Chinese tried to cure 
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the problem by banning the sale and importation of opium. The East India Company 
circumvented the ban by purchasing tea on credit from China. The Chinese merchants 
would then go to Calcutta and receive opium as payment. Opium was also smuggled 
into China via Canton by British traders aboard "opium clipper fleets". In response, 
the emperor replaced the corrupt viceroy of Canton with Lin Tse-Hsu, who 
confiscated and destroyed an estimated 2.6 million pounds of opium belonging to 
British merchants in 1839. This infuriated the British and sparked the first Opium 
War from 1839 to 1842. The war ended with a decisive British victory, leading to the 
Treaty of Nanking, which lowered Chinese tariffs and gave control of Hong Kong 
island to the British. In 1856, the second Opium war began, which also allowed 
French traders to operate in China. The grip of opium on the Chinese people would 
remain strong until the conclusion of World War II and the formation of the People's 
Republic of China. 
In order to control opium production, the International Opium Commission 
was founded in 1909. In 1924, a Commission composed of 62 countries met and 
passed laws to regulate the production and trade of opium. Currently, opium 
cultivation is regulated by the International Narcotics Control Board of the United 
Nations. India is the only country that produces significant amounts of opium for 
legal use.97 
2.3.2 Opium Alkaloids 
Opium is the air-dried exudate obtained from lacerating the immature capsules 
of Papaver somniferum L. or its variety album De Candolle (Fam. Papaveraceae).96 
Opium contains numerous non-alkaloidal constituents including various sugars and 
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several simple organic acids (e.g. fumaric acid, lactic acid, oxaloacetic acid and 
meconic acid). The alkaloid content is 10-20% by weight with more than 40 different 
compounds present. However, only 5 of these alkaloids account for the majority of 
weight; the morphinans (morphine (120), codeine (4) and thebaine (121)), the 
benzylisoquinoline papaverine (122) and the phthalide isoquinoline noscapine (123) 
(Figure 13). 
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Figure 13. The major alkaloids of opium. 
The identification of opium alkaloids began in concert with modem chemistry 
in the early 1800's. The Parisian Derosne described the isolation of a "salt of opium" 
in 1803, although the identity of the compound is unclear. A year later, Seguin also 
described such a salt, but it too has never been identified. In 1803, the German 
pharmacist Friedrich Wilhelm Adam Sertiirner began his work on opium, initially 
dealing with the isolation of meconic acid. In 1806, he published a detailed account 
on the isolation of the narcotic component of opium, "principium somniferum". 
Sertiirner described the substance as a member of a new class of organic bases that 
were "salifyable" (able to form salts with both organic and inorganic acids).96 
32 
Another German pharmacist, Karl Friedrich Wilhelm Meissner, called these bases 
"alkaloid" meaning "alkali -like". In 1817, Serttirner wrote a review on his research, 
and it was in this publication that the name 'morphine' was first used, named after 
Morpheus the god of dream. Serttirner believed morphine to be composed of carbon, 
oxygen, hydrogen and nitrogen, although the exact structure was not predicted. In 
1833, Macfarlane and Co. (now Macfarlane-Smith) developed a method for 
commercial scale isolation of morphine. lo3 Soon after, morphine became a popular 
drug for the treatment of pain. Its use as an immediate analgesic began after the 
invention of the hypodermic needle in 1853, previously opium pills and tincture were 
used. 
The structural elucidation of morphine began soon after its isolation. In 1831, 
Liebig proposed the formula of morphine as C34H3606NZ. The correct formula, 
C17Hl90 3N, was determined by Laurent in 1847. Many researchers tried to determine 
the structure through derivatization, resulting in the synthesis of heroin by Wright in 
1874 and codeine by Grimaux in 1881. For decades it was believed that morphine 
contained an oxazine functionality; in fact this is the origin of the common name for 
tetrahydro-l,4-oxazine, "morpholine". 96 The correct structure was proposed in 1925 
by Gulland and Robinson through a series of degradations. Their work led directly to 
the characterization of codeine, which was first isolated in 1833 by Robiquet. The 
correct structure of morphine was confirmed by x-ray crystallography in 1955 by 
Mackay and Hodgkin.98 A more detailed account on the structural elucidation of 
opium alkaloid has been published by Butora and Hudlicky.99 
33 
2.3.3 Biosynthesis of Opium Alkaloids 
All opium alkaloids produced in poppy plants originate from the amino acid 
tyrosine (124), which is first converted into dopamine (125) and 4-
hydroxyphenylacetaldehyde (126) (Figure 14).100 (S)-Norcoc1aurine synthase 
catalyzes a Pictet-Spengler-type condensation reaction between 125 and 126 to 
produce (S)-norcoc1aurine (127). Phenolic and nitrogen methylations, catalyzed by S-
adenosylmethionine-dependant methyltransferases, afford (S)-reticuline (128) which 
is epimerized into (R)-reticuline (129) through a stereoselective reduction of its 
iminium ion after oxidation. lOl (R)-reticuline (129) is converted into salutaridine 
(130) by an oxidative coupling between the ortho position of one phenol ring and the 
para position of the other. Briefly, formation of phenoxide ions and abstraction of a 
nonbonding electron from each oxygen atom occurs to give two radicals which 
couple before a keto-enol tautomerization. Salutaridine (130) is selectively reduced 
by the NADPH-dependant salutaridine reductase to give salutaridinol (131) which is 
v 
converted into acetate derivative 132. Spontaneous (non-enzymatic) elimination of 
the acetate in a SN2' (or possibly a SN1) process gives thebaine (121). Demethylation 
of the C-6 enol ether is performed by an unknown enzyme(s). This provides 
neopinone (133), which is in equilibrium with codeinone (134). Codeinone reductase 
produces the C-6 alcohol in codeine (4), while a demethylation reaction gives 
morphine (120). 
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Figure 14. Biosynthesis of opium alkaloids. 
2.3.4 Pharmacology 
Morphine is still one of the most effective treatments available for pain relief. 
It is especially useful for dull, constant pain rather than sharp, periodic pain.103 In 
general, morphine works by lowering the brain's awareness of pain. Unfortunately, 
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the side effects can often outweigh the benefits. These include; depression of the 
respiratory system, constipation, nausea, pupil constriction, hallucinations, memory 
loss and physical dependence, just to name a few. Some of the worst effects occur 
when a chronic addict stops using, resulting in chills, excessive sweating, abdominal 
cramps, muscle spasms, irritability, tremors, and increased heart rate. 
Codeine is one of the most widely used drugs in the world, with the majority 
produced semi-synthetically from morphine.103 It is typically administered orally as a 
salt (sulfate or phosphate) in combination with a non-narcotic analgesic (e.g. aspirin, 
ibuprofen). It is used for the relief of mild to moderate pain (arthralgia, back pain, 
dental pain, headaches, myalgia, surgical pain), for the treatment of non-productive 
coughing, and diarrhea. Codeine is approximately 60% as effective orally as 
parenterally, resulting from less first-pass metabolism in the liver. Codeine itself has a 
relatively low affinity for opioid receptors (-0.1 % of morphine). The effects are 
attributed to the O-demethylation of codeine to morphine by cytochrome P450 2D6 
(CYP2D6).104 Approximately 10% of codeine undergoes O-demethylation, while 
most (-80%) is glycosylated to codeine-6-g1ucuronide (135). The n;mainder is 
converted to norcodeine (136) (Figure 15). Morphine is metabolized into two 
glycosylated products, morphine-6-glucuronide (137) and morphine-3-g1ucuronide 
(138), the former having relevant opioid activity. Researchers in Holland have 
suggested that codeine-6-g1ucuronide (135) is actually responsible for the analgesic 
effects of codeine. 105 They found that people who lack the CYP450 2D6 enzyme for 
the O-demethylation are still able to experience the effect of codeine. 
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Figure 15. Metabolism of codeine (4). 
The adverse effects of morphine and codeine were recognized soon after their 
isolation. This led researchers to try and develop a safer, more efficacious, and non-
addictive opiate. In 1897, a chemist at Bayer pharmaceuticals named Felix Hoffmann 
acetylated morphine to produce diacetylmorphine (139). This transformation was first 
performed by C. R. Alder Wright in 1874, but was not considered significant at the 
time. Bayer named the morphine derivative "heroin" after the German word 
"heroisch", meaning heroic. Up until 1910, Bayer marketed heroin as a cough 
suppressant and as a non-addictive substitute for morphine. Eventually it was 
discovered that the increased lipophilic character of heroin results in better transport 
throughout the body, particularly across the blood-brain barrier. Heroin is 
metabolized into 6-monoacetylmorphine (140) or 3-monoacetylmorphine (141), the 
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former having appreciable activity (Figure 16). Both metabolites can be further 
hydrolyzed to morphine itself. 
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Figure 16. Metabolism of diacetylmorphine. 
In 1939, while trying to develop a substitute for atropine, researchers 
synthesized meperidine (Demerol) (142). This was the first opiate discovered with a 
structure drastically different from morphine.94 This led to the development of 
methadone (143), another non-opium alkaloid with activity at opioid receptors. The 
effects of methadone start slower, last longer and are not as intense as morphine. This, 
along with its oral activity, has made it a popular drug to treat morphine addiction. In 
1942, Weijlard and Erikson synthesized nalorphine (144) and found it cQuld reverse 
the respiratory depression produced by morphine, making it the first opiate antagonist 
ever developed. Nalorphine is actually a mixed agonist-antagonist, a detailed 
description of this property will be discussed later. 
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Figure 17. Opioid receptor ligands. 
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The first significant attempt to explain opioid receptor binding was postulated 
by Beckett and Casy in 1954.106 It was assumed that morphine and its analogs 
required the following binding interactions for activity; 1. a positively charged 
nitrogen (ionized at physiological pH), 2. correctly oriented aromatic ring in relation 
to the nitrogen (making specific van der Waals interactions), 3. C-3 phenol group 
(hydrogen bonded in the binding site), and 4. an empty binding pocket which allows 
the ethylene bridge fit tightly so to properly orient the rest of the molecule. 
In 1971, Goldstein suggested that the different activities of opioid agonists, 
antagonists, and mixed agonists-antagonists resulted from the existence of multiple 
opiate receptors.107 It was theorized that radiolabeled drugs could demonstrate the 
existence of multiple receptors, unfortunately none could be obtained with high/ 
specific activity. However, subsequent research proved that Goldstein was in fact 
correct. Simultaneously, three separate research groups (1. Pert and Snyder,IOS 2. 
Simon, Hiller and Edelman,109 and 3. TereniusllO) identified multiple opioid receptors 
in the CNS through use of radiolabeled opioid ligands. 
G 
Soon it was theorized that morphine was not the natural ligand of the opioid 
receptors. In 1975, Kosterlitz observed that the brain extracts of guinea pigs contained 
a substance that inhibits acetylcholine release from nerves and that this inhibition is 
blocked by naloxone (145) (an opioid receptor antagonist).111 Ultimately Kosterlitz 
identified the agents responsible as pentapeptides Tyr-Gly-Gly-Phe-Met (Met-
enkephalin (146)) and Try-Gly-Gly-Phe-Leu (Leu-enkephalin (147)). The term 
"enkephalin" is derived from the Greek meaning "in the head", their location in the 
body.103 At least 15 endogenous peptides (5 to 33 amino acids in length) have been 
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documented, each a member of the enkephalin, endorphine or dynorphin class of 
opioid peptides. A fourth class (deltorphins) have been isolated from the skin of the 
giant leaf frog (Phyllomedusa bicoior).l13 These opioid heptapeptides are unusual in 
that they contain the D-isomer of tyrosine. Researchers started to recognize a common 
structural feature required for relevant activity in opium alkaloids, opioid peptides 
and other compounds which induce analgesic activities. The pharmacophore appears 
to be the combination of an aromatic ring, and the specific 3-dimensional disposition 
of a nitrogen either 3 or 4 atoms away (Figure 18).102 In addition to the phenyl and 
amino functionalities, the remaining portion of the molecule makes favorable 
interactions within the binding site. Although not fully understood, additional H-
bonding is believed to partially account for the increased activity of more 'flexible' 
compounds such as carfentanil (148), which is approximately 10,000 more potent 
than morphine. 114 
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Figure 18. Proposed pharmacophore of opioid agonists. 
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This proposed pharmacophore model helps explain the activity of opioid 
agonists, but fails to account for the antagonists. Nalorphine (144) and morphine 
(120) differ only in the substituent on the piperidine ring (N-allyl vs. N-methyl) yet 
have drastically different effects. As mentioned earlier, there are multiple opioid 
receptors in the CNS, which accounts for the discrepancy. Three main opioid 
receptors are now known; mu (Il), delta (8), and kappa (K). It was once believed that 
the sigma (0") receptors were also a type of opioid receptor. However, 
pharmacological testing demonstrated that compounds structurally unrelated to 
opioids activated sigma receptors and isolation! cloning experiments revealed drastic 
structural differencesY5 The opioid receptors are G-protein coupled receptors found 
imbedded the cell membranes of neurons. They are widely, but unevenly, distributed 
throughout the CNS.116 
The mu (Il) receptors are located in the brain (laminae III and N of the cortex, 
thalamus, periaqueductal gray), and spinal cord (substantia gelatinosa). Agonist 
activation of the Il-receptors produce analgesia, euphoria, respiratory depression, 
miosis, decreased gastrointestinal motility, and physical dependence. Upon binding of 
an agonist, the Il-receptor changes conformation opening up an ion channel across the 
cell membrane. Potassium ions flow out of the cell, hyperpolarizing the membrane 
potential, and thus disrupting the action potential. Another consequence is the 
decreased influx of calcium ions into the nerve terminal, resulting in the release of 
fewer neurotransmitters. Both events disrupt the transmission of pain signals 
throughout the CNS. The endogenous Il-receptor agonists are the enkephalins and B-
endorphin, while morphine is the classic exogenous agonist. In the 1960's K.W. 
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Bentley developed a series of bridged oripavines (Diels-Alder adducts of thebaine) 
that became known as the 'super-potent' Jl-receptor agonists. ll7 This class includes 
etrophine (149) whose high hydrophobicity and affinity for the Jl-receptor makes this 
compounds unsuitable for humans; it is currently used to immobilize large animals 
(e.g. elephants and bears). Antagonists of the Jl-receptor include naloxone (145) and 
naltrexone (150), both of which treat opioid abuse. The former is use as an emergency 
room antidote, while the latter is used for long-term care. 
The kappa (K) receptors are located in the brain (hypothalamus, periaqueductal 
gray, claustrum), and spinal cord (substantia gelatinosa). Agonist activation of a K-
receptor initiates a shape change that closes a calcium channel, normally open in an 
active nerve. This prevents the release of neurotransmitters and thus prevents pain 
signaling. The nerves controlled by K-receptors are those induced by non-thermal 
stimuli. Conversely, the Jl-receptors are associated with all forms of pain stimuli. The 
endogenous ligands for the K-receptors are the dynorphin class of opioid peptides. 
Agonist activation of the K-receptors produces analgesia, miosis, respiratory 
f2' 
depression, dysphoria, urinary retention, delayed digestion and some psychomimetic 
effects (i.e. disorientation and/or depersonalization). However, K-receptor agonists do 
not induce dangerous side effects such as addiction and physical dependence. Many 
believe that the K-receptor provides the best hope for a safe analgesic. This theory is 
based on the results obtained from some mixed agonist-antagonist compounds. As 
mentioned earlier, naloxone (145) and naltrexone (150) are Jl-receptor antagonists and 
thus do not provide any analgesic effects. A related compound, nalorphine (144), is a 
Jl-receptor antagonist but is also a mild K-receptor agonist. Unfortunately, nalorphine 
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also induces hallucinations by interacting with the sigma-receptor. However, there 
still remains the possibility that a highly selective K-receptor agonist could be 
developed. Such a compound could be the safe, potent, and non-addictive pain killer 
researchers have been searching for. 
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Figure 19. Selective opioid receptor ligands. 
The delta (8) receptors are located in the brain (pontine nucleus, amygdala, 
olfactory bulbs, and deep cortex). Agonist activation of the 8-receptors produces 
analgesia, euphoria, physical dependence, and possibly seizures and respiratory 
depression. When an agonist binds, the 8-receptor changes conformation and initiates 
the fragmentation of a messenger Gi-protein. The ai-subunit of the G-protein inhibits 
adenyl ate cyclase, a membrane-bound enzyme responsible for the production of 
cAMP. The transmission of pain throughout the CNS requires cAMP to act as a 
secondary messenger, thus its absence explains activity of 8-receptor agonists. The 
endogenous agonists are the enkephalins (Met and Leu). An example of an exogenous 
agonist is 7-spiroindanyloxymorphone (151), whose excellent selectivity for the 8-
receptor is a result of specific interaction with the indane ring off C-7. Similarly, 
antagonists such as naltrindole (152) are highly selective due to hydrophobic 
interactions between the extra rings on the opiate skeleton, indole in this case. 
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2.3.5 Selected Syntheses 
Opium has been utilized in medicinal and spiritual preparations for at least 
5000 years.96 Interest in preparing opium alkaloids began shortly after the isolation 
and characterization of morphine in 1806. Chemists sought to synthesize morphine 
even before the structure had been confirmed. In fact, the first reported synthesis by 
Gates and Tschudi in 1952 assisted in the structural elucidation.99 Since that time, 
numerous racemic and enantioselective syntheses have been disclosed, as well as 
synthetic approaches to the morphinan skeleton. 
Despite years of accumulated knowledge, morphine still represents a 
formidable challenge to synthetic chemists. In particular, the pentacyclic framework, 
five continuous stereo genic centres, and C-13 quaternary centre are challenging to 
construct. Hudlicky has suggested that the difficulty does not come from its 
complexity, but rather its "total dissonance".II8 The polarization of morphine cannot 
be assigned in a way which avoids an incorrect sign on a electronegative atom (Figure 
20). 
nomenclature phenol priority assignment 
morphine (120) 
amine priority 
aSSignment 
Figure 20. Morphine nomenclature and polarization assignments. I 18 
The following section highlights some of the most important syntheses 
published to date. Several comprehensive reviews have been recently written 
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covering all formal, total, and synthetic approaches to morphine and its 
derivatives.118-122 
Gates (1952)123 
Gates published the first total synthesis of morphine (120) as a brief two page 
communication in 1952.123 Four years later, a detailed account of this seminal work 
was disclosed. 124 The synthesis begins with the conversion of 2,6-dihydronaphthalene 
(153) into ortho quinone 156 via a nitrosation! reduction! oxidation protocol (Scheme 
16). Conjugate addition of ethyl cyanoacetate to 156 was followed by an oxidation-
decarbonylation procedure to yield nitrile 157. A Diels-Alder reaction with 1,3-
butadiene formed 158. 
HO,(» i-iii Bz0l)0 iv Bz0l)0 
- I~ -~ ~ OH 0 ~ ~ OMe 
0 OMe 
153 154 155 
lV-Vii 
~Og 0 0 
MeO ~ 0 x ON viii-ix O~ - I - ~ I ~ G OMe ~ OH ~ ~ OMe 
~ CN NC OMe OMe 
158 157 156 
Reagents and conditions: (i) BzCI, pyridine, dioxane; (ii) NaN02, AcOH; (iii) a) Pd/C, H2, AcOH; b) 
FeCh; (iv) a) S02; b) (MeO)2S02/K2C03; (v) KOH; (vi) NaN02, AcOH; (vii) a) Pd/C, H2; b) FeCh; 
(viii) a) NCCH2C02Et, EtOH, NEt3; b) K3Fe(CN)6; (ix) KOH, MeOH; (x) 1,3-butadiene, AcOH. 
Scheme 16. Gates' synthesis of Diels-Alder product 159.123 
Gates used a copper chromite reductive amination procedure to close the 
heterocyclic D-ring. Keto amide 159 was reduced using Wolf-Kishner conditions, and 
then methylated to give N-methyl piperidine 160. Resolution of 160 was 
accomplished via a crystallization protocol employing D-dibenzoyltartaric acid. At 
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this stage, the undesired stereochemistry at the C-14 position needed to be corrected. 
Bromination of ketone 161, followed by treatment with 2,4-dinitrophenylhydrazine, 
acidic isomerisation, and hydrogenation provided 162. Closure of the E-ring 
proceeded by bromination of 162 followed by treatment with 2,4-
dinitrophenylhydrazine, which activated the C-5 position for attack by the phenolic 
hydroxyl. The synthesis was completed by hydrolysis, hydrogenation of the aryl 
halide and enone reduction. M'Og ~O~ ~O~ 1 1 MeO ..0 0 i MeO ..0 0 ii-iii MeO ..0 
- -
..0 OH ~\'. NH ~ "'H NMe ~ eN 
0 
158 159 160 ! iv-vi 
M~~ M'O~ Meo~ 1..0 1 x-xi HO ..0 vii-ix HO ..0 q 
- -" 
. NMe H NMe o "'H NMe 
o ..0 0 
163 162 161 
! xii-xiii 
morphine (120) 
Reagents and conditions: (i) 68-98 atm H2, CuO, Cr203, EtOH, 135°C; (ii) N2H4, KOH; (iii) a) Mel, 
NaH; b) LiAlH4; (iv) H2S04, H20; (v) KOH, (HOCH2CH2hO; (vi) KOtBu, Ph2CO; (vii) a) Br2; b) 2,4-
DNPH; (viii) HCl; (ix) H2, Pt02; (x) a) Br2; b) 2,4-DNPH; (xi) HCl; (xii) LiAIH4, THF; (xiii) pyridine-
HCl,220°C. 
Scheme 17. Gates' synthesis of morphine. 123 
46 
Rice (1980)125-6 
Rice completed arguably the most practical synthesis of morphine in 1980 
using a biomimetic approach. Carboxylic acid 165 and amine 166 (Scheme 18) are 
structurally similar to dopamine (125) and 4-hydroxyphenylacetaldehyde (126), the 
two coupling partners in the biosynthesis of morphine (Figure 14). Condensation 
between 165 and 166 provided an amide which was cyclized using a Bischler-
Napieralski reaction. Reduction of the resulting cyclic imine with sodium 
cyanoborohydride was followed by a dissolving metal reduction and treatment with 
phenyl formate to provide formamide 168. Bromination of the aryl ring was followed 
by ketal formation to afford olefin 169. Grewe cyclization and acidic hydrolysis 
provided ketone 170, an intermediate with four of the five rings installed. Acidic 
deformylation in the presence of methanol yielded the N-methyl piperidine ring, 
while bromination of the cyclohexanone ring initiated closure of the dihydrofuran 
ring. Hydrogenation of the aryl bromide provided dihydrocodeinone (171) a formal 
product in the synthesis of morphine and other opium alkaloids. 
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Reagents and conditions: (i) NaHS03; (ii) KCN, H2S04; (iii) 166, 200T; (iv) POCl3, MeCN; (v) 
NaCNBH3, MeOH; (vi) Li, NH3, THF, t-BuOH, -55 to -65°C; (vii) PhOCHO, EtOAc; (viii) (CH20H)z, 
THF, MeS03H, rot.; (ix) CH3CONHBr, O°C; (x) HC02H-H20 (5:1), rot.; (xi) NH4oHF, Gf3S03H, O°C; 
(xii) a) MeOH, HCl, reflux; b) NH3-H20, iPrOH; (xiii) H2, Pd/C, AcOH, HCOH; (xiv) Br2, AcOH; 
(xv) NaOH, CHCl3; (xvi) H2, AcOH-HCHO; (xvii) ClC02Et; (xviii) PhSeCl; (xix) NaI04; (xx) NaBH4; 
(xxi) BBr3, CHCl30 
Scheme 18. Rice's synthesis of morphine 0 125-126 
Evans (1982)127 
Evans completed one of the more creative syntheses of morphine in 1982. The 
synthesis begins with the bromination of diacid 172 and is followed by a cyc1opropyl 
rearrangement to furnish the terminal olefin 174 (Scheme 19). Treatment of the 
tetrahydropyridine 175, which was prepared in 2 steps from 1-methylpiperidin-4-one, 
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with n-butyllithium provided a lithiated species which condensed with dibromide 174 
to yield isoquinoline derivative 176. The corresponding perchlorate salt 177 reacted 
with diazomethane to form aziridinium 178, which underwent a Kornblum-type 
oxidation with dimethyl sulfoxide to afford aldehyde 180. The B-ring was formed via 
a Lewis acid catalyzed ring closure and provided alcohol 181. The hydroxyl was 
removed by a mesylation/ hydride elimination procedure, while a Lemieux-Johnson 
oxidation installed the ketone functionality. The resulting tetracycle 182 can be 
epimerized using a Gates procedure124 to the natural isomer and thus complete a 
formal synthesis. 
~O?S MeO ~ 
c><C02H i-ii r>(Br iii l:Br ~ 
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+ 
C02H Br Br N 
Me 
172 173 174 1 iv-v 175 
Q:oMe I~ 
- OMe 
Q:oMe I~ 
_ OMe vii-viii 
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l1?M' - -lX)Me ~e We = NMe : ~NMe H ---- A GC104 v G OVH 178 ge 179 oe 177 176 
,....s, ,....5, 
! OMe 
Q:oMe ~ M'O~ I~ ~I I~ - OMe ix x-xii MeO ___ morphine (120) WMe -- - "'H NMe-= OH HN 
CHO Me 0 
180 181 182 
Reagents and conditions: (i) BH3, THF; (ii) PBr3, HBr, DCM; (iii) ZnBr2, PhH, SO°C; (iv) a) nBuLi, 
THF, -lOoC; b) 175, Et20, -7SoC; (v) NaI, K2C03, MeCN, SO°C; (vi) a) HCI04, Et20; b) MeOH; (vii) 
CH2N2, Et20; (viii) DMSO, r.t.; (ix) BF)"Et20, PhMe, -lOoC; (x) MsCI, NEt3; (xi) LiEt3BH; (xii) OS04, 
NaI04• 
Scheme 19. Evans' formal synthesis of morphine. 127 
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Parker (1992)128-9 
In 1992, Parker disclosed a formal synthesis of morphine by a tandem radical 
cyclization strategy. Birch reduction of m-methoxyphenethylamine (183) and 
tosylation of the primary amine was followed by acidic hydrolysis of the enol ether 
(Scheme 20). Treatment with methyl iodide effected the formation of enone 184. 
Luche reduction of the ketone provided an allylic alcohol which directed the 
epoxidation of the olefin. Epoxy alcohol 185 was treated with titanium isopropoxide 
to provide an allylic diol, whose distal hydroxyl was protected as its tert-
butyldimethylsilyl ether. Mitsunobu coupling of alcohol 186 with phenol 187 and 
desilylation with hydrofluoric acid afforded advanced intermediate 188. Treatment of 
188 with tri-n-butyltin hydride at 130DC in a sealed tube resulted in a tandem 
cyclization followed by fragmentation! elimination of the thiophenyl radical. This 
remarkable sequence links the aryl and cyclohexene rings and forms the B-ring with 
the desired stereochemistry at C-13 and C-14. A dissolving metal reduction removed 
the tosyl group and generated a nitrogen radical, or anion, which attacked the B-
carbon of the styrene moiety thus providing the piperidine ring. A Swefnoxidation 
completes the formal synthesis by producing (+I-)-dihydrocodeinone (171). 
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morphine (120) 
J5NM~T~. VI-VII --HO . xSNMeTS HO ~ TBDMSO 
185 186 
Meo~ . HO~SPh 
Br 
187 
viii-ix 
Reagents and conditions: (i) LiINH3, t-BuOH, -68°C; (ii) a) TsCI, NEt3, THF; b) IN HCI; (iii) Mel, 
K2C03, CO(Meh; (iv) NaBH4, CeCI3, MeOH; (v) m-CPBA, DCM, O°C; (vi) Ti(OiPr)4, PhH, 70°C; 
(vii) TBDMSOTf, i-Pr2NEt, -78°C; (viii) PBU3, DEAD, THF, O°C; (ix) 10% HF, MeCN; (x) n-
BU3SnH, AIBN, PhH, 130°C, sealed tube; (xi) LiINH3, t-BuOH, THF, -78°C; (xii) (COClh, DMSO, 
o°c to r.t. 
Scheme 20. Parker's formal synthesis of morphine. 128 
Parker has also described an asymmetric route to morphine through the 
preparation of a single isomer of chiral epoxy alcohol 185.130 The most obvious 
methods are a chiral reduction of enone 184 or a Sharpless kinetic resolvtion of the 
v 
racemic allylic alcohol. Parker notes that these methods are not ideal for 3-
substituted-2-cyc1ohexanones and therefore attempted to use Terashima's reagent 
instead. The poor selectivity (e.e. -5%) of this method led to the development of the 
route shown in Scheme 21. Bromination of enone 184 in the presence of 
triethylamine yielded bromo-enone 190, a suitable substrate for a Corey-Bakshi-
Shibata reduction. Reduction with the (S)-isomer of the oxazaborolidine reagent 
afforded alcohol 192 with an e.e. of >82%. Reduction of C-Br bond with a sodium-
mercury amalgam was followed by meta-chloroperoxybenzoic acid-mediated 
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epoxidation to give the chiral morphine intermediate 185 with an 80% e.e. (Mosher's 
ester analysis). 
ENMeTs ?" i --a 
184 
Br ?" 
$Ph 
\-~_BO 
Me 
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£
NMeTs 
-----. 
a ii 
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Br£NMeT~ .. 
" III-IV 
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HO 
c;~NMeTs 
HoD 
192 185 
Reagents and conditions: (i) Br2, NEt3; (ii) 191, catechol borane; (iii) Na(Hg), THF, MeOH; (iv) m-
CPBA 
Scheme 21. Parker's asymmetric synthesis of epoxide 185.130 
Overman (1993)131 
Overman published an enantiodivergent approach to both morphine and 
dihydrocodeinone in 1993. As with many other syntheses, Overman coupled together 
the aryl A-ring with C-ring early in the synthesis. The aryl portion started from 
aldehyde 193, which was converted in two steps to ketal 194 (Scheme 22). Lithiation 
and exposure to iodine, followed by acidic hydrolysis and phenol protection afforded 
aldehyde 195. Reaction with dimethylsulfonium methylide formed an epoxide which 
~ 
underwent a Lewis acid-catalyzed rearrangement to construct homologous aldehyde 
196. Overman formed the coupling partner 202 using an asymmetric Mannich 
reaction which he developed in 1993.132 First, the commercially available 2-
allylcyc1ohex-2-enone (197) was selectively reduced using catecholborane (R)-
oxazaborolidine 198 to afford alcohol 199, an intermediate in the synthesis of (-)-
morphine (natural isomer). The (S)-isomer of oxazaborolidine 198 could just as easily 
been used to provide an intermediate in the synthesis of (+ )-morphine (unnatural 
isomer). Alcohol 199 was condensed with phenyl isocyanate, and the resulting 
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intermediate was oxidized with osmium tetroxide to provide a diol which was then 
protected as its acetonide. Carbamate 200 was reacted with n-butyl lithium in the 
presence of CuI(PPh3)z, and then treated with PhMe2SiLi to provide allylsilane 201. 
Acidic hydrolysis of the acetonide and subsequent reductive amination with 
dibenzosuberylamine (DBS-NH2) and sodium cyanoborohydride provided coupling 
partner 202. 
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MeO OMe 
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o H QH QCONHPh 
CYn-1-v~-i~---~~ ~~~~~HDBS 
197 199 200 SiMe2Ph SiMe2Ph 
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DBS= 
Reagents and conditions: (i) HC(OMe)3, HCI; (ii) NaH, CICH20Me; (iii) n-BuLi, 12; (iv) 6N HCI; (v) 
BnBr, K2C03; (vi) CH2SMe2; (vii) BF3"Et20, THF; (viii) 198, catechol borane; (ix) PhN=C=P; (x) 
OS04, NMO, (CH3hCO, H+; (xi) a) n-BuLi, THF, -30°C; b) Cul(PPh3b DoC; c) PhMe2SiLi, DoC; (xii) 
p-TsOH, NaI04, MeOH; (xiii) DBS-NH2' NaCNBH3. 
Scheme 22. Overman's synthesis of morphine precursors 196 and 202. 131 
Reaction between aldehyde 196 and homoallylic amine 202 in the presence of 
zinc(II)iodide gave octahydroisoquinoline 204 as a 20: 1 mixture of diastereomers. 
The selectivity of the reaction results from a preferential approach of an (E)-iminium 
ion intermediate 203 to the cyclohexenylsilane ring from the face opposite to the silyl 
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group. Heck cyclization using Pd(OCOCF3h(PPh3)2 gave the unsaturated morphinan 
205. Removal of the benzyl ether, followed by treatment of the resulting phenol with 
camphorsulfonic acid and 3,5-dinitroperoxybenzoic acid, afforded 206. Oxidation and 
hydrogenolysis of the DBS group provided dihydrocodeinone (171) a formal product 
in the synthesis of morphine and other opium alkaloids. 
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'~~ ;POM' ~\ 
mHOBS+ 
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BnO ~ \:~:;.-- H OBn 
SiMe2Ph OMe c& OMe 202 196 203 204 
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Reagents and conditions: (i) ZnI2' EtOH, 60°C; (ii) Pd(OCOCF3h(PPh3h, PMP, PhMe, 120°C; (iii) 
c;; 
BF)"Et20, EtSH; (iv) 3,5-(N02hPhC03, campS03H, DCM, O°C;(v) TPAP, NMO; (vi) H2, Pd(OHh, 
HCHO. 
Scheme 23. Overman's formal synthesis of morphine. 131 
Trost (2002)133 
Trost's asymmetric allylic alkylation (AAA) procedure has been extensively 
used in the synthesis of many natural productS.134 In 2002, Trost applied this 
methodology to the synthesis of morphine. The synthesis begins with the reaction of 
glutaraldehyde (207) with a Horner-Wadsworth-Emmons reagent to provide a 
cyclohexenol derivative which was protected as its 2,2,2-trichlorethoxycarbonate. The 
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palladium-catalyzed AAA reaction between acrylate 208 and phenol 210 was 
performed in the presence of diphosphine ligand 109. This method provided the 
coupled product 211 with an e.e. of 96%. 
207 
MeOQ 
I 0 HO .0..-:: 
209 
i-ii 
-
iii 
-
208 
I 0 Meo~ HO .0 ..-:: 
Br 
210 
iv 
211 
Reagents and conditions: (i) methyl 2-(dimethoxyphosphoryl)acetate, K2C03, H20; (ii) Troc-CI, 
pyridine, DoC; (iii) Br2, AcOH, NaOAc, r.t.; (iv) 109, % [{(Tj3-C3H5)PdCI}z], NEt3, DCM, r.t. 
Scheme 24. Trost's synthesis of codeine intermediate 211. l33, 135 
Aldehyde 211 was protected as a dimethoxy ketal prior to ester reduction with 
diisobutylaluminum hydride. Allylic alcohol 212 was reacted with acetone 
cyanohydrin in a modified Mitsunobu reaction to afford nitrile 214 after acidic 
hydrolysis of the ketal. A palladium(II)acetate catalyzed Heck reaction fOJimed the C-
13/ C-14 bond and three of the rings in morphine. The synthetic route to 
benzaldehyde 214 had been previously described by Trost when it was used in the 
synthesis of (-)-galanthamine.135 Olefination of benzaldehyde 214, followed by 
chemoselective reduction of the (E)-vinyl bromide, produced cyclization substrate 
215. A second Heck reaction, also catalyzed by palladium(II)acetate, formed the D-
ring. Allylic oxidation with selenium dioxide proceeded at the least hindered position 
(C-6) to provide a ketone. Treatment with diisobutylaluminum hydride and then 
methylamine was followed by a sodium borohydride reduction. This sequence 
55 
furnished the N-methyl amine and allylic alcohol functionalities in advanced 
intermediate 217. Irradiation with a 150W tungsten lamp effected the closure of the 
piperidine ring and completed the synthesis of codeine, which can be demethylated 
using a procedure developed by Rice136 to give morphine. 
Me~ MeOp M~~ M~~ I ~ ..-:;0 I~ I ~ ..-:;0 I ~ ..-:;0 i-ii CH(OCH3l2 .... 
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Reagents and conditions: (i) p-TsOH, CH(OMe)3, MeOH; (ii) DIBAL-H, PhMe, -78°C; (iii) PPh3, 
acetone cyanohydrin, DIAD, Et20; (iv) p-TsOH, THF, HzO; (v) Pd(OAc)z, dppp, AgZC03, PhMe, 
107°C; (vi) CBr4, PPh3, DCM; (vii) Pd(PPh3)4, n-Bu3SnH, PhCH3; (viii) Pd(OAc)z, dppp, AgZC03, 
PhMe; (ix) a) Se02, dioxane, sand, 75°C; b) DMP, r.t.; (x) a) DIBAL-H, DCM, EtzO; b) NH4Br, 
MeNH2; c) NaBH4; (xi) LDA, THF, 150W tungsten bulb; (xii) BBr3, DCM, r.t. 
Scheme 25. Trost's synthesis of morphine. 133 
Fukuyama (2006)137 
In a similar manner to Overman,131 Fukuyama employed a Mannich-type 
reaction in the synthesis of morphine. The synthesis begins with the preparation of 
two coupling pieces, 220 and 221. The former was prepared in a three step procedure 
from ketal 218, while the latter was previously synthesized by Fukuyama (Scheme 
26).138 This preliminary study employed racemic 221, although a chiral version has 
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also been prepared. Treatment of phenol 220 with a palladium-ligand complex 
initiated its 1,4-addition to epoxide 221 and provided ether 222. 
MeO MeO MeO 221 
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MeO OMe 
j~~BS 
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Meo~ ?Me 
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----'-'---" 0 I 
'.,· ... ~OTBS 
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Reagents and conditions: (i) AcOH, THF, H20, O°C; (ii) MeOCH2PPh3Cl, NaHMDS, THF; O°C; (iii) 
HCl, MeOH, 40°C; (iv) Pd2(dbah, P(2-furyl)3, MeCN, r.t. 
Scheme 26. Fukuyama's synthesis of morphine intermediate 222.137-138 
A Mitsunobu reaction between p-nitrobenzoic and allylic alcohol 222, 
desilylation and a second Mitsunobu with 2-hydroxy-2-methylpropanenitrile provided 
nitrile 223 (Scheme 27). Ester hydrolysis and silylation of the resulting hydroxyl were 
performed prior to nitrile reduction and methyl carbamate formation. The next step 
was an intramolecular Heck coupling which provided a silyl enol ether that was 
immediately treated with tetra-n-butylammonium fluoride under basic c6nditions to 
afforded ketone 225; Closure of the Band D-rings was accomplished in a single step 
by heating ketal 225 in methanolic hydrogen chloride; a transformation which 
Fukuyama believed to proceed through a Mannich-type reaction. Using a procedure 
developed by Itoh and Saegusa,139 ketone 226 was converted to its silyl enol ether 
derivative and then treated with palladium(II)acetate. The resulting enone was 
oxidized with hydrogen peroxide to produce epoxide 227. Treatment with sodium 
borohydride yielded an alcohol which was converted into its thiocarbamate 
derivative. Exposure to radical conditions induced an epoxide opening reaction and 
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Barton-McCombie deoxygenation to yield allylic alcohol 228, which was then 
oxidized with Dess-Martin periodinane. Treatment with lithium aluminum hydride 
reduced both the ketone and methyl carbamate functionalities to provide codeine, 
which was easily demethylated using Rice's boron(III) bromide procedure136 to give 
morphine. 
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Reagents and conditions: (i) p-nitrobenzoic acid, DEAD, PPh3, PhMe, THF, DoC; (ii) CSA, MeOH; 
(iii) 2-hydroxy-2-methylpropanenitrile, DEAD, PPh3, PhMe, DoC; (iv) LiBH4' EtzO, MeOH, DoC; (v) 
TBS-CI, imidazole, DMF, r.t.; (vi) a) DIBAL-H, DCM, -78°C; b) NaBH4, MeOH, -78°C; (vii) 
CICOzMe, KZC03; (viii) a) Pdz(dba)3, P(o-toly1)3, NEt3, MeCN, reflux; b) TBAF, r.t.; (ix) HCI, MeOH, 
reflux; (x) TMS-CI, LHMDS, THF, DoC; (xi) Pd(OAch, MeCN, r.t.; (xii) HzOz, HzO, NaOH, MeCN, 
DoC; (xiii) NaBH4, MeOH, DCM; (xiv) TCDI, DMAP, CICH2CH2CI, 60°C; (xv) Et3B, n-Bu3SnH, 
THF, r.t.; (xvi) Dess-Martin periodinane, DCM, r.t.; (xvii) LiAIH4' THF; (xviii) BBr3, DCM, r.t. 
Scheme 27. Fukuyama's synthesis of morphine. 137 
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Hudlicky's Radical Cyclization Approach (1996i40-3 
In parallel to Parker's efforts,128-30 Hudlicky has developed several approaches 
to the morphine skeleton via a radical cyclization. In each instance, the chirality of the 
starting materials arose from the enzymatic cis-dihydroxylation of an aryl substrate. 
The first approach discussed employs the 1,2-diol metabolite of I-bromo-2-(2-
bromoethyl)benzene (229) (Scheme 28). Selective reduction of the unsubstituted 
olefin using potassium azodicarboxylate (PAD) under acidic conditions provides diol 
230. Acetonide protection was followed by displacement of the alkyl bromide with 
oxazol-2(3H)-one. Exposure of vinyl bromide 231 to n-tributyltin hydride, and then 
an acidic Dowex resin (50X8-100), afforded a 2: 1 mixture of 232a and 232b. The 
synthesis continued with the latter because of its relative abundance to the former, 
even though it contains the unnatural stereochemistry seen in morphine. Protection of 
the homoallylic hydroxyl with tert-butyldimethylsilyl trifluoromethanesulfonate was 
followed by a Mitsunobu coupling reaction with the allylic hydroxyl and phenol 233. 
An intramolecular radical cyclization between the aryl bromide and olefin of 234 
proceeded with excellent stereospecificity providing only diastereomer 235. 
Reduction of the dihydrooxazolone ring with DIBAL-H, desilylation, and Swern 
oxidation afforded a keto aldehyde intermediate 236 which was immediately treated 
with trifluoromethanesulfonic acid to initiate closure of the D-ring. Reduction of 
ketone 237 and epimerization of the C-14 position144 would provide ent-codeine or 
ent-morphine upon demethylation. If carbamate 235 is reduced directly, the resulting 
hydroxyl 238 serves as another means of forming the ClO-Cll bond after mesylation 
and displacement. 
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Reagents and conditions: (i) E. coli JM109 (pDTG602); (ii) PAD, AcOH, MeOH; (iii) 2,2-DMP, p-
TsOH; (iv) oxazol-2(3H)-one, NaH, DMSO; (v) n-Bu3SnH, AIBN, PhH, reflux; (vi) DoJ'ex 50XS-lOO, 
MeOH, H20; (vii) TBDMS-OTf, i-Pr2NEt, THF, -7SoC; (viii) 233, DEAD, n-Bu3P, THF, DoC; (ix) n-
BU3SnH, AIBN, PhH, reflux; (x) TBAF, THF; (xi) DIBAL-H, DCM, DoC; (xii) CICOCOCl, DMSO, 
NEt3, DCM, -7SoC to DoC; (xiii) CF3S03H; (xiv) MsCl, NEt3, THF; (xv) AICb, PhH, reflux. 
Scheme 28. Hudlicky's approach to the morphine skeleton.140 
Hudlicky's second radical cyclization approach began with the toluene 
dioxygenase mediated dihydroxylation of (2-bromoethyl)benzene (240) (Scheme 29). 
As with the first approach, diazene reduction occurs on the unsubstituted alkene to 
provide 1,2-diol 241. Silylation of the homoallylic alcohol and Mitsunobu inversion 
of the allylic hydroxyl with benzoic acid afforded 242. Displacement of the alkyl 
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halide with oxazol-2(3H)-one and basic ester hydrolysis produced allylic alcohol 243. 
A second Mitsunobu reaction with phenol 233 provided ester 244. Radical cyclization 
was effected with tris(trimethylsilyl)silane and azobisisobutyronitrile to afford 
pentacycle 245a, and evidence for the formation of 245b. The method to close the D-
ring previously employed by Hudlicky would complete the morphine skeleton. 
HO" 
HO" 
240 
&sr :-<:::: ~ SzO........... . £ sr £N~ HO W TSSO'" -<:::: 
241 
-..; V-VI 
TSSO'" -
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233 
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vii 
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0." ~ r- ,/0 viii Q-sr NJ: 
-'~N 
TSSO"'V "H ' 
MoO 0.,: r "",,0 
TSDMSO"l) 
245a 244 
Reagents and conditions: (i) E. coli JM109 (pDTG602); (ii) PAD, AcOH, MeOH; (iii) TBS-OTf, i-
Pr2NEt, THF, -78°C; (iv) PhC02H, n-Bu3P, DEAD, THF; (v) oxazol-2(3H)-one, Na~ DMSO; (vi) 
NaOH, H20; (vii) 233, n-Bu3P, DEAD, THF; (viii) (TMS)3SiH, AIBN, PhH, 140°C, sealed tube. 
Scheme 29. Hudlicky's second approach to morphine skeleton. 142 
Hudlicky's Heck Cyclization Approach (1999)143,145-9 
In addition to the radical cyclization approach, Hudlicky also explored the 
possibility of an analogous Heck reaction to form the C 12-C 13 bond. The first route 
discussed begins with the cis-dihydrodiol obtained from the oxidation of (2-
bromoethyl)benzene (Scheme 30). Olefin reduction provided 1,2-diol 241 which was 
first treated with N,N -dicyclohexylcarbodiimide/ benzoic acid and then oxazolidine-
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2,4-dione to furnish alkene 246. Selective reduction with sodium borohydride and 
treatment with aluminum chloride effected a cyclization reaction to provide 
carbamate 247. Chloride elimination with 1,8-diazabicyclo[S.4.0]undec-7-ene and 
basic ester hydrolysis yielded diol 248. 
Sr 
HO',: C HO"O 
241 246 
QH 
"='"- HO"CQr 
248 
i-ii 
-
Reagents and conditions: (i) PhC02H, DCC, DCM; (ii) oxazolidine-2,4-dione, tetramethylguanidine, 
THF, reflux; (iii) NaBH4' MeOH; (iv) AICI3, DCM; (v) DBU, DMSO, reflux; (vi) LiOH, MeOH. 
Scheme 30. Hudlicky's synthesis of isoquinoline derivative 248. 143,145 
The homoallylic hydroxyl of 248 was protected with 4-toluenesulfonyl 
chloride and a Mitsunobu inversion of the allylic hydroxyl with benzoic acid provided 
249 (Scheme 31). Basic hydrolysis with sodium methoxide initiated the formation of 
vinyl epoxide 250. Regioselective opening with potassium salt 251, and protection of 
the resulting hydroxyl as its tert-butyldimethylsilyl ether, afforded 25~. A Heck 
. " 
reaction catalyzed by tetrakis(triphenylphosphine)palladium(O) provided pentacyclic 
carbamate 253. Reduction with diisobutylaluminum hydride and desilylation 
furnished dihydroxyl 254. Hydrogenation with Adams' catalyst and double hydroxyl 
oxidation with Swern conditions provided aldehyde 255. Treatment with 
trifluoromethanesulfonic acid closed the D-ring and produced hydroxyl 256. As 
previously described, this compound can be easily converted (-)-morphine. 
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Reagents and conditions: (i) TsCI, pyridine, DMAP; (ii) PhC02H, PPh3, DEAD, THF; (iii) MeONa, 
MeOH, THF; (iv) 251, DME, 18-crown-6; (v) TBS-OTf, , i-Pr2NEt, DCM; (vi) Pd(PPh3)4, Proton 
Sponge™, PhMe; (vii) DIBAL-H, DCM; (viii) TBAF, THF;(ix) H2, Pt02, AcOH;c (x) (COCI)z, 
DMSO, NEt3, DCM; (xi) CF3S03H. 
Scheme 31. Hudlicky's third approach to morphine skeleton. 148 
In 2007, Hudlicky employed two intramolecular Heck cyc1izations in the total 
synthesis of (+ )-codeine. 147 This synthesis exploits the same 1,2-diol 241 discussed in 
previous approaches (Scheme 32). The diacetate derivative 257 was treated with 
methylamine and then di-tert-butyl dicarbonate. This sequence displaced the bromide, 
protected the resulting secondary amine and hydrolyzed the acetates. Silylation of the 
distal hydroxyl provided allylic alcohol 258, which was reacted with phenol 259 
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under Mitsunobu conditions to afford aryl bromide 260. The first Heck reaction, 
catalyzed by palladium(II) acetate, formed the dihydrofuran E-ring. The resulting 
aldehyde 261 was converted to vinyl bromide 262 via a Wittig reaction. The second 
Heck cyclization closed the B-ring and provided tetrahydrophenanthrene derivative 
263. Removal of the silyl group revealed a hydroxyl which was inverted by a 2-
iodoxybenzoic acid oxidation! borohydride reduction procedure. Hydrolysis of the 
tert-butyl carbamate 264 provided a secondary amine suitable for the final ring 
closure. Oxymercuration of the styrene olefin produced a mercurium ion which was 
quenched by attack of the ethylamino group on the C-9 position. Subsequent 
reduction with LAH completed the total synthesis of (+)-codeine (4). 
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Reagents and conditions: (i) AC20, NEt3, DMAP, DCM, ODC; (ii) a) MeNH2, K2C03, THF, _40DC to 
r.t.; b) (BochO, NEt3, MeOH; (iii) TBS-CI, imidazole, DCM, -78DC to r.t.; (iv) n-Bu3P,,,DIAD, THF, 
ODC; (v) Pd(OAch, Ag2C03, dppf, PhMe, 11ODC; (vi) PPh3CH2Br2, t-BuOK, THF, -60DC; (vii) 
Pd(OAch, Ag2C03, dppp, PhMe, llODC; (viii) TBAF, THF, r.t.; (ix) IBX, DMF, r.t.; (x) NaBH4, 
CeCh'7H20, MeOH, ODC; (xi) TFA-DCM (1:4), ODC; (xii) a) Hg(OAch, NEt3, THF; b) LiAlH4' r.t. 
Scheme 32. Hudlicky's synthesis of ( + )-codeine. 147 
Hudlicky also synthesized the natural (-)-isomer of codeine from the same 
1,2-diol 241, demonstrating the enantiodivergent character of this approach. In this 
synthesis, displacement of the bromide with methylamine and subsequent tert-butyl 
carbamate protection provided diol 265 (Scheme 33). Protection of the distal 
hydroxyl with 4-toluenesulfonyl chloride and Mitsunobu inversion of the allylic 
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hydroxyl with 4-nitrobenzoic acid yielded ester 266. Exposure to sodium methoxide 
hydrolyzed the ester and formed vinyl epoxide 267. Regioselective ring opening with 
potassium salt 268 and subsequent silylation of the C-6 hydroxyl afforded ether 269. 
This compound is identical to 260 (Scheme 32) except for the sign of its optical 
rotation. 
CBr HO", ~ , .. 1-11 -HO'" HO"'CNMeBociii_iV -HO'" 
241 265 
~ 
X:&NMeBOC 
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267 
Meo~ 
KOYCHO 
Br 
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vi-vii 
Meo~ 
~CHO 
0, Br 
"",·A\NMeBoc 
TBsoN I 
Reagents and conditions: (i) AC20, NEt3, DMAP, DCM, ODC; (ii) a) MeNH2, K2C03, THF, _40DC to 
r.t.; b) (BochO, NEt3, MeOH; (iii) TsCI, NEt3, DMAP, DCM, ODC to r.t.; (iv) 4-nitrobenzoic acid, 
DIAD, PPh3, THF, ODC; (v) NaOMe, MeOH, ODC; (vi) 268, 18-crown-6, DME-DMF (1:1); 80DC; (vii) 
TBSCI, imidazole, DCM. 
Scheme 33. Hudlicky's synthesis of (-)-codeine.149 
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3. Results and Discussion 
3.1 Formal Enantiodivergent Synthesis of Balanol 
3.1.1 Formal Synthesis of (+)-Balanol 
In 2008, the Hudlicky group published a formal enantiodivergent synthesis of 
(+ )-and (-)-balanol (3) from 1,3-cyc1ohexadiene oxide.61 ,2 The synthesis intercepted 
the bis-benzyl-protected intermediates 119a and 119b from the Lampe and Hughes 
route.65 Although several formal syntheses employing these intermediates have been 
published,65-7, 81 none reported optical data. Our own samples of 119a and 119b were 
in -95% enantiomeric excess, as determined by the Mosher ester/ 19F NMR method. 
Each suffered from cross contamination of the opposite enantiomer, resulting from 
the incomplete separation of benzoate diastereomers 116a and 116b near the 
beginning of the synthesis (see Section 2.2.3, Scheme 15). Hence, we sought to 
design a second enantiodivergent synthesis of balanol, one which would provide 
accurate optical data for the intermediates in question. The synthesis will make use of 
the cis-dihydrodiol 5 obtained from the chemoenzymatic dihydroxylation of 
bromobenzene by the toluene dioxygenase enzyme. 18 The optical purity of this 
compound has been confirmed through its use in several enantioselective syntheses of 
naturally occurring products. 1 We envisioned an enantiodivergent route to (+)- and (-
)-balanol (3) proceeding thorough vinyl aziridines 6 and 7 respectively (Figure 21). 
Opening of each aziridine with an oxygen nuc1eophile will generate the necessary 
trans-stereochemistry seen in the targets. Reduction of the vinyl bromide moiety and 
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an oxidative cleavage/ reductive amination protocol with benzylamine provides 
access to the formal compounds 119a and 119b. 
PH QR o-~~."= NR (+)-balanol (3) ====> O:::R ====> .,J).'OR , 
Bn 0 
OH OR 
119b 271 6 D Br . "'OH 
OH 
5 
OH OR d"~o." 6:"NHR .,,~R ~ (-)-balanol (3) ====> 
BrD"'OR 
~ ~ ====> ====> 
~n 0 : "OH 
OH OR 
119a 272 7 
Figure 21. Retrosynthetic analysis of an enantiodivergent route to (+)- and (-)-
balanol (3) 
Our approach to the (+)-balanol intermediate 119a began with the preparation 
of tosyl-aziridine 273, a compound utilized by the Hudlicky group in the 
enantioselective synthesis of (+)-pancratistatin.33 Our first attempts to open the 
aziridine used acetic acid as the oxygen nucleophile (Scheme 34). We found that 
v 
copper(II) trifluoromethanesulfonate and boron trifluoride etherate did provide the 
desired trans-product 274, albeit in modest yields (Table 1). The best results were 
seen when trimethylsilyl trifluoromethanesulfonate was used as the catalyst. A slight 
increase in yield was observed when five equivalents of acetic acid were used instead 
of one. 
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NTs 
aziridine QAc 
j)~ Br~"'o .,)j'b opening D NHTS ii with AcOH -- ~ Br : "'OH Table 1 Br : "0 
OH 6~ 6~ 6~ 
5 272 273 274 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, Lt.; (ii) PhI=NTs, Cu(acac)2, MeCN, DoC, 
77% over 2 steps 
Scheme 34. Opening of aziridine 273 with acetic acid 
Table 1. Opening of aziridine 273 with acetic acid 
Entry 
1 
2 
3 
4 
Catalyst 
Cu(OTfh 
BF3'OEt2 
TMSOTf 
TMSOTf 
Solvent 
DCM 
DCM 
DCM 
DCM 
Equiv. AcOH 
1 
1 
1 
5 
Yield (%) 
63 
55 
74 
77 
We sought to reduce the vinyl bromide functionality through use of a hydrogenation 
protocol (Figure 22). Several catalysts were screened with the hope of obtaining the 
saturated product 275a. The first attempts (Table 2, Entries 1 and 2) did not reduce 
the vinyl halide, but did epimerize the O-acetyl functionality. All other catalysts 
screened reduced the vinyl bromide. Unfortunately, each provided a mixture of cis 
and trans- O-acetyl products, 275a and 275b. We observed the formation of a third 
compound, hydrogenolysis product 276, for all but two experiments (Table 2, Entries 
5 and 6). Complete separation of the compounds via flash column chromatography 
proved difficult. Hence, we decided to explore other options. 
QAc QAc OAc 
D NHTS vinyl halide 0:NHTS aNHTS a NHTS reduction + + Br : "0 Table 2 : "0 : 0 : 0 
6~ 6~ 6~ 6~ 
274 275a 275b 276 
Figure 22. Reduction of vinyl bromide 274 
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Table 2. Reduction of vinyl bromide 274 
Entry Catalyst Reagent Solvent Ratio 275a:275b:276[a] 
1 RU3(CO)12 MeOH _[b] 
2 Raney Ni MeOH _[b] 
3 5% Pdf C MeOH 3:1:5 
4 Pd(OAch MeOH 2:5:8 
5 Pt02 MeOH 7:3 
6 Pt02 EtOH 8:3 
7 Pt02 K2C03 EtOH 6:1:3 
8 Pt02 NEt3 EtOAc 4:1:5 
tal approximate ratio determined from IH NMR spectra; [bl recovered starting with epimerized OAc 
We questioned whether the steric andf or electronic affects of the acetonide attributed 
to the unfavourable results. Deprotection was accomplished by loading acetonide 274 
on silica gel, then removing the solvent and heating to 50°C; a reaction easily 
performed on a rotary evaporator (Scheme 35). We tested the resulting 1,2-diol 
substrate 277 against the same conditions used for acetonide-protected product 274 
with remarkably similar results (Table 3). The most favourable result, a 7:3 ratio of 
diastereomers, was achieved with Adams' catalyst in ethanol. Once again, complete 
separation of the mixture proved troublesome. 
QAc QAc 
: NHTs : NHTs 0~0 Br~"'o Br~"'oH 
b~ OH 
274 277 
vinyl halide 
reduction 
Table 3 
Reagents and conditions: (i) Si02, 50°C, 81 % 
QAc 
CX
· . NHTs + 
. "OH 
OH 
278a 
Scheme 35. Hydrogenation of vinyl bromide 274 
OAc 
~NHTS + "CXNHTS 
V"'OH : "OH 
OH OH 
278b 279 
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Table 3. Hydrogenation of vinyl bromide 277 
Entry Catalyst Reagent Solvent Ratio 278a:278b:279[a] 
1 RU3(CO)12 MeOH [b] 
2 Raney Ni MeOH _[b] 
3 5% Pdf C MeOH 3:2:5 
4 Pd(OAc)z MeOH 3:1:8 
5 Pt02 MeOH 3:1 
6 Pt02 EtOH 7:2 
7 Pt02 K2C03 EtOH 4:2:5 
8 Pt02 NEt3 EtOAc 4: 1:5 
La] approximate ratio determined from IH NMR spectra; Lb] recovered starting with epimerized OAc 
We speculated that the acetyl group hydrolysis product of 274 might be a better 
substrate for our hydrogenation procedures. We screened a series of basic hydrolysis 
procedures with the hope that allylic alcohol 280a could be isolated (Figure 23). 
Hydrolysis with potassium or sodium carbonate salts occurred smoothly, but 
epimerized the hydroxyl group to a 4: 1 ratio of trans- and cis-products (Table 4, 
Entries 1 and 2). The isolated yields of the sodium and potassium hydroxide 
experiments were lower, and also epimerized the allylic alcohol group. 
QAc 
0 NHTS 
BrAyJ"'O 
b~ 
274 
hydrolysis 
Table 4 
OH 
Do NHTs I + Br ~ "'0 
b~ 
280a 
OH 
)yNHTS 
Br~"'o t;: 
b~ .. 
280b 
Figure 23. Hydrolysis of acetate 274 
Table 4. Hydrolysis of acetyl 274 
Entry Reagent Solvent Temp. Yield Ratio 280a:280b[a] 
1 K2C03 MeOH ODC - r.t. 82% 4:1 
2 Na2C03 MeOH ODC - r.t. 88% 4:1 
3 NaOH MeOH ODC - r.t. 67% 7:2 
4 KOH MeOH O°C - r.t. 61% 8:3 
La] approximate ratio determined from !H NMR spectra 
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At this stage we chose to pursue a two-step reduction route. Specifically, reduce the 
carbon-bromide bond and then reduce the olefin. We selected a radical debromination 
procedure to accomplish the first step (Figure 24). Our procedure used tributyltin 
hydride in the presence of the radical initiator azobisisobutyronitrile (AIBN). We ran 
three experiments, differing only in concentration (Table 5). Each afforded a mixture 
of the trans- and cis-isomers, 281a and 281b respectively. A concentration of 1.0 M 
provided an excellent ratio of 15: 1 in favour of the trans-isomer. However, we were 
unable to completely separate the isomers (GeIMS analysis). 
OAc 
:- radical 
,aNHTS debromination I • Br 0 "'0 Table 5 
6i--
QAc 
0:: NHTs I + ", 
o 0 6i--
OAc 
aNHTS 
o 0 6i--
274 281a 281b 
Figure 24. Radical debromination of 274 
Table 5. Radical debromination of 274 
Entry Reagents Solvent Concentration[a] Ratio 281a:281b [b] 
1 BU3Sn-H, AIBN THF 0.5 M 
2 BU3Sn-H, AIBN THF 1.0 M 
3 BU3Sn-H, AIBN THF 2.0 M 
tal concentration of BU3Sn-H; tbl approximate ratio determined from IH NMR spectra 
3:1 
15:1 
8:1 
In order to rule out the steric and! or electronic effects of the acetonide, we tested our 
radical debromination procedures on the free 1,2-diol 277. Once again, three 
experiments were run with varying concentrations of hydride reagent (Table 6). Once 
again we obtained an inseparable mixture of isomers. 
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Figure 25. Radical debromination of 277 
Table 6. Radical debromination of 277 
Entry Reagents Solvent Concentration[a] Ratio 282a:282b [b] 
1 BU3Sn-H, AIBN THF 0.5 M 
2 BU3Sn-H, AIBN THF 1.0 M 
3 BU3Sn-H, AIBN THF 2.0 M 
La] concentration of BU3Sn-H; Lb] approximate ratio determined from IH NMR spectra 
4:1 
8:1 
9:1 
Before continuing with the two-step reduction, we questioned whether the olefin 
functionality could be reduced without the use of a hydrogenation procedure. The 
mixture of diastereomers 281a and 281b, obtained from our first radical 
debromination experiments, were subjected to a reduction procedure using potassium 
azodicarboxylate (PAD) (Figure 26). Only starting material was isolated from these 
experiments, even when a large excess of PAD was used (Table 7). 
OAe OAe 
aNHTS PAD (xNHTS reduction C-> )( • 
: 0 Table 7 : 0 
o~ 0-t--
281 275 
Figure 26. Potassium azodicarboxylate reduction of olefin 281 
Table 7. Potassium azodicarboxylate reduction of olefin 281 
Entry 
1 
2 
La] equivalents of PAD 
Reagents 
PAD,AcOH 
PAD,AcOH 
Solvent 
MeOH 
MeOH 
Equivalents[a] 
4 
20 
Result 
SM 
SM 
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We also tested the mixture of diastereomers 282a and 282b, obtained from our radical 
debromination experiments on 1,2-diol 277 (Figure 27): Once again, the experiments 
did not provide any new products (Table 8). 
OAe 
~NHTS 
V"'OH OH 
282 
PAD 
reduction 
)( 
Table 8 
OAe 
~NHTS 
V"'OH 
OH 
278 
Figure 27. Potassium azodicarboxylate reduction of olefin 282 
Table 8. Potassium azodicarboxylate reduction of olefin 282 
Entry 
1 
2 
tal equivalents of PAD 
Reagents 
PAD,AcOH 
PAD,AcOH 
Solvent 
MeOH 
MeOH 
Equivalents[a] 
4 
20 
Result 
SM 
SM 
Frustrated with the aforementioned results, we decided to abandon any routes that 
would proceed through O-acetyl product 274. Our next strategy was to open tosyl 
aziridine 273 with benzyl alcohol (Figure 28). In principle, the O-benzyl functionality 
could be deprotected during a hydrogenation procedure which simultaneously reduces 
the vinyl halide moiety. We screened different catalysts for their ability ta selectively 
open the vinyl tosyl aziridine. Our first trials, using Cu(OTfh, BF3'OEh, and 
TMSOTf, were capable of facilitating the regioselective opening of aziridine 273 
(Table 9, Entries 1 to 3). However, in each instance a mixture of trans- and cis-O-
benzyl diastereomers were obtained. As with our experiments using acetic acid, 
TMSOTf offered the most favourable ratio (5:1) of epimers. We found complete 
separation of these diastereomers difficult, and thus impractical for a multi-step 
synthesis. We also tried two non-conventional catalysts, namely ~-cyc1odextrin and 
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cerium ammonium nitrate (Table 9, Entries 6 and 7). In each case, no new products 
were formed. 
273 
aziridine 
opening 
with BnOH 
Table 9 
• 
9Bn 
D: NHTs I + Br : -"0 
b-} 
283a 
OBn 
~NHTS 
BrAyJ-"o 
b-} 
283b 
Figure 28. Opening of tosyl aziridine 273 with benzyl alcohol 
Table 9. Opening of tosyl aziridine 273 with benzyl alcohol 
Entry Catalyst Solvent Temp. Ratio (283a:283b Ya] 
1 Cu(OTf)2 DCM r.t. 7:2 
2 BF3·OEt2 DCM r.t. 3:2 
3 TMSOTf DCM r.t. 5:1 
4 p-cyclodextrin MeCN r.t. 
5 p-cyclodextrin MeCN reflux 
6 (N1I4)2Ce(N03)6 MeCN r.t. 
7 (N1I4)2Ce(N03)6 MeCN reflux 
tal approximate ratio determined from IH NMR spectra 
Result 
77% 
74% 
82% 
SM 
SM 
SM 
SM 
At this stage, we questioned whether the tosyl-aziridine functionality could be opened 
after the carbon-bromide bond had been reduced. Treatment of vinyl bromide 273 to a 
tributyltin hydride radical debromination protocol, first reported in r;Hudlicky's 
synthesis of (+)-pancratistatin,33 afforded olefin 54 (Scheme 36). We sought to open 
this aziridine with a hydroxide anion. Our experiments with Cu(OTf)2 and p-
cyclodextrin were unsuccessful, as only starting material was isolated (Table 10, 
Entries 1 to 3). Ceric ammonium nitrate did not produce any new compounds at 
ambient temperature, while elevated temperatures decomposed the starting material. 
Ultimately, we found that an excess of potassium hydroxide in dimethyl sulfoxide 
provided allylic alcohol 284. The reaction is high yielding so long as the temperature 
does not exceed 40°C. 
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NTs d~' 
.';:)"0 i -- : 0 6-} 6-} 
273 54 
Reagents and conditions: (i) BU3Sn-H, AIBN, THF 
Scheme 36. Opening of vinyl aziridine 273 
Table 10. Opening of vinyl aziridine 273 
9H 
aziridine 0:NHTS opening .. Table 10 
: 0 6-} 
284 
Entry Reagents Solvent Temp. Result 
1 Cu(OTf)2 MeCN/ H20 r.t. SM 
2 p-cyc1odextrin MeCN/ H20 reflux SM 
3 p-cyc1odextrin acetone/ H20 reflux SM 
4 (NH4)2Ce(N03)6 acetone/ H20 r.t to reflux decomposition[a] 
5 KOH DMSO 80°C 284 (27%) 
6 KOH DMSO 40°C 284 (93%) 
La] no new products observed at r.t. (TLC monitoring), while multiple spots (<10) observed at elevated 
temperatures (i.e. > 50°C) 
Our next goal was to study the reduction of the olefin functionality. Previously, we 
had hypothesized that a free hydroxyl group would prevent epimerization during a 
hydrogenation reaction. Now we could test our theory using allylic alcohol 284 as a 
substrate (Figure 29). Our first experiments used 5% palladium on carbon, either in 
the presence or absence of triethylamine (Table 11, Entries 1 and 2). Our hypothesis 
proved correct, as we were able to isolate the saturated product 285 without any 
evidence of its epimer. Our last two experiments used Adams' catalyst and either 
triethylamine or potassium carbonate as the basic additive. We observed a substantial 
increase in isolated yield, particularly when the latter base was used. 
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olefin 
hydrogenation 
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Table 11 
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Figure 29. Hydrogenation of olefin 284 
Table 11. Hydrogenation of olefin 284 
Entry Catalyst Reagent Solvent 
1 5% Pdf C MeOH 
2 5% Pdf C NEt3 MeOH 
3 Pt02 NEt3 MeOH 
4 Pt02 K2C03 MeOH 
tal lower yield possibly a result of hydrogenolysis (1 H NMR evidence) 
Yield (%) 
44[a] 
54[a] 
86 
92 
We were pleased with these results, but questioned whether we could avoid the 
radical debromination step and thus reduce the route to 285. We decided to test our 
KOH aziridine opening procedure on the vinyl bromide substrate 273 (Figure 30). 
One again, we varied the temperature in different experiments and concluded that a 
lower temperature offered a higher yield (Table 12). 
273 
aziridine 
opening 
Table 12 
QH 
,0: NHTs I . 
Br : -"0 
o~ 
280a 
Figure 30. Opening of tosyl aziridine 273 with hydroxide 
Table 12. Opening of tosyl aziridine 273 with hydroxide 
Entry 
1 
2 
Reagents 
KOH 
KOH 
Solvent 
DMSO 
DMSO 
Temp. Yield (%) 
40 
94 
77 
Finally, we employed our Adams' catalyst hydrogenation procedures to vinyl 
bromide 280a (Figure 31). As with the unsubstituted olefin 284, the addition of 
potassium carbonate afforded the highest isolated yield (Table 13). 
QH 
~NHTS 
Br-Y"'o b-} 
280a 
olefin 
hydrogenation 
• 
Table 13 
286 
Figure 31. Reduction of vinyl bromide 280a with Adams' catalyst 
Table 13. Reduction of vinyl bromide 280a with Adams' catalyst 
Entry 
1 
2 
Catalyst Reagent Solvent 
MeOH 
MeOH 
Yield (%) 
75 
77 
Our group's first generation formal synthesis of ( +)- and (-)-balanol employed 
a cyclic carbamate moiety as a means of simultaneously protecting both the oxygen 
and nitrogen atoms.61 -2 Hence, we sought to use a similar strategy in our second 
generational approach. Exposure of cyclohexanol derivative 286 to triphosgene 
furnished N-tosyl carbamate 287 (Scheme 37). A dissolving metal reductign with NaJ 
naphthalene removed the tosyl functionality and provided cyclic carbamate 288. 
QH Q-{O 0 Q-{ 
0:NHTS i aNTS ii a NH - -: "0 : 0 : 0 b-} b-} b-} 
286 287 288 
Reagents and conditions: (i) triphosgene, NEt3, DCM, O°C, 93%; (ii) Na/ naphthalene, DME, -78°C, 
92% 
Scheme 37. Synthesis of cyclic carbamate 288 
78 
The next step in the synthesis involved the derivatization of cyclic carbamate 288 
with 4-(benzyloxy)benzoyl chloride (Figure 32). Experiments utilizing nitrogenous 
bases, specifically triethylamine and pyridine, were troublesome (Table 14, Entries 1 
and 2). In those instances, a large excess of acid chloride was required to obtain 
relatively low amounts of product. Fortunately, sodium hydride in tetrahydrofuran 
with 1 equivalent of acid chloride provided the desired amide 289 in excellent yield. 
288 
amide 
formation 
Table 14 
289 
Figure 32. Derivatization of cyclic carbamate 288 
Table 14. Derivatization of cyclic carbamate 288 
Entry 
1 
2 
3 
Base 
NEt3 
pyridine 
NaH 
Solvent 
DCM 
DCM 
THF 
Temp 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
[allow yield a consequence of high amounts of starting material recovered 
" \C 
Result 
20% [a] 
25%[a] 
91% 
Acidic hydrolysis of acetonide 289 with AcOHI THFI H20 afforded 1,2-diol 290 
(Scheme 38). Oxidative cleavage with sodium periodate provided a dialdehyde 
species which was used without purification. A reductive amination protocol with 
benzylamine constructed the azepane core of balanol. Mild basic hydrolysis of the 
cyclic carbamate moiety completed the formal synthesis of ( + )-balanol. 
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OBn pip 
00° o 
289 290 291 
iv 
-
119b 118b 
Reagents and conditions: (i) AcOHITHFIH20 (9:3:1), reflux, 83%; (ii) NaI04, acetone/H20 (8:2), r.t.; 
(iii) Bn-NH2' AcOH, NaBH3CN, 3A mol. sieves, MeOH, -78°C to r.t., 60% over two steps; (iv) IN 
NaOH, THF, _20°C, 56% 
Scheme 38. Formal synthesis of (+ )-balanol 
3.1.2 Synthesis of (-)-Balanol 
As mention previously, we sought to develop an enantiodivergent route to 
both isomers of balanol from cis-dihydrodiol 5. The route to (-)-balanol intermediate 
" 119b, completed with Bradford Sullivan, begins with the aziridinaiion of the 
acetonide derivative of diol 5 using a procedure developed by Corey (Scheme 39).150 
Opening of acetyl-aziridine 292 with acetic acid was followed by reduction of vinyl 
halide moiety with Adams' catalyst. Basic hydrolysis, and then sequential exposure to 
methyl chloroformate and then sodium hydride afforded cyclic carbamate 295. 
Derivatization with 4-(benzyloxy)benzoyl chloride, acetonide hydrolysis and an 
oxidative cleavage/ reductive amination yielded azepane 118a. Basic hydrolysis with 
sodium hydroxide completed the formal synthesis of (-)-balanol. 
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Br~"'OH ~ 
OH 
5 
ix-x 
OH 
296 
118a 
OAc 
iv 
--
0::,NHAC Br~'o 
b~ 
292 293 
vi-viii 
----
295 294 
OH d·"~rO-°B" 
~n 0 
119a 
Reagents and conditions: (i) 2,2-DMP, acetone, p-TsOH; (ii) N-bromoacetamide, SnBr4, MeCN, -
30°C; (iii) KHMDS, n-BuNBr, DME, O°C, 68% over three steps; (iv) AcOH, TMSOTf, DCM, Lt., 
88%; (v) H2 (1 atm), Pt02, EtOAc, 84%; (vi) NaOMe, MeOH, reflux; (vii) methyl chloroformate, 
NEt3, DCM, DMAP, Lt., 73% over two steps; (viii) NaH, THF, reflux, 83%; (ix) p-BnOC6~COCI, 
DCM, DMAP, NEt3, O°C, 82%; (x) AcOHffHFIH20 (9:3:1), reflux, 88%; (xi) a) NaIO~ acetoneIH20 
(8:2), r.t.; b) Bn-NH2, AcOH, NaBH3CN, 3A mol. sieves, MeOH, -78°C to r.t., 64% over two steps; 
(xii) IN NaOH, THF, -20°C, 86% 
Scheme 39. Formal synthesis of (-)-balanol 
The preceding work describes one of the few enantiodivergent routes to 
balanol. Differential aziridination of the acetonide derivative of cis-dihydrodiol 5 
allowed access to both formal intermediates while avoiding the synthesis and 
separation of diastereomers seen in previous enantiodivergent strategies. 
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3.2 Synthetic Approaches to Codeine 
Opium alkaloids are among the most commonly used and important 
pharmaceuticals in medicine. Unfortunately, only a few regions are able to grow the 
poppy plants which produce these drugs in significant amounts. This has left the 
Western world, the predominant users, reliant on only a few countries for their opium. 
One solution to this problem would be the development of a fully synthetic route to 
these drugs from readily available materials. Although many elegant syntheses of 
opium alkaloids have been developed, not one is practical enough to supplant the 
natural sources. One of the goals of the Hudlicky research group is to develop an 
economically viable and environmentally benign synthetic route to the opium 
alkaloids. The present thesis will outline the most current work by the Hudlicky group 
on the synthesis of (+)-codeine (Figure 33). 
(+)-codeine (4) 
Figure 33. Carbon numbering and ring nomenclature of ( + )-codeine. 
All of the strategies discussed commence with the TDO-mediated 
dihydroxylation of (3-bromoethylbenzene. This provides large quantities of 
enantiomerically pure cis-dihydrodiol 8, the carbon source for the C and D-rings of 
(+ )-codeine (Figure 34). A Mitsunobu reaction with an arene substrate can be used to 
fasten the A-ring and install the ether linkage. The C12 and C13 bond, and hence the 
E-ring, can be formed via an intramolecular Heck coupling reaction. The majority of 
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the research discussed in this thesis will focus on the closure of the Band D-rings 
from a cyclohexenone species 298. 
MeO& 1,4-
o ,."-, 
"'\ 
" 
"'H NMe 
HO ,4-
(+)-codeine (4) 298 
1,4-
Meo» 
R 
o Sr 
\,A(\NMeR =:> 
RO"'U I 
297 
Figure 34. Retrosynthetic analysis of (+)-codeine 
3.2.1 Enol Ether Approach 
6sr HO". ~ HO'" ,4-
8 
The first strategy explored utilizes a Mitsunobu coupling reaction between 
allylic alcohol 258 and arene 259, originally described by Hudlicky in 2007. 147 
Synthesis of the 258 commences with the PAD reduction and acetylation of cis-
dihydrodiol 8 (Scheme 40). Treatment with methylamine and K2C03 displaced the 
bromide and produced a secondary amine derivative and simultaneously hydrolyzed 
the acetates. Subsequent exposure to Boc anhydride and triethylamine protected the 
amine. Silylation of the homoallylic hydroxyl with TBS-CI provided C-riitg fragment 
258. 
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&& 5B' aB' aB' 1-':::: i HO", -.:::: ii HO", -.:::: iii ACO,,: -.:::: 
-- -- --~ HO'" ~ HO'" , AcO" 
240 8 241 257 
iv ! 
aNMeBo' aNMeBOO HO", -.:::: v HO", -.:::: -TBSO'" HO'" 
258 265 
Reagents and conditions: (i) E. coli JM109 (pDTG602), 5g/L; (ii) PAD, AcOH, MeOH, -20°C, 60%; 
(iii) AC20, NEt3, DMAP, O°C, 67%; (iv) a) NH2Me, K2C03, THF, sealed tube; b) Boc20, NEt3, DCM, 
O°C - r.t., 50% over two steps; (v) TBS-CI, imidazole, DCM, -78°C - r.t., 88% 
Scheme 40. Synthesis of C-ring fragment 258 
The arene fragment 259 was prepared through the NBS bromination of iso-vanillin 
(299) (Scheme 41). 
MeOn ' 
1 I 
HO ~CHO-
299 
Reagents and conditions: (i) NBS, CHCh, reflux 
Scheme 41. Synthesis of A-ring fragment 259 
MeOIl1 
HOYCHO 
Br 
259 
A Mitsunobu reaction between the A-ring and C-ring fragments afforded ether 
260 (Scheme 42). A palladium(II) acetate catalyzed intramolecular Heck reaction 
closed the dihydrofuran ring and provided 261, a common intermediate in Hudlicky's 
2007 synthesis of ( + )-codeine. 147 
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Meolll 
HOYCHO 
HO". ~ 259 &NMeBOC Br TBSO'" 
258 
Meolll 
/'("CHO 
o Br ' ~NMeBOC 
TBSO"'U I 
260 
Meo~ I 
.4- CHO 
o "', 
. I NMeBoc 
TBSO" 
ii 
-
261 
Reagents and conditions: (i) 259, DIAD, n-Bu3P, THF, ODC - r.t., 55%; (ii) Pd(OAch, Ag2C03, dppf, 
toluene, IIODC, 82% 
Scheme 42. Synthesis of tetrahydrodibenzofuran 261 
We envisioned the final two rings of ( + )-codeine closing from enol ether intermediate 
300 (Figure 35). Treatment with acid should remove the Boc carbamate, hydrolyze 
the enol ether, and tautomerize the cyclohexenone ring. If the secondary amine 
condenses on the aldehyde, the resulting iminium could be attacked by the enol ring 
in order to form the C9-C 14 bond and provide (+ )-codeinone (134), a precursor to 
(+ )-codeine.151 
H+ 
----- .. 
300 
Meo~o 1.4- I 
0 .. ", 
I NHMe 
HO ::::,... 
301 
Band D-ring 
closures 
---------- .. 
134 
Figure 35. Proposed route to close the B- and D-rings from enol ether 300 
Our synthesis of enol ether 300 began by reacting Wittig reagent 302 with aldehyde 
261 to produce 303 as a mixture of cis and trans enol ethers. Desilylation with TBAF 
revealed a cyclohexenol ring that is an oxidation away from our target molecule 300. 
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261 303 304 
Reagents and conditions: (i) chloride salt of 302, n-BuLi, THF, -78°e - r.t., 70%; (ii) TBAF, THF, ooe 
-r.t., 74% 
Scheme 43. Synthesis of cyc1ohexenol304 
We anticipated that the oxidation of hydroxyl 304 would give us the 2-cyc1ohexenone 
or 3-cyc1ohexenone (conjugated) product, or perhaps a mixture of the two. In 
Hudlicky's 2007 (+ )-codeine synthesis, the C6 hydroxyl was oxidized using an 2-
iodoxybenzoic acid (rnX) procedure. When cyc1ohexenol 304 was subjected to 
identical conditions (Table 15, Entry 1) the starting material was decomposed. We 
employed several different oxidation procedures without success. Either we recovered 
the starting material or obtained a complex mixture of compounds. Identification of 
products is complicated by the rotameric nature of the compounds, in addition to the 
presence of cis and trans isomers. Specifically, NMR analysis of a single compound 
,> 
would appear as four compounds; two conformational isomers (rotarrl~rs) of two 
geometric isomers (cis and trans). 
304 
oxidation 
)( 
Table 15 
300 
Figure 36. Attempted oxidation of cyc1ohexenol 304 
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Table 15. Attempted oxidation of cyc1ohexenol 304 
Entry Oxidant Reagent(s) Solvent Temp. Result 
1 IBX DMF r.t. decomposition [a] 
2 IBX DMSO r.t. decomposition [a] 
3 TEMPO KBrlHCIO DCM r.t. SM 
4 DMP DCM decomposition[a] 
5 TPAP NMO DCM O°C-r.t. SM 
6 p- nitrobenzaldehyde AIMe3 
taj complex mixture of unidentifiable compounds 
toluene reflux SM 
When chromate oxidants (i.e. PCC and PDC) were used we isolated benzaldehyde 
305, with the loss of a carbon atom. Strangely, the hydroxyl was not oxidized, even 
when multiple equivalent of chromate was employed. 
304 
chromate 
oxidation 
Table 16 
Meo~ I b h O 
o .,\\ 
. I NMeBoc 
HO" 
305 
Figure 37. Chromate oxidation of enol ether 304 
Table 16. Chromate oxidation of enol ether 304 
Entry 
1 
2 
Oxidant 
PCC 
PDC 
Solvent 
DCM 
DCM 
Temp. 
r.t. 
r.t. 
Result 
305 (67%) 
305 (65%) 
We questioned whether the C6 hydroxyl of 305 could be oxidized to cyc1ohexenone 
306, understanding that the aldehyde could be preferentially homologated with Wittig 
reagent 302 over the ketone. The IBX and Dess-Martin periodinane (DMP) 
procedure we tested decomposed the starting material (Table 17, Entries 1 to 3). The 
chromate and modified Oppenauer oxidation protocols we screened did not produce 
any new products. 
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Figure 38. Attempted oxidation of cyc1ohexenol 305 
Table 17. Attempted oxidation of cyc1ohexenol 305 
Entry Oxidant Reagents Solvent Temp. Result 
1 IBX DMF r.t. decomposition [a] 
2 IBX DMSO r.t. decomposition[a] 
3 DMP DCM r.t. decomposition [a] 
4 PCC DCM r.t. SM 
5 PDC DCM r.t. SM 
6 p- nitrobenzaldehyde AIMe3 toluene reflux SM 
tal complex mixture of unidentifiable compounds 
3.2.2 Aza-Prins Reaction Approach 
The Prins reaction is an effective method for forming carbon-carbon bonds via 
an electrophilic addition between a carbonyl and an alkene. An aza-Prins replaces the 
electrophilic carbonyl with an iminium ion. We envisioned the exposure of enol ether 
304 to TFA resulting in the formation of an iminium-trifluoroacetate salt which could 
be attacked by the C-ring olefin. When we tested our hypothesis, we did not isolate 
the aza-Prins product. However, upon workup we isolated the unstable enamine 307, 
which we immediately reduced with NaCNBH3 to obtain N-methyl piperidine 308 
(Scheme 44). This was strong evidence for the formation of the iminium ion 
intermediate. 
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i 
--
, ii 
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Meow I~ 0 ... ,; ............... NMe 
HO" 
304 307 308 
Reagents and conditions: (i) TFA, DCM, O°C - r.t.; (ii) NaCNBH3, AcOH, MeOH, O°C - r.t., 41 % 
over two steps 
Scheme 44. Synthesis of N-methyl piperidine 308 
We speculated that if the iminium could be trapped as a salt, we could find conditions 
to promote the aza-Prins reaction. To this end, we reacted enol ether 304 with 
perchloric acid and trifluoroacetic acid (Table 18). Unfortunately, these conditions 
decomposed the starting material. 
MeO MeO 
salt 
formation 
)( . 
Table 18 
304 309 
Figure 39. Attempted formation of iminium salt 309 
Table 18. Attempted formation of iminium salt 309 
Entry 
1 
2 
Acid 
3% perchloric acid 
TFA 
Solvent 
DCM 
DCM 
La] complex mixture of unidentifiable compounds 
3.2.3 Ketal Approach 
Temp. Result 
decomposition[a] 
decomposition[a] 
At this stage of the project we elected to abandon the enol ether protected 
aldehyde 303 in favour of a ketal group. We hoped that the lack of cis and trans 
geometric isomers would simplify the identification of any new products produced. 
89 
Furthermore, the enol ether had undergone an undesired reaction with chromate 
oxidants (see Section 3.2.1). Exposure of enol ether 303 to excess ethylene glycol 
promoted the formation of ethylene ketal 310 (Scheme 45). The isolated yield of ketal 
310 was very poor, a consequence of the acid labile Boc and TBS groups. 
Desilylation with TBAF provided cyc1ohexenol 311. 
MeO 
i ii 
-- --
TBSO'" 
303 310 311 
Reagents and conditions: (i) ethylene glycol, p-TsOH, benzene, reflux, 18%; (ii) TBAF, THF, O°C_ 
r.t.,92% 
Scheme 45. Synthesis of ethylene ketal 311 
We questioned whether replacement of the enol ether with an ethylene ketal would 
affect the outcome of the C6 hydroxyl oxidation procedures (Figure 40). We tried 
many of the same oxidation conditions tested on enol ether 304 (Table 19). Once 
again, the hypervalent iodine reagents (i.e. DMP and IBX) decomposed the starting 
material into an inseparable mixture of unidentifiable compounds. The chromate 
oxidants (i.e. PCC and PDC) and TEMPO did not react with the hydroxyl or the ketal. 
311 
oxidation 
)( 
Table 19 
312 
Figure 40. Attempted oxidation of cyc1ohexenol 311 
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Table 19. Attempted oxidation of cyclohexeno1311 
Entry 
1 
2 
3 
4 
5 
6 
Oxidant 
rnx 
rnx 
TEMPO 
DMP 
PCC 
PDC 
Reagents 
KBr/HClO 
[a] complex mixture of unidentifiable compounds 
Solvent 
DMF 
DMSO 
DCM 
DCM 
DCM 
DCM 
Temp. 
, O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
Result 
decomposition [a] 
decomposition[a] 
SM 
decomposition[a] 
SM 
SM 
From the aforementioned results we concluded that the unsuccessful 
oxidations were, in part, caused by either the olefin or the protected aldehyde (ketal or 
enol ether). We elected to try and oxidize the C6 hydroxyl of a substrate lacking an 
oxygenated substituent at Cll and an alkene in the C-ring. We subjected 
benzaldehyde 305, obtained from the chromate oxidation of enol ether 304, to a 
palladium-catalyzed hydrogenation procedure. This reduced the ClO aldehyde and 
olefin functionalities to provide cyclohexanol 313, which was easily oxidized to 
cyclohexanone 314 using rnx (Scheme 46). 
Meo~ 1 9 ....,;0 
o "'\ 
. 1 NMeBoc 
HO" 
i 
-
MeO?8 19 
o "'\ 
. NMeBoc 
HO" 
ii 
-
305 313 314 
Reagents and conditions: (i) 5% Pd/C, H2 (1 atm), MeOH, 54%; (ii) IBX, DMF, O°C - r.t., 77%. 
Scheme 46. Synthesis of cyclohexanone 314 
We attempted this newly developed synthetic route on ketal 311, selected in favour of 
the hydrogenation-labile enol ether 304. As anticipated, reduction of olefin 311 
followed by exposure to rnx afforded cyclohexanone 316. 
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Reagents and conditions: (i) 5% PdlC, Hz (1 atm), MeOH, 82%; (ii) IBX, DMF, O°C - r.t., 85% 
Scheme 47. Synthesis of cyclohexanone 316 
Pleased with these results, we sought to find a method to reintroduce the olefin 
functionality into the C-ring. For our preliminary study, we employed cyclohexanone 
314, simply because we had no other use for this compound. The obvious method for 
reintroduction of the alkene is the oxidation of a silyl enol ether derivative via a 
Saegusa oxidation. Sequential exposure of 314 to LDA and then TMS-CI provided 
silyl enol ether 317 (Scheme 48). Its reaction with Pd(OAc)2 produced enone 318 via 
an oxo-allyl palladium complex. 
Meo~ I~ 
o "'\ 
NMeBoc 
o 
i 
-
Meo~ I~ 
o "'\ 
NMeBoc 
TMSO ~ 
ii 
-
Meo~ I~ 
o "'\ 
NMeBoc 
o ~ 
314 317 318 
Reagents and conditions: (i) a) LDA, THF, -78~C; b) TMS-Cl; (ii) Pd(OAch, MeCN, 76% over two 
steps 
Scheme 48. Saegusa oxidation of cyclohexanone 314 
Fortunately, the Saegusa oxidation of cyclohexanone 314 proceeded as successfully 
as the test substrate. With 320, we finally had an enone A-ring with a latent aldehyde 
at the C9 position. Unfortunately, this synthetic route to enone 320 is not trivial. As 
mentioned previously, the ketal formation from enol ether 303 is a poor yielding 
reaction. 
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Reagents and conditions: (i) a) NaHMDS, THF, -78°C; b) TMS-CI; (ii) Pd(OAc h, MeCN, 81 % over 
two steps 
Scheme 49. Saegusa oxidation of cyclohexanone 316 
In order to circumvent the ketal construction from enol ether 303, we elected to 
develop an alternative route to enone 320. Our first approach was to introduce the 
ethylene ketal moiety into the A-ring fragment prior to the Mitsunobu coupling step. 
Protection of 2-bromo iso-vanillin (259) as its methoxymethyl ether and subsequent 
Wittig reaction with 302 provided enol ether 322 (Scheme 50). Ketalization with 
ethylene glycol afforded arene 323 in a satisfactory yield. 
I ~ I ~ I ~ I ~ Meoy . Meoy .. Meo~ ... MeoX?JO HO ~ CHO MOMO ~ CHO MOMO ~ .& OMe HO ~ 0 
Br Br Br Br 
259 321 322 323 
Reagents and conditions: (i) MOM-CI, EtN(iPrh DCM, O°C; (ii) chloride salt of 302, n:BuLi, THF, -
78°C - r.t.; (iii) ethylene glycol, p-TsOH, 64% over three steps 
Scheme 50. Synthesis of ethylene ketal 323 
A Mitsunobu coupling reaction between allylic alcohol 258 and arene 323 provided 
ether 324, setting up an intramolecular Heck reaction to form the C12-C13 bond 
(Scheme 51). 
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Meo~ 9~ Meo~ 9\ HO~O ~o) 
cS'NMeBoc Br 0 ' Br HO,., '<:::: 323 ~NMeBOC TBSO'" TBSO"'U I 
258 324 
Reagents and conditions: (i) 323, DIAD, n-Bu3P, THF, ooe - Lt., 78% 
Scheme 51. Synthesis of ether 324 
The Heck reaction conditions which had furnished tetrahydodibenzofuran 261 
decomposed ether 324 (Table 20, Entry 1). We screened conditions employing 
tris( dibenzylideneacetone )dipalladium(O) and obtained the desired product in modest 
yields. Ultimately, palladium(II) acetate in concert with P(o-tolyl)3 gave us the best 
result, 94% of tetrahydodibenzofuran 310. 
Me0)QJ0 1.0 ~ 
o 
o Br ~NMeBoc 
TBSO"'U I 
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Heck 
reaction 
Table 20 
MeO 
TBSO'" 
310 
Figure 41. Intramolecular Heck reaction of ether 324 
Table 20. Intramolecular Heck reaction of ether 324 
Entry Pd Catalyst Reagents Solvent Temp. 
1 Pd(OAc)2 Ag2C03, dppf toluene 110°C 
2 Pd(dba)2 P(o-tolyl)3, NEt3 MeCN reflux 
3 Pd(dba)2 P(o-tolyl)3, NEt3 toluene llO°C 
4 Pd(OAch P(o-tolylh, NEt3 
Lal complex mixture of compounds 
toluene nooe 
Result 
decomposition [a] 
310 (27%) 
310 (22%) 
310 (94%) 
Desilylation of 310, hydrogenation with 5% PdlC, and oxidation with IBX afforded 
cyclohexanone 316. A Saegusa oxidation completed our efficient route to enone 320. 
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~ M~W~ ~) ~ 
NMe80c 
o 0 
310 316 320 
Reagents and conditions: (i) TBAF, THF, QOC - Lt.; (ii) 5% Pd/C, H2 (1 atm), MeOH; (iii) IBX, DMF, 
QOC - r.t.; (iv) a) LDA, THF, -78°C; b) TMS-Cl; (v) Pd(OAch, MeCN 
Scheme 52. Synthesis of enone 320 
With enone 320 in hand, we sought to develop a method to close the two remaining 
rings of (+ )-codeine. In principle, acidic conditions should reveal the aldehyde, 
remove the Boc carbamate, and promote the formation iminium 325 (Figure 42). 
Tautomerization of the enone, and subsequent attack of the resulting 1,3-dienol 326 
should close the C 14-C9 bond. 
320 325 326 134 
Figure 42. Theoretical acid-promoted closure of the B- and D-rings 
In Fukuyama's 2006 synthesis of morphine,137 the B- and D-rings were 
formed in a single step from a substrate similar to enone 320 (Section 2.3.5, 
compound 225 in Scheme 27). Fukuyama believed the closures proceeded through a 
Mannich-type reaction and not an aldol condensation! Michael addition. When we 
employed identical conditions, 320 in refIuxing methanolic hydrogen chloride, we 
obtained tetracycle 327 (Scheme 53). Clearly the favoured process is the 1,4 
conjugate addition of the amine to the enone followed by enol ether formation. 
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Reagents and conditions: (i) Hel, MeOH, reflux, 74% 
Scheme 53. Synthesis of 1,4 conjugate addition product 327 
We began the search for acidic conditions that would deprotect the ketal! Boc groups, 
and initiate closure of the B- and D-rings (Figure 43). All of our attempts employed 
trifluoroacetic acid and each afforded the Michael addition product 328. 
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deprotection 
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Table 21 
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Figure 43. Acidic deprotection of ketal 320 
Table 21. Acidic deprotection of ketal 320 
Entry 
1 
2 
3 
Acid 
TFA 
TFA 
TFA 
Solvent 
DCM 
MeCN 
THF 
Temp. 
reflux 
reflux 
reflux 
Result 
3,Z8 (45%) 
3'28 (61%) 
328 (76%) 
We resubmitted piperidine 328 to acidic conditions (Le. TFA in THF) in an attempt to 
promote a retro-Michael reaction! iminium ion formation sequence (Scheme 54). 
However, we could not find evidence for the formation of (+ )-codeinone (134). 
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328 134 
Reagents and conditions: (i) TFA, THF, reflux 
Scheme 54. Attempted retro Michael reaction on piperidine 328 
We also attempted to selectively hydrolyze the ketal over the Boc carbamate using 
aqueous acidic conditions (Figure 44). We hoped that the free aldehyde would serve 
as a better electrophile and favour iminium ion formation over 1,4 conjugate addition. 
All of the conditions we evaluated did hydrolyze the ketal, nevertheless, the Michael 
addition product 329 was isolated (Table 22). 
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Figure 44. Aqueous acidic deprotection of ketal 320 
Table 22. Aqueous acidic deprotection of ketal 320 
Entry Acid Solvent Temp. 
1 aq. AcOH MeCN 
2 aq. AcOH MeCN 
3 aq. HCI MeCN 
4 aq. HCI MeCN 
Result 
SM 
329 (51%) 
SM 
329 (77%) 
We subjected piperidine 329 to conditions we hoped would promote a retro Michael 
reaction (Scheme 55). Once again, we were unable to find evidence for the formation 
of (+ )-codeinone (134). 
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329 134 
Reagents and conditions: (i) TFA, THF, reflux 
Scheme 55. Attempted retro Michael reaction on piperidine 329 
We attempted to design a route which avoided the selective hydrolysis of a ketal or an 
enol ether in the presence of a N-Boc carbamate. To this end, we prepared A-ring 
fragment 330 by reacting the MOM-protected 2-bromo iso-vanillin derivative 321 
with Wittig reagent 302. Acidic hydrolysis provided aldehyde 330 in 24% yield over 
the three steps. 
I " I I" ii-iii Meo~ . Meo~ . 
HO b CHO - MOMO b CHO-
Meo~ 
HO~O 
Br Br Br 
259 321 330 
Reagents and conditions: (i) MOM-CI, EtN(iPrh, DCM, DOC; (ii) chloride salt of 302, n-BuLi, THF, -
78°C - r.t.; (iii) p-TsOH, THF, reflux, 24% over three steps 
Scheme 56. Synthesis of A-ring fragment 330 
When we tried our standard Mitsunobu conditions to couple allylic alcohol 258 with 
arene 330, the starting materials were decomposed (Table 23, Entry 1). All other 
conditions we explored were also unsuccessful. 
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Meo'll1 
HO~O 
Br 
HO". "-':: -----*)(--.-
Meo'll1 
~O 
o Br ~NMeBoc 
TBSO"'U I c5NMeBoc 330 Table 23 TBSO'" 
258 331 
Figure 45. Attempted Mitsunobu coupling between allylic alcohol 258 and arene 330 
Table 23. Attempted Mitsunobu coupling between allylic alcohol 258 and arene 330 
Entry Reagents 
1 DIAD, nBu3P 
2 DIAD, PPh3 
3 DIAD, nBu3P 
La] complex mixture of compounds 
3.2.4 Prins Reaction Approach 
Solvent 
THF 
THF 
toluene 
Temp. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
Result 
decomposition [a] 
decomposition [a] 
decomposition[a] 
The failure of the Mitsunobu coupling between arene 330 and allylic alcohol 
258 necessitated an alternative approach. Hence, we attempted to develop a procedure 
to selectively deprotect the enol ether functionality of 303 over the acid labile Boc 
and TBS groups (Figure 46). We theorized that the resulting aldehyde, 332, could 
undergo a Prins reaction to close the B-ring. A subsequent dehydration reaction 
would provide alkene 263, an intermediate in Hudlicky's 2007 synthesis of (+)-
codeine .147 
MeO MeO MeO 
b selective 
OMe deprotection 
,.\'\ ----------- ... 
I NMeBoc 
1. Prins 
------------.. 
2. Dehydration 
TBSO'" TBSO'" TBSO'" 
303 332 263 
Figure 46. Selective enol ether deprotection 
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Our first strategy to selectively remove the enol ether functionality employed a 
BrjZinsted acid (Figure 47). Treatment of enol ether 303 with 3% perchloric acid at 
room temperature resulted in the decomposition of the starting material (Table 24). 
When the same reaction was performed at O°C, the desilylation product 304 was 
isolated. The TBS ether appeared to be the most labile group under these conditions, 
hence we abandoned this approach. 
MeO 
TBSO'" 
303 
Brrzlnsted acid 
enol ether 
deprotection 
• 
Table 24 
304 
Figure 47. Attempted enol ether deprotection with a BrjZinsted acid 
Table 24. Attempted enol ether deprotection with a BrjZinsted acid 
Entry 
1 
2 
BrrjJnsted acid 
3% HCI04 
3% HCI04 
tal complex mixture of compounds 
Solvent 
THF 
THF 
Temp. Result 
decomposition [a] 
304 (63%) 
Our second strategy was to attempt a Lewis acid-catalyzed enol ether deprotection 
(Figure 48). Tokunaga has successfully employed copper(II) chloride in the removal 
of enol ether groupS.152 When we treated enol ether 303 with 0.1 equivalents of 
copper(II) chloride in acetonitrile at 40°C we obtained a mixture of benzaldehyde 
derivatives 261 and 305 along with the phenyl acetaldehyde derivatives 332 and 333 
(Table 25, Entry 1). We speculated that the two former products were a result of 
aerobic benzylic oxidation. Hence, we began to purge the reaction mixture with 
argon. The degassed experiments proved more favourable, as we no longer observed 
the formation of benzaldehyde derivatives 261 and 305. We ran the reactions at 
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various temperatures (O°C to 80°C) and found that 40°C provided the highest ratio of 
332. Before continuing, we exposed our 3: 1 mixture to TBS-CI to obtain only 332. 
MeO 
TBSO'" 
303 
Lewis acid 
enol ether 
deprotection 
• 
Table 25 
M:W~ h~ • 
. I NMeBoc 
RO" 
261 R=TBS 
305R=H 
332 R= TBS 
333R=H 
Figure 48. Attempted enol ether deprotection with a Lewis acid 
Table 25. Attempted enol ether deprotection with a Lewis acid 
Entry CuCl2 Equiv. Solvent Temp. Degassed Ratio (261 :305:332:333 P] 
1 0.1 MeCN 40°C no 1:2:1.2:2 
2 0.1 MeCN O°C yes - [b] 
3 0.1 MeCN r.t. yes 0:0:1:4 
4 0.1 MeCN 40°C yes 0:0:1:3 
5 0.1 MeCN 80°C yes 0:0:1:10 
6 1 MeCN 40°C yes 0:0:1:9 
[a] approximate ratio determined from IH NMR spectra; [6] recovered starting material 
We subjected phenylacetaldehyde 332 to Lewis acid conditions in an effort to obtain 
cyclized product 334 (Figure 49). All of the conditions attempted, with either 
scandium(llI) triflate or trimethylaluminium, did not produce any new compounds 
t2 
(Table 26). 
MeO 
TBSO'" 
332 
Prins 
Reaction 
)( 
Table 26 
Meo~ I ~ NMeBoc 
o .",_-.1 
OH 
TBSO'" ~ 
334 
Figure 49. Attempted Prins reaction on phenyl acetaldehyde 332 
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Table 26. Attempted Prins reaction on phenylacetaldehyde 332 
Entry 
1 
2 
3 
Lewis Acid 
AIMe3 
ScOTf3 
ScOTf3 
Solvent 
DCM 
DCM 
DCM 
Temp. Result 
SM 
SM 
SM 
When we utilized trimethylaluminium in DCM at room temperature we isolated the 
methylated product 335 (Scheme 57). Although our efforts thus far have been 
unsuccessful, we remain optimistic that conditions to promote a Prins cyclization can 
be found. 
MeO 
i 
-
TBSO'" 
332 335 
Reagents and conditions: (i) A1Me3, DeM, r.t. 
Scheme 57. Methylation of phenyl acetaldehyde 332 
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4. Conclusions and Future Work 
The preceding study reviewed our latest efforts in two areas of research; 1. the 
enantiodivergent synthesis of balanol, and 2. chemoenzymatic synthetic approaches to 
codeine. We have developed an enantiodivergent synthesis of the (+)- and (-)-isomers 
of balanol commencing from a single cis-dihydrodiol obtained through the TDO-
mediated dihydroxylation of bromobenzene. We have explored various synthetic 
strategies to construct the unnatural isomer of codeine from the TDO-oxidation 
product of ~-bromoethylbenzene. The majority of the research disclosed focused on 
the closure of the carbocyclic B-ring and the heterocyclic D-ring. Unfortunately, we 
were unable to find suitable conditions to promote this transformation. In the future, 
we plan to extensively investigate the Prins and aza-Prins approaches by screening 
Lewis and Br¢nsted acids. 
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5. Experimental Section 
5.1 General experimental procedures 
All non-aqueous reactions were carried out in an argon atmosphere using standard 
Schlenk techniques for the exclusion of moisture and air. Methylene chloride was 
distilled from calcium hydride. Tetrahydrofuran and benzene were dried over 
sodiumlbenzophenone. Analytical thin-layer chromatography was performed on 
Silicycle 60 A 250 !-lm TLC plates with F-254 indicator. Flash column 
chromatography was performed using 200-400 mesh silica gel. Melting points were 
recorded on a Hoover Unimelt apparatus and are uncorrected. IR spectra were 
recorded as thin films on NaCI plates and were obtained on a Perkin-Elmer One FT-
IR spectrometer. Optical rotation was measured on a Perkin Elmer 341 polarimeter 
using a sodium (589, D line) lamp and are reported as follows: [ah T DC (c = g/lOO 
mL, solvent). IH NMR spectra were recorded on a Bruker (300 MHz or 600 MHz) 
spectrometer and are reported in ppm using tetramethylsilane (0.00 ppm) or solvent 
(CDCh; 7.24 ppm, acetone-d6: 2.05 ppm, DMSO-d6: 2.50, CD30D: 3.31~ppm, D20: 
2.80) as an internal standard. Data are reported as (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, br = broad; coupling constant(s) in Hz, integration. Proton-
decoupled 13C NMR spectra were recorded at 150 or 75 MHz and are reported in ppm 
using solvent as an internal standard (CDCh: 77.23 ppm, acetone-d6: 206.68 ppm, 
DMSO-d6: 39.51 ppm, CD30D: 49.15 ppm). Combustion analyses were performed 
by Atlantic Microlabs, Norcross, GA. Mass spectra were recorded on KreatuslMsI 
Concept IS mass spectrometer at Brock University. The GCIMS data was obtained on 
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a Perkin-Elmer Clarus 500 Gas Chromatograph and Mass Spectrometer using a 
Perkin Elmer Elite-5MS column, 10 m, 0.25 mmID, 2 mLlmin helium flow. 
S.2 Balanol Project Experimental Procedures 
rI:.-y0 rit0Bn 
l.,J,,'NrJ 
N ° Bn 
118a 
(3aR,SaR)-S-benzyl-3-[4-(benzyloxy)benzoyl]octahydro-2H-[1,3]oxazolo[4,S-
c]azepin-2-one (lISa) 
To a stirred solution of 296 (58 mg, 0.151 mmol) in acetone (3 mL) was added a 
suspension of NaI04 (322 mg, 1.51 mmol) in distilled water. The reaction was stirred 
at room temperature for 6 h, then the solvent was removed. The crude residue was 
triturated with ethyl acetate (3 x 5 mL), then washed with brine (2 x 5 mL). The 
resulting solution was filtered through a plug of silica gel and concentrated under 
reduced pressure to yield (4S,SR)-3-[4-(benzyloxy)benzoyl]-2-oxo-S-(3-oxopropyl)-
1,3-oxazolidine-4-carbaldehyde which was used without further purification. The 
dialdehyde intermediate was dissolved in dry MeOH (3 mL) and cooled to -78°C in 
an acetone and liquid N2 bath. To this solution was added 3 A molecular sieves (150 
mg), followed by NaCNBH3 (10 mg, 0.166 mmol) then AcOH (17.3 ~L, 0.302 mmol) 
and finally benzyl amine (18.2 ~L, 0.166 mmol). The reaction was warmed to room 
temperature slowly over 24 h before concentrating under reduced pressure. The 
resulting residue was triturated with ethyl acetate (3 x 5 mL) and washed with 
NaHC03 (1 x 3 mL). The organic layer was washed with brine (3 mL), then dried 
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with Na2S04 before concentrating. The crude material was recrystallized from ethyl 
ether-hexanes to yield 47 mg (68%) of the title compound as a pale yellow solid: mp 
126-128 °C (ethyl ether-hexanes); RfO.68 (2:1 hexanes-ethyl acetate); [a]D23 -17.9 (c 
0.07, CHCl); IR (film) v 3029, 2835, 1783, 1679, 1604, 1300, 1253, 1119 em-I; IH 
NMR (300 MHz, CDCl)) 0 7.73 (d, J = 8.7 Hz, 2H), 7.37-7.43 (m, 4H), 7.32-7.37 (m, 
2H), 7.29-7.32 (m, 4H), 6.98 (d, J = 8.7 Hz, 2H), 5.11 (s, 2H), 4.90 (td, J = 3.2, 10.5 
Hz, 1H), 4.39 (td, J = 7.1, 9.6 Hz, 1H), 3.71 (d, J = 13.2 Hz, 1H), 3.64 (d, J = 13.2 
Hz, 1H), 3.44 (dd, J = 6.6, 11.1 Hz, 1H), 2.65-2.70 (m, 1H), 2.60-2.65 (m, 1H), 2.55-
2.60 (m, 1H), 2.35-2.39 (m, 1H), 1.73-1.77 (m, 1H), 1.70-1.73 (m, 1H), 1.66-1.70 (m, 
1H) ppm; 13C NMR (300 MHz, CDCl)) 0 169.7, 162.8, 154.1, 138.9, 136.1, 132.3, 
128.7, 128.4, 128.2, 127.5, 125.2, 114.1, 78.0, 70.1, 63.0, 61.8, 55.3, 51.4, 31.2, 26.4 
ppm; MS (El) m/z (%): 412 (M-C02); 44(20), 91(100), 160(76), 161(10); HRMS 
(M-C02) calcd for C27H2SN202 412.2151, found 412.2151; Anal. ca1cd: C 73.66, H 
6.18, found C 73.55, H 6.20. 
118b 
(3aS, 7 as)-5-Benzyl-3-( 4-benzyloxy-benzoyl)-octahydro-l-oxa-3,5-diaza -azulen-2-
one (118b) 
A stirred solution of amide 289 (20 mg, 0.047 mmol) in 1 mL of 9:3: 1 
(AcOH:tetrahydrofuran:H20) was brought to reflux for 16 h then cooled to room 
temperature and concentrated under reduced pressure. The resulting residue was 
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triturated with benzene (2 x 1 mL) and CHCh (2 x 1 mL), filtered through a plug of 
Si02 then recrystallized from CHCh to yield (3aS,4S,5R,7aS)-3-(4-Benzyloxy-
benzoyl)-4,5-dihydroxy-hexahydro-benzooxazol-2-one (290) (15 mg, 83%) as a 
white solid: mp 166-167 DC (hexanes-ethyl acetate); Rf 0.31 (1:1 hexanes-ethyl 
acetate); [a]D23 +80.2 (c 0.47, CHCh); IR (film) v 3684, 3091, 1794, 1604, 1511, 
1422, 1303, 1215, 1029 em-I; IH NMR (300 MHz, CDCh) 0 7.68 (d, J = 8.8 Hz, 
2H), 7.29-7.44 (m, 5H), 6.98 (d, J = 8.8 Hz, 2H), 5.93 (br s, 10H), 5.11 (s, 2H), 4.34 
(dd, J = 9.7, 11.1 Hz, 1H), 4.07 (dd, J = 2.6,5.5 Hz, 1H), 3.95-4.05 (m, lH), 3.87 (dd, 
J = 3.1, 9.6 Hz, 1H), 3.10 (br s, 10H), 2.26 (ddd, J = 0.1,3.1, 14.7 Hz, 1H), 2.01-2.10 
(m, 2H), 1.54-1.59 (m, 1H) ppm; 13C NMR (75 MHz, CDCh) 0 173.6, 163.1, 153.6, 
136.0, 132. 1 (2xC), 128.7, 128.3(2xC), 127.6(2xC), 124.6, 114.2(2xC), 77.6, 72.7, 
70.2, 68.6, 64.6, 26.7, 22.2 ppm; MS (EI) mlz (%): 383 (M), 43(12), 83(20), 84(10), 
85(13),91(100),211(15); HRMS calcd for C2IH2IN06 383.1369, found 383.1369. 
To a stirred solution of (3aS,4S,5R,7aS)-3-(4-Benzyloxy-benzoyl)-4,5-dihydroxy-
hexahydro-benzooxazol-2-one (290) (58 mg, 0.151 mmol) in 10:1 acetone-H20 (2 
mL) was added Nal04 (600 mg, 3.00 mmol). The resulting suspension was stirred at 
room temperature for 6 h, before the solvent was removed under reduced pressure. 
The crude residue was triturated with ethyl acetate (3 x 5 mL), then washed with 
brine (2 x 5 mL). The resulting organic layers were filtered through a plug of silica 
gel and concentrated under reduced pressure to yield (4R,5S)-3-(4-Benzyloxy-
benzoyl)-2-oxo-5-(3-oxo-propyl)-oxazolidine-4-carbaldehyde (291), which was 
used without further purification. Dialdehyde 291 was dissolved in dry MeOH (2 mL) 
and cooled to -78 DC in an acetone and liquid N2 bath. To this solution was added 3 A 
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molecular sieves (100 mg), followed by NaCNBH3 (10 mg, 0.166 mmol), then AcOH 
(17 ilL, 0.302 mmol), and finally benzylamine (18 ilL, 0.166 mmol). The reaction 
was warmed to room temperature slowly over 24 h before concentrating under 
reduced pressure. The resulting residue was triturated with ethyl acetate (3 x 2 mL) 
and washed with NaHC03 (1 x 2 mL). The organic layer was washed with brine (1 
mL), then dried over Na2S04. The crude material was recrystallized from ethyl ether-
hexanes to yield 11Sb (38 mg, 60% over 2 steps) as a pale yellow solid: mp 126-128 
°C (ethyl ether-hexanes): Rj 0.68 (2:1 hexanes-ethyl acetate); [a]D23 +31.1 (c 0.9, 
CHCb); IR (film) v 3029, 2835, 1783, 1679, 1604, 1300, 1253, 1119 cm-I; IH NMR 
(300 MHz, CDCb) () 7.74 (d, J = 8.6 Hz, 2H), 7.28-7.44 (m, lOH), 6.98 (d, J = 8.6 
Hz, 2H), 5.11 (s, 2H), 4.90 (t, J = 8.5 Hz, 1H), 4.39 (q, J = 8.7 Hz, 1H), 3.68 (q, J = 
18.6 Hz, 2H), 3.40-3.47 (m, 1H), 2.50-2.73 (m, 3H), 2.33-2.45 (m, 1H), 1.69-1.78 (m, 
3H) ppm; 13C NMR (75 MHz, CDCb) () 169.7, 162.8, 154.1, 138.9, 136.1, 132.5, 
132.3(2xC), 128.8, 128.7, 128.4(2xC), 128.2, 127.5(2xC), 127.2, 125.2, 114.2(2xC), 
114.1, 78.0, 70.1, 63.0, 61.8, 55.3, 51.4, 31.2, 26.3 ppm; MS (EI) mlz (%): 412 (M-
CO2), 44(20), 91(100), 160(76), 161(10); HRMS (M-C02) calcd for C27H28N202 
412.2151, found 412.2151. 
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119a 
N -[ (3R,4R)-1-benzyl-4-hydroxyazepan-3-yl]-4-(benzyloxy )benzamide (119a) 
To a stirred solution of 118a (12 mg, 0.0263 mmol) in freshly distilled THF (0.2 ml) 
was added 1 N NaOH (1 mL) at -20°C. The reaction was warmed to room 
temperature slowly over 12 h before concentrating under reduced pressure. The 
reaction was concentrated, extracted into ethyl ether (5 x 1 mL), washed with brine 
and then dried over Na2S04. The crude product was subjected to flash column 
chromatography (3:1 hexanes-ethyl acetate) to yield 119a (9 mg, 81%) as yellow oil. 
Rf 0.19 (1:3 ethyl acetate-hexanes); [a]D23 -4.7 (c 0.02, CHCb); IR (film) v 3407, 
3377, 2955, 1638, 1611, 1298, 1140 cm-I; IH NMR (300 MHz, CDCb) () 1.55-1.99 
(m, 4H), 2.50 (m, 1H), 2.73 (dd, J = 1.9, 14.3 Hz, 1H), 2.93 (dd, J = 2.0, 14.2 Hz, 
1H), 3.00 (m, 1H), 3.42 (d, J = 13.2 Hz, 1H), 3.74-3.78 (m, 2H), 3.88 (m, 1H), 5.15 
(s, 2H), 6.54 (d, J = 8.7 Hz, 1H), 6.99 (d, J = 6.8 Hz, 2H), 7.22-7.50 (m, 12H); 13C 
NMR (150 MHz, CDCb) () 29.7,31.5,54.4,58.0,59.9,64.2, 70.1, 77.5, 114.5, 126.4, 
127.4, 127.5 (2x C), 128.2, 128.7 (2x C), 128.9 (2x C), 129.0, 129.5 (2x C), 136.4, 
161.4, 167.8 ppm; MS (FAB) mlz (%) 431 (M + H+); 41(34), 43(43),57(51), 71(34), 
91(71), 149(100); HRMS calcd for C27H3IN203 431.2310, found 431.2312. 
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119b 
N -[ (3S,4S)-hexahydro-4-hydroxy -l-(phenylmethyl)-
IH -azepin-3-yl]-4-(phenylmethoxy)benzamido (119b) 
To a stirred solution of azepane 118b (12 mg, 0.026 mmol) in tetrahydrofuran (0.3 
mL) was added I N NaOH (1.5 mL) at -20°C. The reaction mixture was allowed to 
warm to room temperature slowly over 12 h before concentrating under reduced 
pressure. The resulting residue was diluted with H20 (1 mL) and extracted into ethyl 
acetate (5 x 1 mL), then the combined organic layers were washed with brine (1 mL) 
and dried over Na2S04. The crude material was purified via flash column 
chromatography with a solvent system of 3:1 (hexanes-ethyl acetate) to yield 119b 
(6.5 mg, 56 %) as a pale yellow oil: Rf0.31 (3:2, hexane-ethyl acetate); [a]D23 + 5.77 
(c 0.75, CHCh); IR (film) v 3407,3377,2955,1638, 1611, 1298, 1140 cm-I; IH NMR 
(600 MHz, CDCh) D 7.22-7.50 (m, 12H), 6.99 (d, J = 6.8 Hz, 2H), 6.54 (d, J = 8.7 
Hz, 1NH), 5.11 (s, 2H), 3.88 (m, 1H), 3.69-3.78 (m, 1H), 3.63 (d, J = 13&'2 Hz, 1H), 
3.42 (d, J = 13.2 Hz, 1H), 3.00 (m, 1H), 2.93 (dd, J = 2.0, 14.2 Hz, 1H), 2.73 (dd, J = 
1.9,14.3 Hz, 1H), 2.50 (m, 1H), 1.85-1.95(m, 2H), 1.60-1.85 (m, 2H); 13C NMR (150 
MHz, CDCh) D 167.8, 161.4, 136.4(2xC), 129.5(2xC), 129.0, 128.9(2xC), 
128.7(2xC), 128.2(2xC), 127.5(2xC), 127.4(2xC), 126.4, 114.5(2xC), 77.5, 70.1, 
64.2, 59.9, 58.0, 54.4, 31.5, 29.7 ppm; MS (FAB) m/z (%): 431 (M+H+), 41(34), 
43(43), 57(51), 71(34), 91(71), 149(100); HRMS calcd for C27H3IN203 431.2310, 
found 431.2312. 
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274 
(3aS ,4R,5S, 7 as)-7 -bromo-2,2-dimethyl-4-{ [( 4-methylphenyl)sulfonyl]amino}-
3a,4,5,7a-tetrahydro-l,3-benzodioxol-5-yl acetate (274) 
To a stirred solution of tosyl aziridine 273 (200 mg, 0.500 mmol), acetic acid (34 ilL, 
0.500 mmol) in DCM (2 mL) was added trimethylsilyl trifluoromethanesulfonate (9 
ilL, 0.0500 mmol). The reaction was stirred at r.t. for 8 h before being quenched with 
sat. NaHC03 (4 mL) and extracted into DCM (3 x 5 mL). The resulting crude material 
was recrystallized from hexanes-ethyl acetate to yield 274 (170 mg, 74%) as a white 
solid: mp 159-160 °C (hexanes-ethyl acetate); Rf 0.64 (1:1 hexanes-ethyl acetate); 
[a]D23 -119.5 (c 0.1, CHCh); IR (film) v 3684,3271,3019,2928, 1746, 1649, 1430, 
1375, 1334, 1216, 1161, 1093 cm-I; IH NMR (300 MHz, CDCh) & 7.79 (d, J = 7.1 
Hz, 2H), 7.29(d, J = 6.3 Hz, 2H), 6.12 (s, 1H), 5.53 (d, J = 8.1 Hz, 1H), 5.27 (d, J = 
7.4 Hz, 1H), 4.67 (d, J = 4.5 Hz, 1H), 4.25-4.17 (m, 1H), 3.70-3.60 (m, 1H), 2.41 (s, 
3H), 1.95 (s, 3H), 1.33 (s, 3H), 1.30 (s, 3H) ppm; 13C NMR (150 MHz, CDCh) & 
170.9, 143.2, 138.4, 131.8, 129.4 (2C), 127.2 (2C), 121.0, 111.2, 76.9, 75.8, 70.6, 
55.5,27.4,26.0,21.5, 20.8ppm; MS (FAB) mlz (%): 460 (M+1), 91 (82), 79 (20), 80 
(30),81 (18), 136 (26), 137 (29), 139 (40), 155 (100), 186 (26), 187 (42), 88 (32), 189 
(43), 342 (23), 344 (23), 402 (28); HRMS-FAB calcd for CIsH23BrN06S 460.0429, 
found 460.0462. 
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275a 
(3aS ,4R,5S, 7 aR)-2,2-dimethyl-4-{[ (4-methylphenyl)sulfonyl]amino }hexahydro-
1,3-benzodioxol-5-yl acetate (275a) 
To a stirred solution of 274 (75 mg, 0.175 mmol) , NEt3 (0.17 mL, 1.25 mmol) in 
ethyl acetate (1 mL) was added platinum(N)oxide (10 mg, 0.032 mmol) before 
evacuating the reaction flask with H2. The reaction was stirred at room temperature 
and 1 atm for 12 h before filtering through a plug of Si02 and concentrating. The 
crude material was purified using flash column chromatography 2: 1 (hexanes-ethyl 
acetate) and then recrystallized from hexanes-ethyl acetate to yield 275a (22 mg, 
32%) as a white solid: m.p. 155°C; RfO.61 (1:2 hexanes-ethyl acetate); IH NMR (600 
MHz, MeOD) 87.80 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.11 (d, J = 5.7 Hz, 
1H), 4.22-4.16 (m, 1H), 3.67 (dd, J = 8.3, 4.86 Hz, IH), 3.09-2.97 (m, IH), 2.40 (s 
3H), 2.06-1.96 (m, 2H), 1.66-1.52 (m, IH), 1.52-1.41 (m, 2H), 1.15 (s, 3HJ,1.1O-1.02 
(m, 1H), 1.03 (s, 3H) ppm; l3C NMR (150 MHz, CDCh) 8 143.2, 137.2, 129.4, 127.5, 
108.5, 78.2, 73.9, 56.0, 30.0, 27.5, 26.4, 26.2, 21.4, 19.0 ppm; MS (El) mlz (%): 325 
(M); 41(20), 43(51), 59(24), 84(25), 91(98), 96(20), 112(100), 170 (270, 155(66), 
HRMS calcd for CIsH25N06S 383.1403, found 383.1401 
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276 
N-[(3aS,4R,7aR)-2,2-dimethylhexahydro-l,3-benzodioxol-4-yl]-4-
methylbenzenesulfonamide (276) 
To a stirred solution of 274 (50 mg, 0.153 mmol) and NEt3 (0.15 mL, 1.07 mmol) in 
ethyl acetate (2 mL) was added platinum(N)oxide (12 mg, 0.043 mmol) before 
evacuating the reaction flask with H2. The reaction was stirred at room temperature 
with 1 atm of H2 for 12 h before being filtered through a plug of Si02 and 
concentrating. The crude material was purified via flash column chromatography 2: 1 
(hexanes-ethyl acetate) to yield 276 (23 mg, 48%) as a white solid: m.p. 149-148 °C 
(hexanes-ethyl acetate); Rf 0040 (2: 1 hexanes-ethyl acetate); IR (film) v 3330, 2985, 
2939, 1597, 1496, 1326, 1160, 1041 cm-l; IH NMR (300 MHz, CDCh) 8 7.80 (d, J = 
8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H) 5.11 (d, J = 5.7 Hz, 1H), 4.22-4.16 (m, 1H), 
3.76 (dd, J = 8.3, 4.8 Hz, 1H), 3.09-2.97 (m, 1H), 2040 (s, 3H), 2.06-1.96 (m, 2H), 
1.66-1.52 (m, 1H), 1.52-1.41 (m,2H), 1.15 (s, 3H), 1.10-1.03 (m, 1H) 1.02 (s, 3H) 
ppm; 13C NMR (150 MHz, CDCh) 8 143.2, 137.2, 12904 (2C), 127.5 (2C), 108.5, 
78.2, 73.9, 56.0, 30.1, 27.5, 26.5, 26.2, 21.5, 19.0 ppm; MS (El) mlz (%): 325 (M), 41 
(20), 43 (51), 84 (26), 91 (98), 96 (20), 112 (100), 155 (66), 170 (27), HRMS calcd 
for Cl6H23N04S 325.1348, found 325.1348. 
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277 
(lS,4S,5S,6S)-3-bromo-4,5-dihydroxy-6-{[(4-
methylphenyl)sulfonyl]amino }cyclohex-2-en-l-yl acetate (277) 
To a stirred solution of aziridine 273 (100 mg, 0.250 mmol), acetic acid (0.28 mL, 
4.99 mmol) in DCM (1 mL) was added trimethylsilyl trifluoromethanesulfonate (4.5 
~L, 0.0250 mmol). The reaction was stirred at room temperature for 8h before the 
addition of Si02 (200 mg. The resulting slurry was stirred at 50 DC for 12 h, then 
filtered, triturated (benzene then EhO) and concentrated. Recrystallization from 
CHCh-hexanes yielded 277 (86 mg, 81 %) as a white solid: mp 195-197 DC (hexanes-
ethyl acetate); Rf 0.46 (1:2 hexanes-ethyl acetate); [a]D23 -62.61 (c 0.145, MeOH); IH 
NMR (600 MHz, MeOD) 0 7.76 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 5.95 (d, 
J = 2.3 Hz, 1H), 5.10 (dd, J = 2.6, 9.0 Hz, 1H), 4.23 (d, J = 3.8 Hz, 1H), 3.70 (dd, J = 
9.2, 11.1 Hz, 1H), 3.58 (dd, 3.9, 11.1, 1H), 2.41 (s, 3H), 1.64 (s, 3H) ppm; 13C NMR 
(150 MHz, MeOD) 0 170.4, 142.9, 139.6, 129.5 (2xC), 129.1, 126.6 (2xC), 125.5, 
73.2, 72.4, 69.5, 53.8, 19.9, 19.1 ppm; MS (FAB) m/z (%): 420 (M+l), 91 (82), 79 
(20), 80 (30), 81 (18), 136 (26), 137 (29), 139 (40), 155 (100), 186 (26), 187 (42), 88 
(32), 189 (43), 342 (23), 344 (23), 402 (28); HRMS calcd for Cl5Hl9BrN06S 
420.0116, found 420.0119. 
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279 
N-[(lR,2S,3R)-2,3-dihydroxycyclohexyl]-4-methylbenzenesulfonamide (279) 
To a stirred solution of 277 (50 mg, 0.120 mmol), NEt3 (0.12 mL, 0.874 mmol) in 
ethyl acetate (l mL) was added platinum(IV)oxide (7 mg, 0.025 mmol) before 
evacuating the reaction flask with H2. The reaction was stirred at room temperature 
and 1 atm for 12 h before filtering through a plug of Si02 and concentrating. The 
crude material recrystallized from hexanes-ethyl acetate to yield 279 (21 mg, 62%) as 
a white solid; m.p. 112°C (hexanes-ethyl acetate); Rf 0.22 (1:4, hexanes-ethyl 
acetate); IH NMR (300 MHz, MeOD) 0 7.78 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.0 Hz, 
2H), 4.00-3.90 (m, 1H), 3.40-3.26 (m, 4H), 2.44 (s, 3H), 2.04-2.02 (m, 3H), 1.79-1.67 
(m, 3H), 1.79-1.67 (m, 2H), 1.67-1.56 (m, IH), 1.56-1.43 (m, IH), 1.42-1.30 (m, IH), 
1.23- 1.07 (m, IH) ppm; 13C NMR (75 MHz, CDCb) 0 143.1, 138.6, 129.2 (2C), 
126.7 (2C), 73.6,68.9,53.8,29.5,20.0, 18.3 ppm; MS (FAB) mlz (%): 286 (M+l),69 
(22), 89 (24), 90 (21), 91 (100), 95 (24), 96 (46), 97 (39), 105 (22), 107 (36), 112 
(30), 113 (30), 128 (20), 136 (30), 137 (45), 138 (25), 139 (47), 149 (47), 155 (189), 
172 (50), 286 (80); HRMS calcd for C13H19N04S 286.1035, found 286.1035. 
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280a 
N -( (3aS,4R,5S, 7 as)-7 -Bromo-5-hydroxy -2,2-dimethyl-3a,4,5, 7 a-tetrahydro-
benzo[1,3]dioxol-4-yl)-4-methyl-benzenesulfonamide (280a) 
To a stirred solution of N-tosyl aziridine 273 (200 mg, 0,499 mmol), in dimethyl 
sulfoxide (1.5 rnL) was added 10% KOH (1.5 rnL). The resulting reaction mixture 
was heated to 40°C for 2 h before cooling and being neutralized with sat. NH4Cl. The 
crude mixture was extracted into ethyl acetate (3 x 5 rnL), and the combined organic 
layers were dried over Na2S04. The crude material was recrystallized from hexane-
ethyl acetate to yield 280a (196 mg, 94%) as white crystals: mp 155-156 °C (hexanes-
ethyl acetate); Rf 0,43 (1:1, hexanes-ethyl acetate); [a]D23 -22.7 (c 0.7, CHCh); IR 
(film) v 3445, 2993, 2087, 1646, 1216, 1065 cm-I; IH NMR (300 MHz, CDCh) () 7.79 
(d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 6.24 (d, J = 3.1 Hz, 1H), 5,48 (br s, 
1NH), 4.58( d, J= 5.6 Hz, 1H), 4.17 (t, J= 6.7 Hz, 1H), 3.99 (br s, 10H),?79 (d, J= 
4.7 Hz, 1H), 3.33 (t, J = 6.8, 1H), 2,41 (s, 3H), 1.28 (s, 3H), 1.06 (s, 3H) ppm; 13C 
NMR (75 MHz, CDCh) () 144.2, 135.9, 134.1, 129.9, 127.6, 120.6, 111,4, 76.3, 75.9, 
70.0, 56.7, 27.2, 25.9, 21.6 ppm; MS (EI) mlz (%): 402(M-CH3+), 43(40), 59(32), 
65(30), 91(85), 92(16), 97(15), 98(48), 99(68), 139(30), 155(26), 254(100), 255(15); 
HRMS calcd for CIsH17BrNOsS 402.0011, found 402.0004; Anal. ca1cd C 45.94, H 
4.82, found C 45.88, H 4.80. 
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281b 
(3aS ,4R,5S, 7 aR)-2,2-dimethyl-4-{ [(4-methylphenyl)sulfonyl]amino }-3a,4,5, 7 a-
tetrahydro-l,3-benzodioxol-5-yl acetate (281a) 
(3aS ,4R,5R, 7 aR)-2,2-dimethyl-4-{ [(4-methylphenyl)sulfonyl]amino }-3a,4,5, 7 a-
tetrahydro-l,3-benzodioxol-5-yl acetate (281b) 
To a stirred solution of 274 (100 mg, 0.217 mmol) in toluene (2.2 mL) was added n-
BU3SnH (86 ilL, 0.326 mmol). The reaction was placed in a preheated oil bath (78°C) 
before the addition of AIBN (catalytic amount). The reaction was heated at reflux for 
5 h before being cooled to room temperature and concentrated. The crude reaction 
mixture was purified via flash column chromatography (1:1, 1:2, hexanes-ethyl 
acetate) to give 281a and 281b (15:1) as white solids (60 mg, 60%) 
281a: IH NMR (600 MHz, MeOD) 0 7.77 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.0.1 Hz, 
2H) 5.92 (ddd, J = 10.1,3.6,2.2 Hz, IH), 5.76 (d, J = 10.2 Hz, IH), 5.24 ~dd, J = 8.8, 
,.0 
0.8 Hz, IH), 4.89 (s, 3H), 4.10 (s, 3H), 4.11 (dd, J = 9.7, 6.19 Hz, IH), 3.46 (t, J = 
9.74 Hz, IH), 2.43 (s, 3H), 1.86 (s, 3H), 1.28 (s, 3H), 1.26 (s, 3H) ppm; l3C NMR 
(300 MHz, MeOD) 0 ppm; 170.8, 142.6, 139.9, 131.1, 128.9(2C), 126.7(2C), 124.6, 
110.2, 75.7, 72.1, 70.8, 56.3, 26.7, 24.6, 19.9, 19.4, ppm;.MS (EI) mlz (%): 366 (M-
CH3), 43 (100), 44 (20), 59 (23), 80 (36), 91 (75), 98 (32), 99 (48), 108 (45), 109 
(28), 155 (21), 169 (25), 254 (29); HRMS calcd for C18H23N06S 366.1011, found 
325.134366.1011. 
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28lb: IH NMR (600 MHz, MeOD) () 7.77 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.2 Hz, 
2H) 5.97 (dd, J = 10.1,3.5 Hz, IH), 5.16 (t, J = 4.1 Hz" IH), 4.67-4.65 (m, IH), 4.28 
(dd, J = 6.9, 6.9 Hz, IH), 3.58 (dd, J = 7.8, 3.9, IH), 2.43 (s, 3H) , 1.91 (s, 3H) , 1.29 
(s, 3H) , 1.14 (s, 3H) ppm; 13C NMR (300 MHz, MeOD) () 170.3, 143.1, 138.4, 
129.2(2C), 128.8, 126.9, 126.8, 124.6, 109.3, 73.8, 71.3, 67.6, 53.9, 26.3, 24.5, 20.0, 
19.2 ppm; MS (El) m/z (%): 366 (M-CH3), 43 (100),44 (20), 59 (23), 80 (36), 91 
(75), 98 (32), 99 (48), 108 (45), 109 (28), 155 (21), 169 (25), 254 (29); HRMS calcd 
for ClsHz3N06S 366.1011, found 325.134366.1011. 
QAe 
a- NHTs I + : "'OH 
OH 
282a 
OAe 
~NHTS 
ll)"'OH 
OH 
282b 
(lS,4R,5S,6S)-4,5-dihydroxy-6-{[(4-methylphenyl)sulfonyl]amino}cyclohex-2-en-
l-yl acetate (282a) 
(lR,4R,5S,6S)-4,5-dihydroxy-6-{[(4-methylphenyl)sulfonyl]amino}cyclohex-2-en-
l-yl acetate (282b) 
To a stirred solution of 277 (40 mg, 0.095 mmol) in toluene (0.95 mL) was added n-
Bu3SnH (41 ilL, 0.143 mmol). The reaction was placed in a preheated oil bath (78 °C) 
before the addition of AIBN (catalytic amount). The reaction was heated at reflux for 
4 h before being cooled to room temperature and concentrated. The crude reaction 
mixture was purified via flash column chromatography (l: 1, 1 :2, 1 :4, hexanes-ethyl 
acetate) to give 282a and 282b (8: 1 mixture) as an inseparable mixture of white solids 
(23 mg, 65%): mp 194-195 °C (hexanes-ethyl acetate): 
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282a: RjO.27 (1:4 hexanes-ethyl acetate); IR (film) v 3684,3019,1731,1599,1522, 
1426, 1374, 1330, 1215, 1046 cm-l, IH NMR (600 MHz, MeOD) 0 7.7 (d, J = 7.7 Hz, 
2H), 7.37 (d, J = 8.1 Hz, 2H) 5.87 (dd, J = 10.1,3.9 Hz, 1H), 5.69-5.66 (m, 1H), 5.24 
(t, J = 4.1 Hz, 1H), 4.89 (s, 3H), 4.28 (t, J = 3.8, 1H), 3.92 (dd, J = 8.5,3.9, 1H), 3.84 
(dd, J = 8.4, 4.5, 1H), 2.43 (s, 3H) ppm; 13C NMR (150 MHz, MeOD) 0 170.6, 
143.1, 139.5, 131.9, 129.1(2C), 126.5 (2C), 72.6, 69.7, 66.1, 54.6, 19.9, 19.2 ppm; 
MS (EI) mlz (%): 341 (M), 43 (81), 58 (54), 65 (29), 86 (29), 91 (100), 92 (27), 108 
(22), 128 (27), 155 (43); HRMS calcd for Cl5Hl9N06S 341.0933.1348, found 
341.0933. 
282b: Rj 0.27 (1:4 hexanes-ethyl acetate); IR (film) v 3684, 3019, 1731, 1599, 1522, 
1426, 1374, 1330, 1215, 1046 cm-l, H NMR (600 MHz, MeOD) 0 7.7 (d, J = 7.7 Hz, 
2H), 7.37 (d, J = 8.1 Hz, 2H) 5.87 (dd, J = 10.1,3.9 Hz, 1H), 5.69-5.66 (m, 1H), 5.24 
(t, J = 4.1 Hz, 1H), 4.89 (s, 3H), 4.28 (t, J = 3.8, 1H), 3.92 (dd, J = 8.5,3.9, 1H), 3.84 
(dd, J = 8.4,4.5, 1H), 2.43 (s, 3H) ppm; 13C NMR (300 MHz, MeOD) 0 170.3, 143.1, 
138.5, 131.9, 129.2, 128.9(2C), 128.5(2C), 125.3, 68.6, 67.9, 65.3, 53.4, 20.0, 19.3 
:;, -
ppm; MS (EI) mlz (%): 341 (M), 43 (81),58 (54), 65 (29), 86 (29), 91 (100),92 (27), 
108 (22), 128 (27), 155 (43); HRMS calcd for Cl5Hl9N06S 341.0933.1348, found 
341.0933. 
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N-[(3aS,4R,5S,7aR)-5-hydroxy-2,2-dimethyl-3a,4,5,7a-tetrahydro-l,3-
benzodioxol-4-yl]-4-methylbenzenesulfonamide (284) 
To a stirred solution of aziridine 54 (600 mg, 1.875 mmol) , in DMSO (3 mL) was 
added 10% KOH (4 mL). The reaction mixture was heated to 40°C for 2 h and then 
cooled and neutralized. The crude mixture was extracted with ethyl acetate (3 x 10 
mL) and the combined organic layers were dried over Na2S04, filtered and 
concentrated. The crude material recrystallized from hexanes-ethyl acetate to yield 
284 (567 mg, 93%) as a white solid: m.p. 162-164 °C (hexanes-ethyl acetate); Rf 0.45 
(1:2, hexanes-ethyl acetate); [a]D23 -39.509 (c 1.10, CHCb); IR (film) v 3479, 3227, 
2986,2884, 1455, 1380, 1320, 1219, 1090, 1065, 748, 666 cm-l; IH NMR (300 MHz, 
CDCb) 0 7.83 (d, 1 = 8.01 Hz, 2H), 7.34 (d, 1 = 8.3 Hz, 2H), 5.93 (d, 1 = 10.20 Hz, 
IH), 5.87-5.79 (m, IH), 5.01 (s, br) 4.54 (t, 1 = 4.32 Hz, IH), 4.11 (d, 1ft= 7.80 Hz, 
IH), 3.98 (dd, 8.7, 6.0, IH), 3.05 (t, 1 = 8.4 Hz, 3H), 2.44 (s, 3H), 1.27 (s, 3H), 0.88 
(s, 3H) ppm; 13C NMR (75 MHz, MeOD) 8 142.7, 139.2, 134.9, 128.8 (2C), 127.0 
(2C), 122.8, 75.9, 72.1, 69.2, 59.2, 26.6, 24.6, 20.0 ppm; MS (El) mlz (%): 324(M-
CH3), 41(31), 42(18), 43(86),59(20),65(26),69(20),81(31),84(20), 91(100),92(16), 
97(16), 98(56), 99(59), 100(25), 109(18), 127(31), 139(37), 155(25), 253(16), 
217(50),255(24); HRMS calcd for Cl5H18N05S 324.0905, found 324.0905 
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286 
N -( (3aS,4R,5S, 7 aR)-5-Hydroxy -2,2-dimethyl-hexahydro-benzo[1,3]dioxol-4-yl)-
4-methyl-benzenesulfonamide (286) 
To a stirred solution of allylic alcohol 280a (196 mg, 0.468 mmol), in MeOH (2 mL) 
was added K2C03 (10 mg), and platinum(IV)oxide (catalytic amount) before purging 
the reaction flask with H2. The reaction mixture was stirred at room temperature and 1 
atm of H2 for 36 h before being filtered through a plug of Si02. The crude material 
was purified via flash column chromatography (1: 1 then 1:2, hexanes-ethyl acetate) to 
yield 286 (123 mg, 77%) as a white solid: m.p. 155-156 °c (hexanes-ethyl acetate); Rf 
0.30 (1:2 hexanes-ethyl acetate); [a]D23 -105.2 (c 1.32, CHCb); IR (film) v 3381, 
3255, 2985, 2934, 2893, 2765, 1597, 1155, 1088, 753 cm-I; IH NMR (300 MHz, 
CDCb) 0 7.81 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 5.48 (d, J = 6.9 Hz, 1H), 
4.17-4.10 (m, 1H), 3.72 (dd, J = 8.4, 4.9 Hz, 1H), 3~51 (d, J = 3.0 Hz, 1HJ,3.50-3.35 
(m, 1H), 2.97, (q, J= 17.4, 8.3 Hz, 1H), 2.39 (s, 3H), 2.11-2.03 (m, 1H), 1.88-1.80 (m, 
1H), 1.72-1.57 (m, 2H), 1.18 (s, 3H), 0.937 (s, 3H), ppm; BC NMR (75 MHz, CDCb) 
o 143.4, 137.1, 129.7, 129.4, 127.8, 127.4, 108.9, 78.7, 73.6, 70.7, 63.0, 27.5, 27.4, 
26.1, 23.2, 21.5 ppm; MS (EI) mlz (%): 341(M), 43(21), 59(34), 65(29), 82(35), 
83(20), 91(100), 100(28), 128(65), 155(34), HRMS ca1cd for CI6H23NOsS 341.1297 
found 341.1297; Anal. ca1cd: C 56.29, H 6.79, found C 56.21, H 6.70. 
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287 
(3aR,5aS,8aR,8bS)-2,2-dimethyl-8-(toluene-4-sulfonyl)-hexahydro-
[1,3]dioxolo[ 4' ,5' :3,4]benzo[2,1-d]oxazol-7 -one (287) 
To a stirred solution of sulfonamide 286 (600 mg, 1.76 mmol), in methylene chloride 
(5 mL) was added pyridine (1.42 mL, 17.6 mmol) then triphosgene (625 mg, 2.11 
mmol). The reaction was stirred at 0 °C for 30 min before being quenched by the 
addition of water (10 mL) and extracted into methylene chloride (3 x 10 mL). The 
combined organic layers were dried over Na2S04, filtered, and concentrated. The 
crude material was purified via flash column chromatography (2:1, 1:1 then 1:2, 
hexanes-ethyl acetate) to yield 287 (567 mg, 93%) as a white solid: m.p. 197-198 °C 
(hexanes-ethyl acetate); Rf 0.58 (1:1 hexanes-ethyl acetate); [a]D23 -2.56 (c 0.56, 
CHCh); IR (film) v 3557,3027,2987,2890, 1797, 1597, 1495, 1438, 1379, 1180, 
1153 em-I; IH NMR (300 MHz, CDCh) 8 8.01 (d, J == 8.1 Hz, 2H), 7.30\d, J = 8.0 
Hz, 2H), 4.59 (dd, J = 7.6, 5.5 Hz, IH), 4.38-4.32 (m, 1H), 3.90 (td, J = 11.7, 3.5 Hz, 
1H), 3.38 (dd, J = 11.6,8.0 Hz, 1H), 2.42 (s, 3H), 2.32-2.22 (m, 1H), 2.06-1.97 (m, 
1H), 1.90-1.74 (m, 1H), 1.73-1.65 (m, 1H) 1.46 (s, 3H), 1.40 (s, 3H) ppm; 13C NMR 
(75 MHz, CDCh) 8 151.9, 145.6, 133.8, 130.1, 129.7, 128.8, 128.6, 108.9, 76.4, 76.1, 
73.2, 68.4, 28.5, 25.9, 24.7, 22.4, 21.7 ppm; MS (El) mlz (%): 367 (M), 41(23), 
43(52), 65(29), 83(69), 85(45), 91(100), 155(47), 352(48) HRMS ealcd for C17H2I-
N06S 367.1089, found 367.1089; Anal. ealed: C 55.57, H 5.76, found C 55.67, H 
5.60. 
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289 
(3aR,5aS,8aR,8bS)-8-(4-Benzyloxy-benzoyl)-2,2-dimethyl-hexahydro-
[1,3]dioxolo[ 4' ,5' :3,4]benzo[2,1-d]oxazol-7 -one (289) 
To a stirred solution of N-tosyl cyclic carbamate 287 (560 mg, 1.52 mmol), in 
tetrahydrofuran (2 mL) was added sodium naphthalide (0.5 M.) at -78°C until a 
green colour persisted. The reaction mixture was stirred at -78 °c for 30 min before 
being quenched by the addition of sat. NH4CI (5 mL). The crude mixture was 
extracted into diethyl ether (3 x 10 mL), and the combined organic layers were dried 
over Na2S04, filtered and concentrated. The crude reaction mixture was purified via 
flash column chromatography (2: 1, 1: 1 then 1 :2, hexanes-ethyl acetate) to yield 
(3aR,5aS,8aR,8bS)-2,2-dimethyl-hexahydro[1,3]dioxolo[ 4' ,5' :3,4]benzo[2,1-
d]oxazol-7-one (288) (300 mg, 92%) as a white solid: m.p. 134-136 °C (hexanes-
t;;, _ 
ethyl acetate); Rf 0.31 (1:1 hexanes-ethyl acetate); [a]D23 -89.2 (c 2.9, CHCh); IR 
(film) v 3450, 3305, 2987, 2938, 2894, 1860, 1855, 1647, 1547, 1466, 1383, 1239, 
1061 cm-I; IH NMR (300 MHz, CDCh) 8 5.16 (br s, 1H), 4.30-4.25 (m, 1H), 4.07 
(dd, J = 8.8, 5.0 Hz, 1H), 3.81 (td, J = 11.5, 3.6 Hz, 1H), 3.48 (dd, J = 11.5,9.1 Hz, 
1H), 2.42-2.27 (m, 1H), 2.10-2.03 (m, 1H), 1.89-1.79 (m, 1H), 1.57 (br s, 1H), 1.47 
(s, 3H), 1.32 (s, 3H) ppm; BC NMR (150 MHz, CDCh) 8 160.1, 109.4, 77.9, 77.7, 
73.3, 62.9, 28.4, 25.9, 24.7, 24.0 ppm; MS (En mlz (%): 213 (M), 41(31), 43(100), 
55(28), 59(34), 67(48), 82(35), 83(21), 85(22), 98(23), 99(80), 127(22), 198(87), 
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HRMS ca1cd for C lOHI5N04 213.1001, found 213.1001; Anal. calcd C 56.33, H 7.09, 
found C 56.23, H 7.02. 
To a stirred solution of NaH (18.5 mg, 0.774 mmol) in THF (1 mL) was added 
(3aR,5aS,8aR,8bS)-2,2-Dimethyl-hexahydro-[1,3]dioxolo[ 4' ,5' :3,4]benzo[2,1-
d]oxazol-7-one (288) (110 mg, 0.516 mmol), in tetrahydrofuran (1 mL) dropwise at 0 
dc. The reaction was allowed to warm to room temperature over 1 h before the 
addition of 4-benzyloxy benzoyl chloride (127 mg, 0.516 mmol) in four portions over 
2 h. The reaction mixture was stirred for 12 h before being quenched by the addition 
of sat. NH4Cl (2 mL). The tetrahydrofuran was removed under reduced pressure and 
the aqueous layer was extracted into ethyl acetate (3 x 5 mL). The combined organic 
layers were dried over Na2S04, filtered and concentrated. The crude reaction mixture 
was purified via flash column chromatography (4:1, 2:1 then 1:1, hexanes-ethyl 
acetate) to yield 289 (220 mg, 91 %) as a white solid: m.p. 149-150 °C (hexanes-ethyl 
acetate); Rf O.62 (1:1 hexanes-ethyl acetate); [a]D23 + 0.72 (c 2.1, CHCh); IR (film) v 
3682, 3531, 3379, 3066, 3019, 2989, 2937, 2889, 2587, 1952, 1786, 1697, 1603, 
" 
1382, 1256, 1216 cm-I; IH NMR (600 MHz, CDCh) & 7.82 (d, J = 8.3 HZ: 2H), 7.31-
7.42 (m, 5H), 6.97 (d, J = 8.3 Hz, 2H), 5.10 (s, 2H), 4.29 (dd, J = 4.2, 7.9 Hz, 1H), 
4.20-4.27 (m, 2H), 3.94 (dd, J = 3.8, 11.3 Hz, 1H), 2.31-2.36 (m, 1H), 2.15-2.20 (m, 
1H), 1.93-1.97 (m, 1H), 1.88-1.93 (m, 1H), 1.68 (s, 3H), 1.34 (s, 3H) ppm; 13C NMR 
(150 MHz, CDCh) & 169.9, 163.3, 155.1, 136.1, 132.6(2xC), 128.7, 128.3(2xC), 
127.6(2xC), 125.4, 114.3(2xC), 109.6, 78.2, 75.4, 73.7, 70.2, 63.8, 27.9, 25.9, 24.7, 
23.5 ppm; MS (El) mlz (%): 423 (M), 43(67), 65(20), 83(24), 85(68), 91(100), 
124 
92(25), HRMS calcd for C24H25N06 423.1682, found 423.1682; Anal. calcd: C 68.07, 
H 5.95, found C 68.14, H 5.96. 
5.3 Codeine Project Experimental Procedures 
6Br ACO,,: ~ AcO" 
257 
(1R,6S)-Acetic acid 6-acetoxy-2-(2-bromoethyl)-cyclohex-2-enyl ester (257) 
Diol 241 (2 g, 9 mmol) was dissolved in CH2Ch (20 mL) and transferred to a 100 mL 
round-bottomed flask. The flask was cooled externally in an ice bath before 
sequential addition of NEt3 (3.6 mL, 27 mmol), acetic anhydride (1.85 mL, 20 mmol), 
and DMAP (244 mg, 2 mmol). The reaction mixture was allowed to warm to r.t. over 
5 h. The mixture was cooled to 0 °C before being washed with 1 N HCI (2 x 10 mL), 
sat NaHC03 (1 x 10 mL), and brine (1 x 10 mL). The organic layer was dried over 
anhydrous MgS04, and the drying agent removed by filtration through a short column 
'"" (ca 4 em) of silica gel. Evaporation of the organic solvent furnished 257 t4.02, 67%) 
as a yellow oil: [a]23D -120.5 (c 0.9, CH2Ch); Rj O.5 (hexanes-ethyl acetate, 3:1); IR 
(film) v 2947, 1738, 1434 em-I; IH NMR (300 MHz, CDCh) () 5.80 (t, J = 3.3 Hz, 
IH), 5.47 (d, J = 3.3 Hz, IH), 4.99 (dt, J = 11.7, 3.6 Hz, IH), 3.39 (td, J = 7.2, 2.4 Hz, 
2H), 2.53 (m, 2H), 2.24-2.20 (m, 2H), 2.08 (s, 3H), 1.99 (s, 3H), 1.90-1.83 (m, IH), 
1.77-1.71 (m, IH) ppm; 13C NMR (75 MHz, CDCh) () 170.7, 170.2, 131.2, 130.4, 
70.0, 67.3, 37.4, 30.6, 24.0, 22.2, 20.9, 20.9 ppm; HRMS-EI (M+) Ca1cd for 
CI2H1704Br 304.0310, found 304.0317; Anal. calcd: C, 47.23; H, 5.62, found C, 
47.42, H, 5.67. 
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258 
{2-[5-(tert-butyl-dimethyl-silanyloxy)-6-hydroxy-cyclohex-l-enyl]-ethyl}-methyl-
carbamic acid tert-butyl ester (258) 
To a solution of diol265 (426 mg, 2 mmol) in 30 mL of CH2Cl2 at -70°C was added 
triethylamine (0.53 mL, 4 mmol) before the addition of TBS-triflate (0.50 mL, 2.2 
mmol) was added dropwise over 3 min. The reaction stirred for 10 min before being 
quenched by addition of H20 (15 mL). The layers were separated, and the aqueous 
layer extracted with CHCh (2 x 10 mL). The combined organic phase was washed 
with cold 2% aq. HCI, sat. NaHC03, and then dried over MgS04. Evaporation of the 
solvent gave a crude oil, which was purified via flash column chromatography (1:1, 
hexanes-ethyl acetate,) to give 258 (435 mg, 66%) as a clear and colourless oil: Rf 
0.47 (DCM:EtOAc, 96:4); [a]D24 -22.6 (c 0.5, CHCh); IR (film) v 3556, 3475, 2953, 
2857, 1692, 1472, 1392, 1253, 1085 cm-I; IH NMR (600 MHz, CDCb) mixture of 
rotamers b 5.54 (s, 1H), 5.52 (s, 1H), 3.98 (s, 1H), 3.90 (s, 1H), 3.79 (s, 111), 3.77 (s, 
1H), 3.26-3.20 (m, 2H), 2.85 (s, 3H), 2.82 (s, 3H), 2.39 - 2.32 (m, 2H), 2.30 - 2.23 
(m, 2H), 2.13 (br s, 2H), 1.98 (br s, 2H) 1.80 - 1.72 (m, 2H), 1.54 (s, 2H), 1.44 (s, 
18H), 0.9 (s, 18H), 0.11 (s, 6H), 0.10 (s, 6H) ppm; 13C NMR (150 MHz, CDCl) b 
155.7, 134.8, 126.6, 79.0 (br), 71.0,68.8,48.4,47.2,34.1,33.3,32.8,28.4,25.8,25.4, 
25.3,24.3,24.1, 18.1, -4.4, -4.8 ppm; MS (El) mlz (%): 228 (21), 197 (21), 136 (12), 
74 (22), 73 (15), 57 (63), 44 (100) HRMS-El (M+-57) calcd for CI2H30N04Si 
328.1944, found 328.1946; Anal. calcd. for C2oH39N04Si C 62.10, H 10.22, found C 
62.29, H 10.19. 
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259 
2-Bromo-4-methoxy-3-hydroxybenzaldehyde, 259 
To a solution of isovanillin 299 (51 g, 337 mmol) in chloroform (1.1 L) was added N-
bromosuccinimide (72 g, 405 mmol) portion-wise under an atmosphere of nitrogen. 
The mixture was heated at reflux until total consumption of the starting material (TLC 
analysis). The reaction was quenched with H20 and then concentrated. The crude 
mixture was washed with 3: 1 ethyl acetate-methanol (150 mL) and 3: 1 methanol: 
water (150 mL) and dried over Mg2S04 to yield 259 (58.5 g, 75%) as a white solid: Rf 
0.27 (2:1, hexanes-ethyl acetate); m.p. 202-204 °C (ethyl acetate); IR (film) v 3188, 
2922, 1666, 1561, 1493, 1278, 774 cm-I; IH NMR (600 MHz, CDCh) 0 10.24 (s, 
IH), 7.56 (d, J = 8.4 Hz, IH), 6.91 (d, J = 8.4 Hz, IH), 6.05 (s, IH), 3.99 (s, 3H), 1.54 
(s, IH) ppm; 13C NMR (150 MHz, CDCh) 0 190.9, 151.7, 143.2, 127.2, 122.8, 112.9, 
109.3,56.6 ppm; MS (EI) mlz (%) 232 (85), 231 (89),230 (100), 229 (87), 228 (13), 
80 (11), 79 (25), 51 (22), 50 (14); HRMS-EI (M) CSH7Br03 229.91579, found 
229.9578. 
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260 
{2-[6-(2-Bromo-3-formyl-6-methoxy-phenoxy)-5-(tert-butyl-dimethyl-silanyloxy)-
cyclohex-l-enyl]-ethyl}-methyl-carbamic acid tert-butyl ester (260) 
To a stirred solution of DIAD (1.02 mL, 5.207 mmol) in 10 mL anhydrous THF at-
10 °C was added freshly distilled tributyl phosphine (1.69 mL, 5.207 mmol) 
dropwise. The solution was stirred at -10°C for 10 min, then transferred dropwise to 
an anhydrous THF (20 mL) solution of bromoisovanillin 259 (0.925 g, 4.005 mmol) 
and allylic alcohol 258 (1.39 g, 3.605 mmol) at -78°C. Once the addition was 
completed, the reaction vessel was warmed to 0 °C and stirred for 1 h then stirred at 
r.t. for an additional 48 h. The solvent was removed under reduced pressure and the 
crude mixture was subjected to column chromatography (DCM-EtOAc, 100:0,98:2) 
to yield 260 (1.01 g, 55%) as colourless oil: Rf 0.81 (DCM:EtOAc, 96:4); [a]D23 
i 
+75.7 (c 0.7, CHCh); IR (film) v 3007, 2952, 2929, 2857, 1688, 1578, 1481, 1275, 
1252, 1173, 1085, 1028, 1005, 836 cm-I; IH NMR (600 MHz, CDCh) mixture of 
rotamers () 10.30 (s, 2H), 7.75 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 5.85 (s, 
IH), 5.83 (s, IH), 4.57 (s, 2H), 3.98 (br s, 8H), 3.59 (s, IH), 3.44 (s, IH), 3.22 (br s, 
2H), 2.85 (br s, 6H), 2.55 - 2.37 (m, 4H), 2.28 - 2.17 (m, 4H), 2.06 (s, IH), 2.04 (s, 
IH), 1.72 - 1.65 (m, 2H), 1.46 (s, 18H), 0.75 (s, 18H), -0.12 (s, 6H), -0.17 (s, 6H) 
ppm; 13C NMR (150 MHz, CDCh) () 191.3, 157.9, 155.8, 144.6, 130.9, 130.3, 127.7, 
125.9, 123.5, 110.9, 80.3, 79.1, 67.7, 56.1, 48.9, 48.3, 41.5, 35.0, 33.4, 32.7, 28.5, 
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25.6,25.4,20.8, 18.0, -4.9, -5.1 ppm; MS (EI) mlz (%): 312 (28), 269 910), 268 (45), 
237 (24), 136 (31), 109 (14), 75 (27), 73 (33), 57 (47),44 (100); HRMS-EI (M): calcd 
for C28H44N06BrSi 597.2121, found 597.2140; Anal. Calcd. for C28H4~06BrSi C 
56.18, H 7.41, found C 56.09, H 7.65. 
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261 
{2-[ 6-(tert-butyl-dimethyl-silanyloxy )-I-formyl-4-methoxy-6, 7 -dihydro-5aH-
dibenzofuran-9a-yl]-ethyl}-methyl-carbamic acid tert-butyl ester (261) 
Aryl bromide 260 (205 mg, 0.3424 mmol) was dissolved in 5 mL of degassed toluene 
and transferred to a 10 mL Teflon-sealed Schlenck tube containing a magnetic stirring 
bar. Silver carbonate (283.3 mg, 1.0272 mmol), diphenylphosphino ferrocene (57.00 
mg, 0.1027 mmol) and palladium acetate (12 mg, 0.0514 mmol) were added 
sequentially. The tube was flushed with nitrogen, sealed, and placed in a pre-heated 
oil bath at 110°C for 50 min. A small aliquot of the reaction mixture was filtered 
through Celite, and IH NMR analysis of this aliquot indicated complete conversion to 
the product. The remaining black reaction mixture was filtered through Celite and 
washed with several portions of chloroform. The filtrate was adsorbed onto a mixture 
of silica gel and charcoal and then filtered through a plug of silica gel. Column 
chromatography (CH2C}z-EtOAc, 4:1) gave 261 (146 mg, 82%) as a semi-crystalline 
brown solid: Rf 0.79 (DCM:EtOAc, 96:4); [a]D23 +12.5 (c 0.6, CHCh); IR (film) v 
3008, 2953, 2930, 2856, 2734, 1692, 1610, 1571, 1436, 1366, 1285, 1250, 1170, 
129 
1155, 1046, 837 em-I; IH NMR (600 MHz, CDCh) mixture of rotamers () 9.90 (s, 
IH), 9.89 (s, IH), 7.38 (d, J = 8.2 Hz, 2H), 6.93 - 6.86 (m, 2H), 6.49 -6.40 (m, IH), 
6.40 - 6.32 (m, IH), 5.72 - 5.65 (m, 2H), 4.80 - 4.54 (m, 2H), 3.95 (s, 6H), 3.91 (br 
s, 2H), 3.32 (br s, IH), 3.25 - 3.16 (m, IH), 3.03 - 2.93 (m, 2H), 2.78 (s, 6H), 2.30-
2.00 (m, 8H), 1.43 (s, 18H), 0.91 (s, 18H), 0.14 (s, 6H), 0.04 (s, 6H) ppm; 13C NMR 
(150 MHz, CDCh) () 190.6, 155.5, 150.2, 147.5, 133.6, 130.4, 129.8, 129.2, 126.5, 
124.1, 110.4,90.9,89.9, 79.5, 68.8, 68.4, 56.0, 55.9, 51.8, 45.3, 44.6,36.4,35.5,34.7, 
34.6,34.1,31.6,30.5,29.1,28.4,25.8,25.7,25.3,22.7, 20.7,18.1,14.1,11.4, -4.7,-
5.2 ppm; MS (El) miz (%): 162 (12), 144 (17), 136 (12), 118 (13), 117 (18), 92 (32), 
91 (38), 88 (11), 75 (46), 73 (38), 57 (87), 44 (100) HRMS-El (M+-57) Calcd for 
C24H3~06Si 460.2155, found: 460.2150; Anal. calcd. for C 64.96, H 8.37, found C 
64.87, H 8.46 
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265 
[2-(5, 6-Dihydroxy-cyclohex-l-enyl)-ethyl]-methyl-carbamic acid tert-butyl ester, 
265 
Bromide 257 (6.34 g, 20.8 mmol) was dissolved in 20 mL anhydrous THF and 
transferred to a 50 mL thick-walled reaction vessel containing K2C03 (1.61 g, 11.6 
mmol) and a magnetic stirring bar. The reaction vessel was cooled to -40 DC, and 
gaseous methylamine was passed through the solution for 15 min. The reaction vessel 
was sealed, and the mixture stirred at r.t. for 48 h. The vessel was cooled to -40 DC 
before it was carefully opened. Potassium salts were removed by filtration and rinsed 
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with 15 mL DCM. The solvent was removed and the residue taken up in 50 mL 
anhydrous DCM. Triethylamine (5.20 mL, 37.4 mmol) was added to the solution and 
the reaction mixture was cooled to 0 DC in an ice salt bath. Boc anhydride (8.53 g, 
37.4 mmol) was added and the reaction mixture was stirred at r.t for 24 h. The 
reaction was washed with sat. ammonium chloride (3 x 100 mL) and sat. sodium 
carbonate (3 x 120 mL), brine (100 mL), and then dried with Na2S04. The solvent 
was then removed under reduced pressure and the crude mixture was subjected to 
column chromatography (6:1, 1:2, hexanes ethyl acetate) to afford 265 (2.51g, 50% 
over two steps); RfO.07 (ethyl acetate-hexanes, 2:1); IR (film) v 3383, 2974, 2930, 
1693, 1672 , 1396, 1158, 988 cm-I; IH NMR (600 MHz, CDCh) 0 5.43 (br s, 1H), 
4.87 (br s, 1H), 3.96 (br s, 2H), 3.56 (br s, 1H), 2.99 (d, J = 8.8 Hz, 1H), 2.91 (br s, 
1H), 2.86 (s, 3H), 2.42 - 2.30 (m, 1H), 2.18 (d, J = 13.4 Hz, 1H), 2.03 (br s, 2H), 1.74 
- 1.63 (m, 1H), 1.60 - 1.45 (m, 1H), 1.43 (s, 9H) ppm; l3C NMR (150 MHz, CDCh) 
o 157.0, 133.9, 128.8, 79.9, 70.0, 69.8, 48.3, 34.8, 34.0, 28.3, 25.4, 24.8 ppm; MS 
(El) mlz (%): 144 (12), 110 (110), 57 (71), 44 (100); HRMS-EI (M+) Ca1cd for 
CI4H25N04 271.1784, found 271.1785 
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303 
tert-butyl {2-[ (SaS ,6S ,9aR)-6-{ [tert-butyl( dimethyl)silyl]oxy }-4-methoxy-l-[ (E)-2-
methoxyvinyl]-6,7-dihydrodibenzo[b,d]furan-9a(SaH)-yl]ethyl}methylcarbamate 
(303) 
(Methoxymethyl)triphenyl-phosphonium chloride (430 mg, 1.255 mmol) was 
suspended in anhydrous THF (4 mL) and cooled to -78°C. tert-BuLi (1.40 M in THF, 
900 f...lL, 1.255 mmol) was added dropwise. The reaction mixture was then stirred at -
78°C for 15 min. In a second flask, aryl aldehyde 261 (260 mg, 0.502 mmol) was 
dissolved in 8 mL anhydrous THF. The ylid/THF solution was cannulated into the 
aldehyde solution at r.t, and the resulting mixture was stirred for 3 h before being 
filtered through a plug of Si02 and concentrated. The crude material was purified via 
flash column chromatography with a solvent system of 5:1 (hexanes-ethyl acetate) to 
yield 303 (mixture of E & Z isomers, 183 mg , 70 %) as a clear oil: Rf 0,;7 . (hexanes-
ethyl acetate, 1:1); IR (film) v 2930,2855, 1696, 1640, 1504, 1462, 1421, 1391, 1365, 
1279, 1251, 1213, 1155, 1123, 1017,837, 778, 666 cm-I; IH NMR (300 MHz, CDCh) 
mixture of geometric isomers and rotamers 8 7.39 (d, J = 8.7 Hz, 1H), 6.85-6.60 (m, 
4H), 6.15 (d, J = 6Hz, 1H), 6.10-5.80 (m, 3H), 5.80-5.60 (m, 2H), 5.35 (s, 1H), 4.50 
(s, 2H), 4.10-3.90 (m, 2H), 3.90-3.75 (m, 7H), 3.75 (s, 3H), 3.74 (s, 3H), 3.50-3.10 
(m, 2H), 3.10-2.85 (m, 2H), 2.78 (8, 7H), 2.35-2.20 (m, 2H), 2.20-1.75 (m, 9H), 1.71 
(d, J = 6 Hz, 1H), 1.50-1.30 (m, 20H), 1.00-0.80 (m, 20H), 0.15 (s, 6H), 0.05 (s, 6H) 
ppm; BC NMR (75 MHz, CDCh) 8 155.5, 149.1, 147.4, 146.3, 143.7, 143.4, 129.2, 
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124.4, 124.3, 122.8, 118.7, 111.7, 111.4, 101.2, 68.4, 60.5, 60.4, 55.9, 55.8, 28.5, 
28.4, 25.9, 21.0, 18.1, 14.2, -4.7, -5.2 ppm; MS (EI) m/z (%): 184 (50), 135 (15), 84 
(80), 71 (19),43 (100); Calcd for C30H47N06Si 545.3173, found 545.3170. 
304 
tert-butyl {2-[ (5aS,6S,9aR)-6-hydroxy-4-methoxy-l-[(E)-2-methoxyvinyl]-6, 7-
dihydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (304) 
Enol ether 303 (384 mg, 0.7042 mmol) was dissolved in 6 mL of THF at 0 °C, and 
then TBAF (1.0 M in THF, 775 J.lL, 0.7746 mmol) was added. The reaction mixture 
was stirred at r.t for 3 h. A second portion of TBAF (352 J.lL) was added at r.t, and the 
reaction was allowed to stir for an additional 2 h. The reaction was quenched with 
water (10 mL) and extracted into DCM (3 x 15 mL). The organic phase was washed 
with brine and dried over sodium sulfate. The crude material was subjected to column 
chromatography (hexanes-ethyl acetate, 9:1, 4:1, 1:1) to afford 304 (mixture of E & Z 
isomers, 225 mg, 74%) as an oil: Rf 0.2 (hexanes-ethyl acetate, 1:1); IR (film) v 
3426, 2933, 1682, 1572, 1504, 1483, 1423, 1399, 1366, 1282, 1215, 1156, 1098, 
1046, 1015,882 cm-I; IH NMR (300 MHz, CDCh) mixture of geometric isomers and 
rotamers 8 6.79-6.65 (m, 3H), 6.20-6.05 (m, 1H), 6.00-5.85 (m, 1H), 5.85-5.70 (m, 
1H), 4.70-4.25 (m, 1H), 4.00-3.80 (m, 5H), 3.76 (d, J = 3.6 Hz, 1H), 3.71 (s, 3H), 
3.60-3.10 (m, 2H), 3.00-2.50 (m, 7H), 2.50-2.30 (m, 2H), 2.20-1.70 (m, 6H), 1.45 (s, 
12H), 1.40-1.20 (m, 4H), 1.01-0.80 (m, 2H) ppm; 13C NMR (75 MHz, CDCh) 8 
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155.5, 149.3, 147.6, 145.7, 145.4, 143.7, 143.4, 143.1, 130.1, 129.2, 127.6, 125.4, 
124.7, 124.6, 124.4, 123.1, 119.3, 111.7, 111.6, 111.3, 111.2, 101.5, 101.3,96.1,90.3, 
89.6, 79.5, 78.1, 77.3, 77.0, 76.8, 68.2, 67.8, 60.7, 60.6, 57.0, 56.1, 56.0, 55.9, 55.8, 
53.5, 51.4, 51.3, 48.4, 45.2, 44.8, 37.1, 36.6, 36.1, 34.3, 32.0, 29.7, 29.4, 29.0, 28.5, 
24.7,22.7, 14.2, 13.7, 1.0 ppm; MS (EI) mlz (%): 142 (25), 84 (100), 71 (28),57 (43), 
43 (88); HRMS (EI) Ca1cd for CZ4H33N06 431.2308, found 431.2308. 
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305 
tert-butyl-{2-[ (5aS ,6S ,9aR)-I-formyl-6-hydroxy-4-methoxy -6,7-
dihydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (305) 
Method A: To a stirred solution of 304 (40 mg, 0.0927 mmol) in DCM (0.3 mL) was 
added sodium acetate (2.5 mg, 0.0278 mmol) and pyridinium chlorochromate (40 mg, 
0.185 mmol) at 0 dc. The reaction was allowed to warm to room temperature before 
being filtered through SiOz and concentrated under reduced pressure. The crude 
material was purified via flash column chromatography with a solvent system of 3: 1 
(hexanes-ethyl acetate) to yield 305 (26 mg, 67 %) as a colourless oil. 
Method B: To a solution of aryl bromide 261 (400 mg, 0.774 mmol) in THF (3 mL) 
was added TBAF in THF (1.2 mL, 1.161 mmol) at 0 dc. The resulting reaction 
mixture was warmed slowly to room temperature before being quenched with water 
(6 mL). The organic layer was removed under reduced pressure and the resulting 
aqueous layer was extracted with DCM (3 x 10 mL), washed with brine (1 x 5 mL), 
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dried with Na2S04, filtered and concentrated. Purification by flash column 
chromatography (hexanes-ethyl acetate, 1:1) gave 305 (15 mg, 92%) as colourless oil: 
Rf 0.31 (hexanes-ethyl acetate, 1:1); [a]D24 +22.5 (c 0.6, CHCh); IR (film) v 3684, 
3608, 3019, 2978, 2933, 1688, 1612, 1571, 1436, 1285, 1215 cm-I; IH NMR (600 
MHz, CDCh) two rotamers 8 9.90 (s, IH), 9.89 (s, IH), 7.38 (d, J = 8.2 Hz, 2H), 6.86 
- 6.93 (m, 2H), 6.40 - 6.49 (m, IH), 6.32 - 6.40 (m, IH), 5.65 - 5.72 (m, 2H), 4.54 -
4.80 (m, 2H), 3.95 (s, 6H), 3.91 (bs, 2H), 3.32 (bs, IH), 3.16 - 3.25 (m, IH), 2.93 -
3.03 (m, 2H), 2.78 (s, 6H), 2.01 - 2.29 (m, 8H), 1.43 (s, 18H), ppm; l3C NMR (150 
MHz, CDCh) two rotamers 8 190.6, 155.5, 150.2, 147.5, 133.6, 130.4, 129.8, 129.2, 
126.5, 124.1, 110.4, 90.9, 89.9, 79.5, 68.8, 68.4, 56.0, 55.9, 51.8, 45.3, 44.6, 36.4, 
35.5,34.7, 34.6, 34.1, 31.6, 30.5, 29.1, 28.4, 25.8, 25.7, 25.3, 22.7, 20.7, 18.1, 14.1, 
11.4, -4.7, -5.2 ppm; MS (EI) mlz (%): 162 (12), 144 (17), 136 (12), 118 (13), 117 
(18),92 (32), 91 (38), 88 (11), 75 (46), 73 (38), 57 (87),44 (100); HRMS (EI) (M+-
57) calcd for C24H34N06Si 460.2155, found 460.2150. 
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308 
(4aS,5S,8aR)-3-methoxy-ll-methyl-5,6,10,1l,12,13-hexahydro-4aH,9H-
[1 ]benzofuro[3a,3,21g] [3]benzazocin-5-o1 (308) 
Enol ether 304 (23 mg, 0.34 mmol) was dissolved in a 4: 1 mixture of DCM and TFA 
(0.5 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred 
overnight before being quenched with cold sat. NaHC03 (2 mL) and extracted into 
135 
CHCh (3 x 4 mL). The combined organic layers were dried with Na2S04, filtered and 
concentrated. The resulting enamine 307 was dissolved in dry MeOH (0.3 mL) and 
cooled to 0 °C before the addition of NaCNBH3 (7 mg, 0.11 mmol) and AcOH (19 
[lL, 0.34 mmol). The reaction mixture was warmed to room temperature and stirred 
overnight before being quenched with cold sat. NaHC03 (2 mL). The MeOH was 
removed under reduced pressure and the aqueous layer extracted with CHCh (3 x 3 
mL) dried with Na2S04, filtered, and concentrated. Purification by flash column 
chromatography (DCM -ethyl acetate, 4: 1) gave 308 (146 mg, 41 %) as colourless oil: 
Rf 0.49 (DCM-ethyl acetate, 96:4); IR (film) v 3656, 3019, 2978, 2932, 2589, 1729, 
1689, 1612, 1480, 1215 cm-I; IH NMR (600 MHz, CDCh) two rotamers () 6.71 (d, J 
= 8.1 Hz, 1H), (d, J = 8.1 Hz, 1H), 5.74-5.68 (m, 1H), 4.32 (m, 1H), 4.00-4.93 (m, 
1H), 3.87 (s, 3H), 3.13-3.05 (m, 1H), 2.85-2.76 (m, 1H), 2.74-2.65 (m, 1H), 2.59-2.52 
(m, 2H), 2.46-2.38 (m, 2H), 2.31 (s, 3H), 2.17-2.11 (m, 1H), 2.01-1.96 (m, 1H), 1.83-
1.75 (m, 1H) 1.32-1.25 (m, 2H) ppm; 13C NMR (150 MHz, CDCh) two rotamers () 
143.8,132.2,129.6,122.7,122.1,111.2,96.1,67.8,60.5, 55.8, 52.6, 47.5,33.0,29.2 
ppm; MS (EI) m/z (%): 42 (27),43 (50),44 (27), 57 (38), 58 (56), 70 (100), 71 (27), 
83 (22), 149 (49), 179 (62), 301 (41); HRMS (EI) calcd for CIsH23N03 301.1678, 
found 301.1678. 
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310 
tert-butyl {2-[ (5aS ,6S,9aR)-6-{[tert-butyl( dimethyl)silyl]oxy }-I-(1,3-dioxolan-2-
ylmethyl)-4-methoxy -6, 7 -dihydrodibenzo[b,d1furan-9a( 5aH)-
yl]ethyl}methylcarbamate (310) 
Method A: To enol ether 303 (30 mg, 0.055 mmol) dissolved in benzene (0.5 mL) 
and ethylene glycol (0.5 mL) was added 1 crystal of pTsOH. The resulting reaction 
mixture was refluxed overnight before being filtered through silica, washing with 
DCM. The organic layer was removed under reduced pressure and the resulting 
aqueous layer extracted with DCM (3 x 3 mL), dried over Na2S04 filtered, and 
concentrated. Purification via flash column chromatography (hexanes-ethyl acetate, 
1:1) gave 310 (6 mg, 18%) as colourless oil. 
Method B: Aryl bromide 324 (2.75 g, 4.19 mmol) was dissolved in 40 mL of 
degassed toluene and transferred to a 150 mL Teflon-sealed Schlenck tub~ containing 
a magnetic stirring bar. P(p-tolylh (290 mg, 0.954 mmol), palladium acetate (213 mg, 
0.954 mmol), and triethylamine (1.34 mL, 9.53 mmol) were added sequentially. The 
tube was flushed with nitrogen, sealed, and placed in a pre-heated oil bath at 110 °C 
for 48 h before being filtered through Celite and silica and washed with ethyl acetate. 
The resulting organics were dried under reduced pressure and purified via flash 
column chromatography (hexanes-ethyl acetate, 10:1) to give 310 (2.2 mg, 94%) as a 
clear oil: RjO.59 (hexanes-ethyl acetate, 2:1); IH NMR (300 MHz, CDCh) 06.79 (d, 
J = 8.3 Hz, IH), 6.74 (d, J = 8.3 Hz, IH), 6.04 - 5.98 (m, IH), 5.75 - 5.71 (m, IH), 
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5.11.5.08 (m, 1H), 4.57 - 4.43 (m, 2H), 4.03 (t, J = 5.3, 1H), 3.91-3.86 (m, 3H), 3.84 
(s, 3H), 3.07 (dd, J = 14.4, 3.6, 1H), 3.00-2.88 (m, 2H), 2.79 (s, 3H), 2.76 (s, 1H), 
2.28-2.22 (m, 1H), 2.01-1.93 (m, 1H), 1.45 (s, 9H), 0.91 (s, 9H), 0.15 (s, 3H), 0.03 (s, 
3H) ppm; 13C NMR (150 MHz, CDCh) (two rotamers) 8 155.5, 146.1, 143.9, 132.3, 
129.4, 124.8, 123.1,111.7,104.7,104.5,89.8,79.4,68.4,65.0,64.9,55.8, 51.4,45.2, 
37.5, 36.3, 35.4, 34.2, 30.8, 29.7, 28.4, 25.8, 25.7, 18.1 ppm; MS (ED m/z (%): 41 
(31), 43 (58), 44 (51), 45 (26), 57 (35), 59 (34), 73 (100), 83 (26), 189 (23); 
HRMS(EI) ca1cd for C31H49N07Si 575.3278, found 575.3288. 
311 
tert-butyl-{ 2-[ (5aS ,6S,9aR)-I-(1,3-dioxolan -2-ylmethyl)-6-hydroxy -4-methoxy-
6,7 -dihydrodibenzo[b ,d]furan-9a( 5aH)-yl]ethyl} methylcarbamate (311) 
To a solution of ketal 310 (20 mg, 0.035 mmol) in THF (0.5 mL) was add~d TBAF in 
THF (0.05 mL, 0.052 mmol) at 0 0c. The resulting reaction mixture was warmed 
slowly to room temperature before being quenched with water (1 mL). The organic 
layer was removed under reduced pressure and the resulting aqueous layer was 
extracted with DCM (3 x 2 mL), dried with Na2S04 filtered and concentrated. 
Purification via flash column chromatography (hexanes-ethyl acetate, 1:1) gave 311 
(15 mg, 92%) as colourless oil: Rf 0.3 (hexanes-ethyl acetate, 2:1); IH NMR (300 
MHz, CDCh) 8 6.82 (d, J = 8.3 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 6.08 - 6.00 (m, 
1H), 5.83 - 5.75 (m, 1H), 4.57 - 4.38 (m, 1H), 4.04-3.99 (m, 2H), 3.91-3.88 (m, 3H), 
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3.88 (s, 3H), 3.45-3.22 (m, 1H), 3.07 (dd, J = 14.4, 3.6, 1H), 2.90(dd, J = 14.4, 6.3, 
1H), 2.78 (s, 3H), 2.47-2.33 (m, 1H), 2.19-2.06 (m, 1H), 2.00-1.90 (m, 3H), 1.44 (s, 
9H) ppm; 13C NMR (150 MHz, CDCh) two rotamers () 155.4, 145.6, 144.0, 129.3, 
124.9, 124.5, 123.7, 111.6, 104.6, 104.5,90.5, 79.5, 68.0, 65.1, 64.9, 64.9, 55.8, 51.7, 
45.2,37.7,36.4,35.5,34.2,29.7,29.2,28.4 ppm; MS (EI) mlz (%): 41 (46),43 (79), 
44 (53),45 (21),49 (23), 55 (46), 56 (21), 57 (80), 59 (34), 69 (24), 73 (100), 83 (25), 
84 (31), 103 (20), 142 (30), 149 (22); HRMS-EI calcd for C25H35N07: 461.2414, 
found 461.2414. 
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313 
tert-butyl-{2-[(5aS,6S,9aS)-6-hydroxy-4-methoxy-1-methyl-6,7,8,9-
tetrahydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (313) 
To aldehyde 305 (100 mg, 0.248 mmol) dissolved in MeOH (0.5 mL) wCl§ added 5% 
Pd/C (catalytic amount). The resulting reaction mixture was put under 1 atm H2 gas 
and stirred overnight. The reaction mixture was then filtered through Si02 and 
concentrated. Purification via flash column chromatography (hexanes-ethyl acetate, 
1: 1) yielded 313 (52 mg, 54%) as a colourless oil: Rf 0.28 (hexanes-ethyl acetate, 
1:1); IR (film) v 3612,3019,2977, 1682, 1506, 1434, 1214 cm-I; IH NMR (600 MHz, 
CDCh) (two rotamers) () 6.67 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 4.38-4.18 
(m, 1H), 3.84 (s, 1H), 3.82-3.74 (m, 1H), 3.27-3.11 (m, 1H), 3.06-2.83 (m, 2H), 2.75 
(s, 3H), 2.25-2.10 (m, 1H), 1.99-1.82 (m, 3H), 1.79-1.66 (m, 1H), 1.50-1.44 (m, 1H), 
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1.41 (s, 9H) ppm; 13C NMR (300 MHz, CDCh) (two rotamers) () 155.5, 146.1, 143.5, 
126.2, 123.5, 111.3, 79.4, 70.5, 49.4, 45.2,37.7,34.2,31.1,28.4,28.3, 18.1 ppm; MS 
(EI) mlz (%): 44 (28), 47 (25), 57 (32), 83 (100), 85 (69), 215 (59),216 (20); HRMS 
(EI) (M, 391) calcd for C22H33NOS 391.2359, found 391.2359. 
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314 
tert-butyl-{2-[(SaS,9aS)-4-methoxy-l-methyl-6-oxo-6,7,8,9-
tetrahydrodibenzo[b,d]furan-9a(SaH)-yl]ethyl}methylcarbamate (314) 
To alcohol 313 (8 mg, 0.020 mmol) dissolved in DMF (0.5 mL) was added IBX (11 
mg, 0.04 mmol) at 0 0c. The resulting reaction mixture was warmed to room 
temperature and stirred overnight before being quenched with water (2 mL) and 
extracted into CHCh (3 x 4 mL). The combined organic layers were washed with 
NaHC03 (3 x 3 mL) and dried over Na2S04. Purification by flasb column 
chromatography (hexanes-ethyl acetate, 2:1) gave 314 (6 mg, 77%) as colourless oil: 
Rf 0.65 (hexanes-ethyl acetate, 1:2); IH NMR (300 MHz, CDCh) (two rotamers) () 
6.69 (d, J = 8.2 Hz, IH), 6.63 (d, J = 8.2 Hz, IH), 4.57 (s, IH), 3.86 (s, IH), 3.29-3.11 
(m, IH), 2.79 (s, 3H), 2.72-2.55 (m, 2H), 2.44-2.32 (m, 2H), 2.27 (s, 3H), 2.17-2.02 
(m, 2H), 1.98-1.85 (m, 2H), 1.84-1.69 (m, 2H), 1.44 (s, 9H) ppm; 13C NMR (150 
MHz, CDCh) (two rotamers) () 207.9, 155.4, 147.9, 143.2, 128.3, 125.1, 124.3, 113.3, 
112.0,89.7, 89.5, 79.7, 56.2, 56.0, 53.9,45.1, 37.3, 37.0, 36.0, 35.6, 34.3, 32.6, 32.0, 
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28.4, 19.5, 19.2, 17.6 ppm; MS (EI) m/z (%): 41 (29),43 (45),57 (56), 230 (35), 231 
(100),248 (44); HRMS-EI calcd for C22H3INOs: 389.2202, found 389.2202. 
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315 
tert-butyl-{2-[(5aS,6S,9aS)-I-(1,3-dioxolan-2-ylmethyl)-6-hydroxy-4-methoxy-
6,7,8,9-tetrahydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (315) 
To a solution of ketal 311 (20 mg, 0.043 mmol) in MeOH (0.5 mL) was added 5% 
Pd/C (catalytic amount). The resulting reaction mixture was put under 1 atm H2 gas 
and stirred overnight. The reaction mixture was then filtered through Si02 and 
concentrated. Purification by flash column chromatography (hexanes-ethyl acetate, 
1:1) gave 315 (16 mg, 82%) as colourless oil: Rf 0.17 (hexanes-ethyl acetate, 1:1); IR 
(film) v 3612,3019,2977, 1682, 1506, 1434, 1214 cm-I; IH NMR (300 MHz, CDCh) 
(two rotamers) () 6.81 (dd, J = 8.4 Hz, IH), 6.73 (dd, J = 8.4 Hz, IH), 5.06 (t, J = 4.6 
Hz, IH), 4.02-3.96 (m, IH), 3.89-3.85 (m, 3H), 3.84 (s, 3H), 3.36-3.22 (m, IH), 3.00 
(dd, J = 14.5, 4.4 Hz, IH), 2.95-2.84 (m, 2H), 2.73 (s, 3H), 2.28-2.11 (m,IH), 1.99-
1.82 (m, 3H), 1.81-1.64 (m, 2H), 1.55-1.44 (m, 3H), 1.40 (s, 9H) ppm; 13C NMR (150 
MHz, CDCh) (two rotamers) () 155.5, 146.8, 143.9, 124.9, 123.5, 111.7, 104.5,92.4, 
79.3, 70.5, 65.0, 64.9, 55.8, 38.6, 35.7, 28.4, 28.0 ppm; MS (EI) m/z (%): 44 (27), 47 
(26), 49 (20), 73 (68), 84 (100), 86 (78); HRMS-EI calcd for C2sH3SN07 463.2570, 
found 463.2570. 
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316 
tert-butyl-{2-[ (5aS ,9aS)-I-(1,3-dioxolan-2-ylmethyl)-4-methoxy-6-oxo-6, 7 ,8,9-
tetrahydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (316) 
To a solution of ketal 315 (13 mg, 0.029 mmol) in DMF (0.5 mL) was added IBX (8 
mg, 0.029 mmol) at 0 DC. The resulting reaction mixture was warmed to room 
temperature and stirred overnight before being quenched with water (2 mL) and 
extracted into CHCh (3 x 4 mL). The combined organic layers were washed with 
NaHC03 (3 x 3 mL) and dried over Na2S04. Purification via flash column 
chromatography (hexanes-ethyl acetate, 1:1) gave 316 (11 mg, 85%) as colourless oil: 
Rf 0.55 (hexanes-ethyl acetate, 1:1); IH NMR (300 MHz, CDCh) () 6.86 (d, J = 8.3 
Hz, IH), 6.76 (d, J = 8.3 Hz, IH), 5.07 (t, J = 4.7 Hz, IH), 4.74-4.57 (m, IH), 4.00-
3.94 (m, IH), 3.86 (s, 3H), 3.86-3.82 (m, 2H), 3.40-3.25 (m, IH), 2.93-2.90 (m, 2H), 
2.81-2.71 (m, 4H), 2.45-2.34 (m, IH), 2.16-2.00 (m,3H), 1.98-1.81 (m,:;4H), 1.41-
1.39 (m 2H), 1.43 (s, 9H) ppm; MS (El) mlz (%): 44 (20), 47 (47),49 (38), 56 (27), 
73 (99), 86 (100), 88 (23), 303 (85); HRMS-El calcd for C2SH3SN07 461.2414, found 
461.2414. 
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318 
tert-butyl-{2-[ (5aS,9aS)-4-methoxy -1-methyl-6-oxo-6,9-
dihydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (318) 
Saturated ketone 314 (105 mg, 0.286 mmol) was dissolved in anhydrous THF (0.4 
mL) and cooled to -78°C before the addition of LDA in THF (0.268 mmol). After 
stirring for 10 min, TMS-CI (37 uL, 0.295 mmol) was added dropwise. The resulting 
reaction mixture was warmed to 0 °C before being quenched with saturated NH4CI (2 
mL) and extracted into EtOAc (3 x 3mL), washed with brine (1 x 2 mL), dried with 
Na2S04, filtered, and concentrated. The organic layer was removed under reduced 
pressure and the resulting crude mixture was dissolved in MeCN (0.5 mL). Pd(OAch 
was added in one portion and the resulting reaction mixture was stirred at room 
temperature overnight. The reaction mixture was quenched with sat. NaHC03 (1 mL) 
extracted into EtOAc (3 x 3 mL), washed with brine (1 x 3 mL), dried w1th Na2S04, 
filtered, and concentrated. Purification by flash column chromatography (hexanes-
ethyl acetate, 1:1) gave 318 (78 mg, 76% over two steps) as colourless oil: Rf 0.31 
(hexanes-ethyl acetate, 1:1); [a]D24 +97.342 (c 1.7, CHCh); IR (film) v 3019, 2979, 
2931, 1683, 1596, 1508, 1426, 1215 cm-I; IH NMR (600 MHz, CDCh) (two 
rotamers) () 6.947 (dt, J = 10.2,4.5 Hz, IH), 6.62 (dd, J = 15.8,8.2 Hz, 2H), 6.19 (d, J 
= 10.2 Hz, IH), 4.62 (s, 3H), 3.29-3.15 (m, IH), 3.01-2.86 (m, IH), 2.75 (s, 3H), 2.30 
(s, 3H), 2.17-2.06 (m, 2H), 2.01-1.98 (m, 2H), 1.86 (s, IH), 1.39 (s, 9H) ppm; 13C 
NMR (150 MHz, CDCh) (two rotamers) () 189.8, 189.4, 185.9, 155.4, 148.1, 147.1, 
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143.3, 129.2, 124.4, 112.3, 86.0, 79.7, 56.1,49.4,45.2, 37.0, 34.4, 33.4, 28.4, 23.2, 
22.8,22.4,21.9, 18.9 ppm; MS (EI) m/z (%): 41 (19),44 (19), 57 (36), 191 (22),229 
(100),230 (25); HRMS-EI calcd for C2SH29NOS 387.2046, found 387.2046. 
320 
tert-butyl-{2-[(5aS,9aS)-1-(1,3-dioxolan-2-ylmethyl)-4-methoxy-6-oxo-6,9-
dihydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}methylcarbamate (320) 
Ketone 316 (150 mg, 0.325 mmol) was dissolved in anhydrous THF (0.5 mL) and 
cooled to -78°C before the addition of NaHMDS in THF (0.325 mmol). After stirring 
for 10 min, TMS-CI (43 uL, 0.358 mmol) was added dropwise. The resulting reaction 
mixture was warmed to 0 °C before being quenched with sat. NH4CI (4 mL) and 
extracted into EtOAc (3 x 5 mL), washed with brine (1 x 2 mL), dried with Na2S04, 
filtered, and concentrated. The organic layer was removed under reduced ]1lressure and 
the resulting crude mixture was dissolved in MeCN (0.5 mL). Pd(OAc)2 (109 mg, 
0.487 mmol) was added in one portion and the resulting reaction mixture was stirred 
at room temperature overnight. The reaction mixture was quenched with saturated 
NaHC03 (3 mL) extracted into EtOAc (3 x 5 mL), washed with brine (1 x 3 mL), 
dried with Na2S04, filtered, and concentrated. Purification via flash column 
chromatography (hexanes-ethyl acetate, 1:2) gave 320 (120 mg, 81 % over two steps) 
as colourless oil: Rf O.29 (hexanes-ethyl acetate, 1:2); [a]D24 +91.57 {c 1.415, CHCh); 
IR (film) v 2978, 2850, 1685, 1625, 1507, 1283 cm-I; IH NMR (300 MHz, CDCh) 
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(two rotamers) 8 6.99-6.89 (m, IH), 6.82 (d, J = 8.2 Hz, IH), 6.73 (d, J = 8.2 Hz, IH), 
6.20 (d, J = 9.4 Hz, IH), 5.05 (t, J = 4.4 Hz, IH), 3.98-3.88 (m, 2H), 3.87-3.79 (m, 
6H), 3.35-3.22 (m, IH), 3.17-3.03 (m, IH), 3.03-2.94 (m, IH), 2.88-2.82 (m, IH), 
2.76 (s, 3H), 2.24-2.09 (m, 2H), 2.06 (m, IH), 1.41 (s, 9H) ppm; 13C NMR (150 MHz, 
CDCb) (two rotamers) 8 155.3, 148.6, 147.2, 143.7, 128.9, 124.5, 124.0, 112.5, 
104.5, 86.3, 79.8, 65.0, 64.9, 60.4, 56.0, 49.6, 45.2, 38.4, 35.7, 34.2, 28.4, 21.0, 14.2 
ppm; MS (En m/z (%): 41(24), 43(81), 57(33), 73(100), 84(20), 301(21); HRMS-EI 
ca1cd for C25H33N07 459.2257, found 459.2206. 
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323 
2-Bromo-3-[1,3]dioxolan-2-ylmethyl-6-methoxy-phenol (323) 
To a solution of bromoisovanilin 259 (20 g, 86.6mmol) in DCM (600 mL) at 0 °C 
was added EtN(iPr)2 (30.1 mL, 173.1 mmol) under an atmosphere of nitrogen. 
Afterwards, MOM-CI (9.8 mL, 129.84 mmol) was added via syringe over,,3 min, and 
then the reaction was stirred for 3 h. The reaction mixture was washed with 200 mL 
of distilled water and the aqueous phase was extracted with ethyl acetate (3 x 80 mL). 
The combined organic phases were washed with brine (150 mL), and then dried over 
MgS04 to afford 321 (29 g) as white solid. The product was used in the next step 
without further purification. A solution of Ph3PCH20CH2CI (13.7 g, 39.9 mmol) in 
THF (75 mL) was cooled to -78°C and t-butyllithium (1.48 M in pentane, 24.5 mL, 
36.4 mmol) was added over 3 min. The solution stirred at -78°C for 10 min then 
warmed to 0 °C and bromoisovanillin methoxy-methyl ether 321 (10.0 g, 36.4 mmol) 
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in THF (10 mL) was added dropwise over 2 min. The reaction mixture was heated to 
reflux for 4 hr, and then cooled to r.t and 100 mL of ethyl acetate was added. To this 
mixture was added distilled water (80 mL) and the biphasic mixture was extracted 
with ethyl acetate (3 x 100 mL). The organic phase was collected and washed with 
brine, then dried over MgS04 to afford 322 (18.2 g), which was taken to the next step 
without further purification. To the Wittig product 322 (18.2 g, 0.06 mol) in THF 
(200 mL) was added ethylene glycol (16.7 mL, 0.3 mol) and p-TsOH (5.7 g, 0.03 
mol). The mixture was heated at reflux for 2 h, cooled, and diluted with ethyl acetate 
and washed with water. The organic phase was dried with brine and then MgS04. The 
solvent was removed under reduced pressure. Column chromatography afforded 323 
(6.74 g, 64% over three steps): Rf 0.39 (2:1, hexanes-ethyl acetate); IR (KBr) v 3609, 
3583,3370,2959,2892,1607,1490,1441,1283,1232, 1199, 1130, 1034,986,941, 
820,802,645 cm-I; IH NMR (300 MHz, CDCb) () 6.85 (d, J = 8.34 Hz, 1H), 6.76 (d, 
J = 8.34 Hz, 1H), 6.00 (s, 1H), 5.10 (t, J = 5.1 Hz, 1H), 3.97 (m, 2H), 3.84 (m, 5H), 
3.07 (d, J = 5.0 Hz, 2H), 2.08 (s, 1H) ppm; 13C NMR (75MHz, CDCb) () 145.9, 
143.1, 128.8, 122.0, 111.3, 109.6, 103.4, 65.0, 56.3, 40.1 ppm; MS (El) ~z (%) 73 
(100),45 (14); HRMS-El CllH13Br03 Calc. 287.9997, found 287.99936; Anal. calcd 
for CllH13Br03 C 45.70, H 4.53, found C 46.25, H 4.55. 
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324 
tert-butyl-[2-«5S,6S)-6-[2-bromo-3-(1,3-dioxolan-2-ylmethyl)-6-
methoxyphenoxy ]-5-{[tert-butyl( dimethyl)silyl]oxy }cyclohex-l-en-l-
yl)ethyl]methylcarbamate (324) 
To a solution of DIAD (1.02 mL, 5.207 mmol) in 10 mL anhydrous THF at -10 DC 
was added freshly distilled tributyl phosphine (1.69 mL, 5.207 mmol).The resulting 
solution was allowed to stir at -10 DC for 10 min before transferring dropwise to an 
anhydrous THF (20 mL) solution of bromoisovanillin derivative 323 (0.925 g, 4.005 
mmol) and protected diol 258 (1.39 g, 3.605 mmol) at -78 DC. Once the addition was 
completed, the reaction vessel was warmed to 0 DC and stirred for 1 h. Then the 
reaction mixture was allowed to warm to r.t and was stirred for an additional 48 h. 
The solvent was removed under reduced pressure and the crude mixture was 
subjected to column chromatography (DCM:EtOAc 100:0 to 98:2) to afford 324 (2.2 
g, 78%) as colourless oil: Rj 0.81 (DCM:EtOAc, 96:4); [a]D24 +75.7 (c 0.7, CHCh); 
IR (film) v 3007, 2952, 2929, 2857, 1688, 1578, 1481, 1275, 1252, 1173, 1085, 1028, 
1005, 836 em-I; IH NMR (600 MHz, CDCh) mixture of rotamers 8 10.30 (s, 2H), 
7.75 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 5.85 (s, 1H), 5.83 (s, 1H), 4.57 (s, 
2H), 3.98 (br s, 8H), 3.59 (s, 1H), 3.44 (s, 1H), 3.22 (br s, 2H), 2.85 (br s, 6H), 2.55-
2.37 (m, 4H), 2.28 - 2.17 (m, 4H), 2.06 (s, 1H), 2.04 (s, 1H), 1.72 - 1.65 (m, 2H), 
1.46 (s, 18H), 0.75 (s, 18H), -0.12 (s, 6H), -0.17 (s, 6H) ppm; 13C NMR (150 MHz, 
147 
CDCh) 0: 191.3, 157.9, 155.8, 144.6, 130.9, 130.3, 127.7, 125.9, 123.5, 110.9, 80.3, 
79.1,67.7,56.1,48.9,48.3,41.5,35.0,33.4,32.7, 28.5,25.6, 25.4, 20.8, 18.0, -4.9,-
5.1; MS (EI) mlz (%): 312 (28), 269 910), 268 (45),237 (24), 136 (31), 109 (14), 75 
(27), 73 (33),57 (47),44 (100); HRMS-EI calcd for C3IHsoBrN07Si 655.2540, found 
655.2541; Anal. calcd. for C 56.70, H 7.67, found C 56.69, H, 7.65. 
327 
(6aS,11bR)-11-(2,2-dimethoxyethyl)-6,8-dimethoxy-3-methyl-2,3,4,6a-
tetrahydro-lH -4,11 b-methano[l ]benzofuro[3,2-d]azocine (327) 
To a solution of ketone 320 (20 mg, 8.6 mmol) in methanol (0.5 mL) was added conc. 
HCI (1 drop). The mixture was heated at reflux for 24 h before being cooled to 0 DC 
and quenched with NaHC03 (2 mL). The organic layer was separated, and the 
resulting aqueous layer was extracted with chloroform (3 x 5 mL). The combined 
organic layers were washed with brine and dried with NaS04. The solvent was 
removed under reduced pressure and subsequent flash column chromatogrpahy 
(95:5:1 CHCh;MeOH:NH40H) afforded 327 (12 mg, 74% yield) as a clear oil: Rf 
0.72, (92:8:1 CHCh: MeOH: NH40H); IR (KBr) v 3518, 3020,2915, 1724, 1489, 
1215 cm-I; IH NMR (600 MHz, CDCh) 0 6.74 (d, J = 8.4 Hz, IH), 6.70 (d, J = 8.4 
Hz, IH), 4.92 (d, J = 6.4 Hz, IH), 4.92 (dd, J = 6.5, 4.3 Hz, IH), 4.51 (s, IH), 3.81 (s, 
3H), 3.69 (s, 3H), 3.52-3.49 (m, IH), 3.34 (s, 3H), 3.31 (s, 3H), 3.04 (dd, J = 14.4,4.3 
Hz, IH), 2.90 (dd, J = 14.4, 6.6 Hz, IH), 2.65-2.58 (m, 2H), 2.27 (s, 3H), 2.26-2.25 
148 
(m, IH), 2.14-2.09 (m, IH), 1.77-1.72 (m, 2H) ppm; 13C NMR (150 MHz, CDCb) 0 
147.2, 143.4, 132.6, 125.6, 123.6, 110.9, 105.1, 92.1,,83.4, 77.2, 77.0, 76.8, 55.6, 
54.8, 54.2, 53.7, 52.8, 45.8, 45.7, 43.0, 35.4, 34.7, 34.1 ppm; MS (EI) mlz (%) 75 
(100), 255 (10), 375 (22); HRMS-EI calcd for C21H29NOs 375.2046, found 375.2046. 
328 
(6aS,11bR)-11-(1,3-dioxolan-2-ylmethyl)-8-methoxy-3-methyl-2,3,4,5-tetrahydro-
IH-4,11b-methano[1]benzofuro[3,2-dJazocin-6-one (328) 
To a solution of a,~-unsaturated ketone 320 (110 mg, 0.24 romol) in THF (1 mL) was 
added TFA (0.5 mL). The resulting reaction mixture was refluxed for 3 h before 
being cooled to 0 °C, and quenched with saturated NaHC03 (4 mL). The crude 
mixture was extracted into CHCb (3 x 5 mL), washed with brine (1 x 2 mL), dried 
with Na2S04, filtered, and concentrated. Purification via flash column 
chromatography (CHCh:MeOH:NH40H, 92:8:1) gave 328 (65 mg, 76%) as 
colourless oil: Rf 0.52 (CHCb:MeOH:NH40H, 92:8:1); [a]D24 -58.108 (c 0.565, 
CHCb); IH NMR (300 MHz, CDCb) (two rotamers) 0 6.82 (d, J = 8.3 Hz, IH), 6.73 
(d, J = 8.4 Hz, IH), 5.02 (t, J = 4.8 Hz, 1H), 4.72 (s, 1H), 3.99-3.91 (m, 2H), 3.86-
3.81 (m, 6H), 3.51-3.44 (m, IH), 3.01 (dd, J = 9.2, 4.8 Hz, 2H), 2.95-2.86 (m, IH), 
2.70-2.56 (m, 2H), 2.49-2.39 (m, 2H), 2.34 (s, 3H), 1.85 (dd, J = 11.9, 1.0 Hz, 1H), 
1.75-1.66 (m, IH) ppm; 13C NMR (150 MHz, CDCb) (two rotamers) 0 205.7, 146.9, 
143.5,131.1,124.6,124.0,111.8,104.7,89.0,64.9,55.8, 49.2, 46.8, 42.8,36.1,35.5, 
149 
34.1 ppm; MS (EI) mlz (%): 44 (41), 73 (100), 215 (21), 217 (21); HRMS-EI ca1cd 
for C2oH2SNOS 359.1733, found 359.1739. 
329 
[(6aS,11bR)-8-methoxy-3-methyl-6-oxo-2,3,4,5,6,6a-hexahydro-lH-4,11b-
methano[l ]benzofuro[3,2-d]azocin-ll-yl]acetaldehyde (329) 
To a solution a,~-unsaturated ketone 320 (200 mg, 0.55 mmol) in MeCN (1 mL) and 
H20 (1 mL) was added conc. HCI dropwise until a pH of 1 was reached. The 
resulting reaction mixture was heated at 45°C for 24 h before being cooled to 0 DC, 
and quenched with saturated NaHC03 (4 mL). The crude mixture was extracted into 
CHCl) (3 x 5 mL), washed with brine (1 x 2 mL), dried with Na2S04, filtered, and 
concentrated. Purification by flash column chromatography (CHCl):MeOH:N~OH, 
92:8:1) gave 329 (135 mg, 77%) as colourless oil: Rf 0.37 (CHCl):MeQH:NH40H, 
92:8:1); [a]D24 -51.08 (c 0.43, CHCl)); IR (film) v 2927, 2870, 1722, 1624, 1506, 
1436, 1283 cm-I; IH NMR (300 MHz, CDCl)) (two rotamers) 8 9.67 (t, J = 1.9 Hz, 
1H), 6.75 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 4.73 (s, 1H), 3.71 (dd, J = 5.8, 
2.1 Hz, 2H), 3.51-3.41 (m, 1H), 2.94-2.84 (m, 1H), 2.70-2.60 (m, 1H), 2.47-2.40 (m, 
2H), 2.39-2.34 (m, 1H), 2.31 (s, 3H), 2.22-2.14 (m, 1H), 1.86-1.77 (m, 1H), 1.72-1.62 
(m, 1H) ppm; 13C NMR (150 MHz, CDCl)) (two rotamers) 8 205.1, 199.0, 147.4, 
144.3, 131.3, 124.6, 119.9, 112.2, 89.0, 60.3, 55.8, 55.6, 48.9, 46.4, 46.2, 42.6, 35.9, 
150 
35.3,34.0,21.0, 14.1 ppm; MS (El) mlz (%): 214 (20),229 (18), 297 (100),298 (20); 
HRMS-El calcd for C18H21N04 315.1471, found 315.1469. 
Meo~ 
HO~O 
Br 
330 
(2-bromo-3-hydroxy-4-methoxyphenyl)acetaldehyde (330) 
To a solution of bromoisovanilin (259) (2.0 g, 8.6 mmol) in DCM (60 mL) at 0 DC 
was added EtN(iPr)2 (3.0 mL, 17.3 mmol), before the dropwise addition of MOM-CI 
(0.98 mL, 12.9 mmol). The reaction was stirred for 3 h and then washed with 20 mL 
of distilled water, and extracted with ethyl acetate (3 x 20 mL). The combined organic 
phases were washed with brine (15 mL), dried over MgS04, and the solvent was 
removed under reduced pressure to provide MOM ether 321, which was taken to the 
next step without further purification. A solution of Ph3PCH20CH2CI (1.4 g, 4.0 
mmol) in THF (10 mL) was cooled to -78 DC and t-butyllithium (1.4 M in pentane, 
2.5 mL, 3.64 mmol) was added dropwise. The resulting mixture was stim'!!d at -78 DC 
for 10 min before being warmed to 0 DC. Bromoisovanillin methoxy-methyl ether 321 
(1.0 g, 3.64 mmol) in THF (2 mL) was added dropwise. The resulting reaction 
mixture was heated to reflux for 4 h before being cooled to r.t. and diluted with 
distilled water (10 mL). The resulting mixture was extracted with ethyl acetate (3 x 10 
mL) and the combined organic phases were washed with brine, dried with MgS04 
and concentrated under reduced pressure. To this crude product in THF (20 mL) was 
added water (10 mL) and p-TsOH (0.57 g, 0.33 mmol). The mixture was heated at 
reflux for 2 h before being diluted with ethyl acetate. The organic layer was washed 
151 
with water, washed with brine, and dried over MgS04. Flash column chromatography 
afforded 330 (0.53 g, 24% over 3 steps): RfO.61 (1:1? hexanes-ethyl acetate); m.p. 
104°C (hexanes-ethyl acetate ); IR (KBr) v 3518,3020,2915, 1724, 1489, 1215 cm-I; 
IH NMR (300 MHz, CDCh) D 9.73 (t, J = 1.8 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 6.76 
(d, J = 8.3 Hz, 1H), 6.04 (s, 1H), 3.91 (s, 3H), 3.80 (d, J = 1.8 Hz, 2H) ppm; 13C 
NMR (75 MHz, CDCh) D 199.0, 146.5, 143.7, 125.4, 122.0, 111.0, 109.7,56.4,49.9 
ppm; MS (EI) mlz (%) 215 (100), 217 (100), 218 (11), 244 (32), 246 (32); HRMS-EI 
ca1cd for C9H9Br03 243.9735, found 243.9735. 
332 
tert-butyl-{2-[(5aS,6S,9aR)-6-{[tert-butyl(dimethyl)silyl]oxy}-4-methoxy-l-(2-
oxoethyl)-6,7 -dihydrodibenzo[b ,d]furan-9a( 5aH)-yl] ethyl } methylcarbamate (332) 
A solution of 303 (180 mg, 0.33 mmol) in MeCN (2 mL) was degassoounder an 
atmosphere of N2 before the addition of CuCh (3 mg, 0.033 mmol). The resulting 
reaction mixture was placed immediately into an oil bath preheated to 40°C and 
stirred for 2 h before being cooled to room temperature and filtered through Si02, 
washing with MeCN, and concentrated. Purification by flash column chromatography 
(hexanes-ethyl acetate, 6:1) gave 332 (33 mg, 20%) as colourless oil: Rf 0.37, (1:1, 
hexanes-ethyl acetate), m.p. 104°C (hexanes-ethyl acetate ); IR (KBr) v 3518, 3020, 
2915, 1724, 1489, 1215 em-I; IH NMR (300 MHz, CDCh) D 9.73 (t, J = 1.8 Hz, 1H), 
6.82 (d, J = 8.3 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.04 (s, 1H), 3.91 (s, 3H), 3.80 (d, J 
152 
= 1.8 Hz, 2H) ppm; 13C NMR (75 MHz, CDCh) (5 199.0, 146.5, 143.7, 125.4, 122.0, 
111.0, 109.7, 56.4, 49.9 ppm; MS (EI) mlz (%) 215 (100), 217 (100), 218 (11), 244 
(32), 246 (32); HRMS-EI calcd for C9H9Br03 243.9735, found 243.9735. 
OH 
TBSO'" 
335 
tert-butyl-{ 2-[ (5aS ,6S,9aR)-6-{ [tert-butyl( dimethyl)silyl]oxy }-1-(2-
hydroxypropyl)-4-methoxy -6,7 -dihydrodibenzo[b,d]furan -9a( 5aH)-
yl]ethyl}methylcarbamate (335) 
To a solution of aldehyde 332 (10 mg, 0.019 mmol) in DCM (0.2 mL) at 0 °C was 
added AIMe3 (19 ~L, 0.19 mmol). The mixture was warmed slowly to room 
temperature and stirred for 30 min before being quenched with water and extracted 
into DCM (3 X 5mL) The combined organic layers were dried with Na2S04 and the 
solvent was removed under reduced pressure. Column chromatography (10:1, 
hexanes-ethyl acetate) afforded 335 (4 mg, 35%) as a clear oil: Rj 0.42 (2:1, hexanes-
ethyl acetate); IH NMR (300 MHz, CDCh) (5 6.77 (d, J = 8.4 Hz, 1H), 6.65 (t, J = 8.0 
Hz, 1H), 6.07 (dd, J = 15.1, 10.0 Hz, 1H), 5.75-5.66 (m, 1H), 4.55 (dd, J = 24.2, 4.53 
Hz, 1H), 4.37 (dd, J = 6.8, 1.2 Hz, 1H), 3.72 (s, 3H), 3.70-3.62 (m, 1H), 3.69 (s, 3H), 
3.52-3.49 (m, 1H), 3.34 (s, 3H), 3.20-3.05 (m, 1H), 3.00-2.86 (m, 1H), 2.71 (s, 3H), 
2.66-2.57 (m, 1H), 2.53-2.48 (m, 1H), 2.24-2.13 (m, 1H), 1.37 (s, 9H), 1.27-1.13 (m, 
1H), 1.08 (m, 2H) 0.87 (s, 9H), 0.098 (s, 3H), -0.017 (s, 3H) ppm; 13C NMR (300 
MHz, CDCh) (5 143.5, 143.4, 129.9, 129.7, 124.6, 124.3, 123.3, 112.5, 89.4, 78.9, 
153 
67.4,67.2,56.1,51.9, 51.8,44.9,41.6,41.1,40.5,40.3,40.2,40.1,39.9, 39.6, 39.5, 
34.2, 32.4, 31.2, 28.5, 26.2, 23.4, 18.3, -4.3, -4.9 ppm; MS (EI) m/z (%): 41 (51),43 
(29), 44 (100), 55 (28), 57 (89), 58 (27), 59 (94), 102 (22), 103 (88), 211 (22), 213 
(75),214 (23), 225 (21), 227 (21), 239 (87); HRMS-EI C30~9N06Si calc. 547.7987, 
found 547.7987. 
154 
6. Selected Spectra 
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